[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023083269A1 - 一种芳杂环类化合物及其应用 - Google Patents

一种芳杂环类化合物及其应用 Download PDF

Info

Publication number
WO2023083269A1
WO2023083269A1 PCT/CN2022/131193 CN2022131193W WO2023083269A1 WO 2023083269 A1 WO2023083269 A1 WO 2023083269A1 CN 2022131193 W CN2022131193 W CN 2022131193W WO 2023083269 A1 WO2023083269 A1 WO 2023083269A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
membered
group
alkyl
Prior art date
Application number
PCT/CN2022/131193
Other languages
English (en)
French (fr)
Inventor
熊兵
李佳
刘同超
周宇波
李聪
李娜
阚伟娟
苏明波
盛丽
胡小蓓
Original Assignee
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院上海药物研究所 filed Critical 中国科学院上海药物研究所
Priority to CN202280075128.7A priority Critical patent/CN118302418A/zh
Priority to EP22892062.5A priority patent/EP4431504A1/en
Publication of WO2023083269A1 publication Critical patent/WO2023083269A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the invention relates to an aromatic heterocyclic compound and its application.
  • Histone methylation is an important type of histone covalent modification in epigenetic regulation. It was previously considered to be a relatively stable epigenetic regulation modification until Shi Yang et al. discovered the first specific lysine in 2004. Acid demethylase-1 (Lysine specific demethylase 1, LSD1, KDM1A), it is gradually recognized that histone methylation and demethylation are a dynamic equilibrium process [Cell, 2004, 119: 941-53. ]. Structurally speaking, LSD1 can be divided into three parts: Tower domain, C-terminal aminooxidase (AOL) domain, and N-terminal SWIRM domain.
  • AOL C-terminal aminooxidase
  • the Tower domain is composed of a group of antiparallel ⁇ -helices, which plays a very important role in the catalytic function of LSD1.
  • the N-terminal domain contains an ⁇ -helix, which can form protein-protein complexes with certain proteins, such as CoREST, NuRD, etc. This shape is conducive to maintaining protein stability, so that the protein is not easy to be deconstructed while performing higher functions. Inactivate.
  • the C-terminal AOL domain is the structural center of the entire LSD1 to perform the catalytic function. It is the center for recognizing FAD, and at the same time it is the site for specific binding to FAD.
  • LSD1 belongs to the amine oxidase family, which relies on FAD to catalyze the oxidation of H3K4 and H3K9 to generate a formaldehyde and a demethylated lysine residue to remove the methyl group.
  • LSD1 regulates many cell signaling pathways, and its dysfunction is closely related to the occurrence and development of many diseases, such as cancer, neurodegenerative diseases, cardiovascular diseases, inflammation, and viral infections.
  • Abnormal high expression of LSD1 occurs in human hematological tumors and solid tumor cells, such as acute myeloid leukemia [Cancer Res.2016,76(7),1975-1988.], small cell lung cancer [Cancer Cell 2015,28(1) ,57-69.], breast cancer, neuroblastoma, colorectal cancer, prostate cancer [Am.J.Clin.Exp.Urol.2014,2(4),273-285.], liver cancer, gastric cancer, oral cavity Cancer, etc. [Future Med.Chem.,2017,9:1227–1242.].
  • LSD1 Inhibiting the activity of LSD1 can inhibit the differentiation, proliferation, migration, invasion and tumor growth of cancer cells [Epigenomics 2016,8(8),1103-1116.]. In addition, the inhibition of LSD1 can enhance the tumor immunotherapy effect of PD-1 antibody, which provides theoretical support for the combination of small molecule LSD1 inhibitors and tumor immunotherapy [Cell, 2018, 174:549-563.e19.]. Therefore, LSD1 is a very potential therapeutic target.
  • the technical problem to be solved by the present invention is the defects of existing LSD1 inhibitors such as single structure, and the present invention provides an aromatic heterocyclic compound and its application.
  • the compounds have good inhibitory activity on LSD1, and can be used as LSD1 inhibitors for the treatment of tumors and the like.
  • the present invention solves the above-mentioned technical problems through the following technical solutions.
  • the present invention provides an aromatic heterocyclic compound as shown in formula I, its pharmaceutically acceptable salt, stereoisomer, racemate, prodrug, co-crystal complex, hydrate or solvate thing;
  • A is a substituted 5-14-membered heteroaryl or a substituted 6-14-membered aryl; wherein the substituted 5-14-membered heteroaryl and substituted 6-14-membered aryl are independently 1, 2 or 3 R a substitutions; the heteroatoms in the 5-14 membered heteroaryl are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4;
  • R is independently CN, F, Cl, Br, I or C 1-3 alkyl, and at least one is CN;
  • R 1 is hydrogen, halogen, substituted or unsubstituted (amino)-(C 1 -C 4 alkylene)-, substituted or unsubstituted C 3-12 cycloalkyl, substituted or unsubstituted 3-10 member Heterocycloalkyl, substituted or unsubstituted C 6 -C 14 aryl or substituted or unsubstituted 5-14 membered heteroaryl, wherein the substituted (amino)-(C 1 -C 4 alkylene) -, substituted C 3-12 cycloalkyl, substituted 3-10 membered heterocycloalkyl, substituted C 6 -C 14 aryl and substituted 5-14 membered heteroaryl are independently 1, 2 or 3 R 1a are substituted; the heteroatoms in the 5-14 membered heteroaryl group are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4; in the saturated 3-10 membered heterocyclic group The heteroatoms
  • R 2 is halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted saturated or unsaturated C 3-10 cycloalkyl, substituted or unsubstituted C 6 -C 14 aryl, substituted or unsubstituted Substituted 3-10 membered heterocyclic group, substituted or unsubstituted 5-14 membered heteroaryl group, substituted or unsubstituted 3-10 membered heterocyclic group-N(R 3 )-, substituted or unsubstituted 3- 10-membered heterocyclyl-(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted N(R 3 ) 2 -(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted 3-10 membered heterocyclic group-O-, substituted or unsubstituted 3-10 membered heterocyclic group-
  • Each R 1a and R 1c is independently F, Cl, Br, I, OH, N(R 3 ) 2 , CN, COOH, CON(R 3 ) 2 , SO 2 N(R 3 ) 2 , C 1- 3 alkyl, C 3-12 cycloalkyl, C 1-3 alkyl-O- or C 3-12 cycloalkyl-O-, wherein the C 1-3 alkyl, C 3-12 cycloalkane Base, C 1-3 alkyl-O- and C 3-12 membered cycloalkyl-O- are optionally substituted by 1, 2 or 3 R 1b ;
  • each R 1b is independently F, Cl, Br, I, OH or NH 2 ;
  • Each R 3 is independently hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-12 cycloalkyl; the substituted C 1-4 alkyl and substituted C 3 -12 cycloalkyl is independently substituted by 1, 2 or 3 R 1b ;
  • L is -NH-, -N(C 1 -C 3 alkyl)-, -O- or does not exist (that is, a link, R 1 is directly connected to M);
  • X and Y are each independently N or C (R 4 );
  • M is C, CH or N
  • R 4 is hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-12 cycloalkyl; the substituted C 1-4 alkyl and substituted C 3-12 Cycloalkyl is independently substituted by 1, 2 or 3 R 1b .
  • the aromatic heterocyclic compound as shown in formula I its pharmaceutically acceptable salt, stereoisomer, racemate, prodrug, co-crystal complex, hydrate or solvate in things,
  • A is a substituted 5-14-membered heteroaryl or a substituted 6-14-membered aryl; wherein the substituted 5-14-membered heteroaryl and substituted 6-14-membered aryl are independently 1, 2 or 3 R a substitutions; the heteroatoms in the 5-14 membered heteroaryl are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4;
  • R is independently CN, F, Cl, Br, I or C 1-3 alkyl, and at least one is CN;
  • R 1 is hydrogen, halogen, substituted or unsubstituted (amino)-(C 1 -C 4 alkylene)-, substituted or unsubstituted C 3-12 cycloalkyl, substituted or unsubstituted 3-10 member Heterocycloalkyl, substituted or unsubstituted C 6 -C 14 aryl or substituted or unsubstituted 5-14 membered heteroaryl, wherein the substituted (amino)-(C 1 -C 4 alkylene) -, substituted C 3-12 cycloalkyl, substituted 3-10 membered heterocycloalkyl, substituted C 6 -C 14 aryl and substituted 5-14 membered heteroaryl are independently 1, 2 or 3 R 1a are substituted; the heteroatoms in the 5-14 membered heteroaryl group are selected from N, O and S, and the number of heteroatoms is 1, 2, 3 or 4; in the saturated 3-10 membered heterocyclic group The heteroatoms
  • R 2 is halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted saturated or unsaturated C 3-10 cycloalkyl, substituted or unsubstituted C 6 -C 14 aryl, substituted or unsubstituted Substituted 3-10 membered heterocyclic group, substituted or unsubstituted 5-14 membered heteroaryl group, substituted or unsubstituted 3-10 membered heterocyclic group-N(R 3 )-, substituted or unsubstituted 3- 10-membered heterocyclyl-(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted N(R 3 ) 2 -(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted 3-10 membered heterocyclic group-O-, substituted or unsubstituted 3-10 membered heterocyclic group-
  • Each R 1a and R 1c is independently F, Cl, Br, I, OH, N(R 3 ) 2 , CN, COOH, CON(R 3 ) 2 , SO 2 N(R 3 ) 2 , C 1- 3 alkyl, C 3-12 cycloalkyl, C 1-3 alkyl-O- or C 3-12 cycloalkyl-O-, wherein the C 1-3 alkyl, C 3-12 cycloalkane Base, C 1-3 alkyl-O- and C 3-12 membered cycloalkyl-O- are optionally substituted by 1, 2 or 3 R 1b ;
  • each R 1b is independently F, Cl, Br, I, OH or NH 2 ;
  • Each R 3 is independently hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-12 cycloalkyl; the substituted C 1-4 alkyl and substituted C 3 -12 cycloalkyl is independently substituted by 1, 2 or 3 R 1b ;
  • L is -NH-, -N(C 1 -C 3 alkyl)-, -O- or does not exist (that is, a link, R 1 is directly connected to M);
  • X and Y are each independently N or C (R 4 );
  • M is C, CH or N
  • R 4 is hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-12 cycloalkyl; the substituted C 1-4 alkyl and substituted C 3-12 Cycloalkyl is independently substituted by 1, 2 or 3 R 1b .
  • aromatic heterocyclic compound as shown in formula I is as follows:
  • Formula I-1 is another example Also for example
  • R 1 , R 2 , L, X, Y, Z 1 , Z 2 and Z 3 are as described in any scheme of the present invention; W 1 and W 2 are each independently N, C(H) or C(R a ); wherein, R can be F, Cl, Br, I or C 1-3 alkyl.
  • A is a substituted 6-14 membered aryl group
  • R 1 is a substituted or unsubstituted C 6 -C 14 aryl group
  • R 2 is a substituted or unsubstituted C 6 -C 14 aryl group
  • the C 6 -C 14 aryl groups are independently phenyl or naphthyl.
  • A is a substituted 5-14 membered heteroaryl
  • R is a substituted or unsubstituted 5-14 membered heteroaryl
  • R is a substituted or unsubstituted 5-14 membered heteroaryl
  • the 5-14 membered heteroaryl group is a 5-10 membered heteroaryl group
  • the heteroatoms are selected from N, O and S, and the number of heteroatoms is 1 or 2; for example another example
  • halogen is independently F, Cl, Br, I, such as Br.
  • R 1 is a substituted or unsubstituted (amino)-(C 1 -C 4 alkylene)-
  • R 2 is a substituted or unsubstituted 3-10 membered heterocyclyl-(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted N(R 3 ) 2 -(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted 3-10 membered heterocyclic group-O-, substituted or unsubstituted 3-10 membered heterocyclic group-(C 1 -C 4 alkylene)-O- or substituted or unsubstituted N(R 3 ) 2 -
  • the (C 1 -C 4 alkylene) is -CH 2 -, -CH 2 CH 2 -, -CH(CH 3 )-, - CH(
  • R 1 is substituted or unsubstituted C 3-12 cycloalkyl
  • R 1a and R 1c are independently C 3-12 cycloalkyl or C 3-12 cycloalkyl-O-
  • R 3 is a substituted or unsubstituted C 3-12 cycloalkyl group
  • R 4 is a substituted or unsubstituted C 3-12 cycloalkyl group
  • said C 3-12 cycloalkyl group is independently C 3-7 Monocyclic cycloalkyl, C 4-12 bridged or parallel cycloalkyl, C 7-12 spiro cycloalkyl;
  • the C 3-7 monocyclic cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • R 1 is a substituted or unsubstituted 3-10 membered heterocycloalkyl group, wherein said 3-10 membered heterocycloalkyl group is independently a C 3-7 monocyclic heterocycloalkyl group, C 4-12 bridged or parallel ring heterocycloalkyl, C 7-12 spiro heterocycloalkyl, where the heteroatoms can be selected from N, O and S, and the number of heteroatoms can be 1 or 2 indivual;
  • the C 3-7 monocyclic heterocycloalkyl can be pyrrolidinyl (For example ), piperidinyl (For example ), piperazinyl (For example ), (For example );
  • the C 4-12 bridged ring or ring-connected heterocycloalkyl group can be (For example ), (For example Also for example another example ), (For example ),
  • the heterocycloalkyl group of the C 7-12 spiro ring can be (For example ).
  • R 2 is a substituted or unsubstituted C 1-4 alkyl
  • R 3 is a substituted or unsubstituted C 1-4 alkyl
  • R 4 is a substituted or unsubstituted C 1-4 alkane
  • the C 1-4 alkyl groups are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl.
  • R 2 is a substituted or unsubstituted saturated or unsaturated C 3-12 cycloalkyl group
  • the saturated C 3-12 cycloalkyl group is a C 3-12 cycloalkyl group, such as cyclopropyl , cyclobutyl, cyclopentyl or cyclohexyl.
  • R 2 is a substituted or unsubstituted 3-10 membered heterocyclic group, a substituted or unsubstituted 3-10 membered heterocyclic group-N(R 3 )-, a substituted or unsubstituted 3-10 Membered heterocyclyl-(C 1 -C 4 alkylene)-N(R 3 )-, substituted or unsubstituted 3-10 membered heterocyclic group-O- or substituted or unsubstituted 3-10 membered heterocyclic ring
  • the 3-10 membered heterocyclyl is independently a 3-10 membered heterocycloalkyl
  • the radicals are independently C 3-7 monocyclic heterocycloalkyl, C 4-12 bridged or parallel ring heterocycloalkyl, C 7-12 spiro heterocycloalkyl, wherein the heteroatoms can
  • the C 4-12 bridged ring or ring-connected heterocycloalkyl group can be (For example ), (For example Also for example another example ), (For example ),
  • the heterocycloalkyl group of the C 7-12 spiro ring can be (For example ).
  • R a is independently C 1-3 alkyl
  • R 1a and R 1c are independently C 1-3 alkyl or C 1-3 alkyl-O-
  • L is -N(C 1 -C 3 alkyl)-
  • the C 1-3 alkyl is independently methyl, ethyl, n-propyl or isopropyl.
  • A is W 1 and W 2 are each independently N, C(H) or C(R a );
  • Ra can be F, Cl, Br, I or C 1-3 alkyl
  • W 1 is N, CH or CF; W 2 is CH.
  • R a is independently CN or F, and at least one is CN.
  • At least one of said R a is CN, and is located at of counterpoint.
  • R 1 is halogen, substituted or unsubstituted C 6 -C 14 aryl, or substituted or unsubstituted 5-14 membered heteroaryl.
  • R 2 is a substituted or unsubstituted 3-10 membered N-containing heterocyclic group, a substituted or unsubstituted 3-10 membered heterocyclic group-(C 1 -C 4 alkylene)-N( R 3 )-, substituted or unsubstituted 3-10 membered heterocyclic group-(C 1 -C 4 alkylene)-O-.
  • each R 1a and R 1c is independently F, Cl, OH, N(R 3 ) 2 , CON(R 3 ) 2 , SO 2 N(R 3 ) 2 , C 1-3 alkane or C 1-3 alkyl-O-, wherein said C 1-3 alkyl and C 1-3 alkyl-O- are optionally substituted by 1, 2 or 3 R 1b , for example by halogen.
  • each R 1b is independently F or NH 2 .
  • R 3 is hydrogen or substituted or unsubstituted C 1-4 alkyl, such as hydrogen or C 1-4 alkyl; another example is hydrogen or methyl.
  • L is -NH-, -O- or absent; eg absent.
  • X and Y are each independently N; that is for
  • X and Y are each independently N or CH; for example for
  • Z 1 , Z 2 and Z 3 are each independently N, C(H)(R 4 ) or CR 4 .
  • R4 is hydrogen or halo; eg H or F.
  • R 4 is hydrogen, halogen or C 1-4 alkyl; eg H, F or methyl.
  • R 1a and R 1c are independently F, Cl, methyl, isopropyl, methyl-O-, SO 2 NH 2 , CF 3 -O-, CF 3 -, OH- or CONH 2 .
  • R1 is Br
  • R1 is Br
  • A is For example preferred
  • R2 is For example preferred
  • R2 is For example
  • the aromatic heterocyclic compound as shown in formula I or its pharmaceutically acceptable salt is a compound of the following structure or its hydrochloride (Table 1):
  • the present invention provides a pharmaceutical composition, which comprises a therapeutically effective amount of substance A and a pharmaceutically acceptable carrier (pharmaceutical excipient); said substance A is an aromatic heterocycle represented by formula I as described above
  • a pharmaceutically acceptable carrier pharmaceutically acceptable carrier
  • said substance A is an aromatic heterocycle represented by formula I as described above
  • the present invention also provides an application of substance A in the preparation of LSD1 inhibitors, said substance A is the aromatic heterocyclic compound represented by formula I as above, its pharmaceutically acceptable salt, stereoisomer One or more of body, racemate, prodrug, co-crystal complex, hydrate or solvate.
  • the LSD1 inhibitor can be used in mammalian organisms; it can also be used in vitro, mainly for experimental purposes, for example: as a standard sample or control sample to provide comparison, or to prepare according to conventional methods in the art As a kit, it provides a rapid test for the effect of inhibiting LSD1.
  • the present invention also provides an application of substance A in the preparation of medicine, said substance A is the aromatic heterocyclic compound represented by formula I as above, its pharmaceutically acceptable salt, stereoisomer, One or more of racemates, prodrugs, co-crystal complexes, hydrates or solvates; the substance A is in a therapeutically effective amount; the drug is used to treat or prevent LSD1-mediated disease.
  • the present invention also provides the application of a substance A in the preparation of medicine, the medicine is a medicine for treating or preventing cancer; the substance A is an aromatic heterocyclic compound represented by formula I as above , one or more of its pharmaceutically acceptable salts, stereoisomers, racemates, prodrugs, co-crystal complexes, hydrates or solvates; the substance A is a therapeutically effective amount of.
  • the present invention also provides a method for inhibiting LSD1, which includes administering a therapeutically effective amount of substance A to a patient; said substance A is an aromatic heterocyclic compound represented by formula I as described above, which is pharmaceutically acceptable One or more of salts, stereoisomers, racemates, prodrugs, co-crystal complexes, hydrates or solvates of .
  • the present invention also provides a method for treating or preventing LSD1-mediated diseases, which comprises administering a therapeutically effective amount of substance A to a patient; said substance A is an aromatic heterocyclic compound represented by formula I as described above , one or more of pharmaceutically acceptable salts, stereoisomers, racemates, prodrugs, co-crystal complexes, hydrates or solvates thereof.
  • the present invention also provides a method for treating or preventing cancer, which comprises administering a therapeutically effective amount of substance A to a patient; said substance A is an aromatic heterocyclic compound represented by formula I as described above, and its pharmaceutical One or more of acceptable salts, stereoisomers, racemates, prodrugs, co-crystal complexes, hydrates or solvates.
  • the disease mediated by LSD1 can be cancer.
  • Cancer as mentioned above is non-limitingly selected from bladder cancer, breast cancer, prostate cancer, pancreatic cancer, thyroid cancer, liver cancer, colon cancer, rectal cancer, esophagus cancer, cervical cancer, ovarian cancer, acute leukemia, acute lymphoblastic leukemia , acute myeloid leukemia (monocytic, myeloblastic, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, chondrosarcoma, chronic lymphocytic leukemia, Chronic myeloid (granulocytic) leukemia, large cell lymphoma, fibrosarcoma, testicular germ cell carcinoma, glioma, lymphoma (Hodgkin or non-Hodgkin), multiple myeloma, lymphoma, One or more of myeloid cancer, neuroblastoma, neuroblastoma, non-small cell lung cancer, and small cell lung cancer.
  • the carbon atom with "*" is a chiral carbon atom, it is in R configuration, S configuration or a mixture thereof.
  • pharmaceutically acceptable salt refers to a salt prepared from a compound of the present invention with a relatively non-toxic, pharmaceutically acceptable acid or base.
  • the base addition can be obtained by contacting the neutral form of such compounds with a sufficient amount of a pharmaceutically acceptable base in pure solution or in a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salts, sodium salts, potassium salts, calcium salts, aluminum salts, magnesium salts, zinc salts, bismuth salts, ammonium salts, diethanolamine salts.
  • acid addition can be achieved by contacting the neutral form of such compounds with a sufficient amount of a pharmaceutically acceptable acid in neat solution or in a suitable inert solvent.
  • a pharmaceutically acceptable acid includes inorganic acid and organic acid (such as trifluoroacetic acid, hydrochloric acid).
  • the compounds represented by formula I of the present invention may contain one or more chiral centers and exist in different optically active forms.
  • the compound contains enantiomers.
  • the present invention includes both these isomers and mixtures of isomers, such as racemic mixtures. Enantiomers may be resolved by methods known in the art, such as crystallization and chiral chromatography. When compounds of formula I contain more than one chiral center, diastereoisomers may exist.
  • the present invention includes resolved optically pure specific isomers as well as mixtures of diastereomers. Diastereoisomers can be resolved by methods known in the art, such as crystallization and preparative chromatography.
  • stereoisomer includes conformational isomers and configurational isomers, wherein configurational isomers mainly include cis-trans isomers and optical isomers.
  • the compounds of the present invention may exist in the form of stereoisomers, and thus encompass all possible stereoisomeric forms, including but not limited to cis-trans isomers, enantiomers, diastereomers, Atropisomers, etc., the compound of the present invention can also be in the form of any combination or any mixture of the aforementioned stereoisomers, such as mesoform, racemate, atropisomer equivalent mixture, etc. exist.
  • a single enantiomer, a single diastereoisomer or a mixture thereof, or a single atropisomer or a mixture thereof When the compounds described herein contain olefinic double bonds, unless otherwise specified, they include cis-isomers and trans-isomers, and any combination thereof.
  • Atropisomers of the present invention are stereoisomers based on axial or planar chirality resulting from restricted intramolecular rotation.
  • the atropisomer of the present invention wherein the compound has the structure of formula I, or the compound of formula I has an isomer produced by an asymmetric carbon, etc., it represents a pair of atropisomers present in each isomer compound any of the body.
  • stereoisomers can be separated, purified and enriched by asymmetric synthesis methods or chiral separation methods (including but not limited to thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.), and can also be obtained by It can be obtained by chiral resolution through bond formation or salt formation with other chiral compounds.
  • asymmetric synthesis methods or chiral separation methods including but not limited to thin layer chromatography, rotary chromatography, column chromatography, gas chromatography, high pressure liquid chromatography, etc.
  • the term "single stereoisomer” means that the mass content of one stereoisomer of the compound of the present invention relative to all stereoisomers of the compound is not less than 95%.
  • the compound of formula I has optical isomers derived from asymmetric carbon, axial asymmetry, etc., and if necessary, single isomers can be obtained by methods known in the art, such as crystallization or chromatography (such as chiral chromatography) and other methods. Split to get.
  • the present invention provides the compounds shown in the above various structures, or their cis-trans isomers, mesomers, racemates, enantiomers, diastereoisomers, atropisomers, Isomers or mixtures thereof, wherein "the mixture thereof” includes any of the aforementioned stereoisomers (such as cis-trans isomers, enantiomers, diastereomers, atropisomers) Mixtures in any form between and/or mixtures (meso, racemate), e.g.
  • mixtures of cis-trans isomers mixtures of enantiomers and diastereoisomers, diastereoisomers Mixtures of isomers, mixtures of atropisomers, or mixtures of cis-trans isomers and racemates, mixtures of enantiomers and diastereoisomers, mixtures of atropisomers with Mixing of diastereomeric mixtures, etc.
  • Compounds of formula I, their stereoisomers and pharmaceutically acceptable salts thereof are intended to encompass compounds of formula I, their pharmaceutically acceptable salts, stereoisomers, racemates, prodrugs, co-crystal complexes, Any isotopically labeled (or "radiolabeled") variant of a hydrate or solvate.
  • Such variants are compounds of formula I, pharmaceutically acceptable salts, stereoisomers, racemates, prodrugs, co-crystal complexes, hydrates or solvates wherein one or more atoms are replaced by atoms A mass or mass number that differs from the atomic mass or mass number normally found in nature by atomic substitution.
  • the radionuclide used will depend on the particular application of the radiolabeled variant. For example, for in vitro receptor labeling and competition assays, 3H or14C are often useful. For radiographic applications, 11C or18F are often useful.
  • isotopic variants of the compounds of the invention may be useful, for example, to investigate the mechanism of action or the distribution of active ingredient components in vivo; due to the relatively easy manufacturability and detectability, compounds labeled with 3 H or 14 C isotopes are particularly suitable for this purpose.
  • the incorporation of isotopes such as deuterium may confer particular therapeutic benefit due to better metabolic stability of the compound, e.g. increasing half-life in vivo or lowering the effective dose required; case constitutes a preferred embodiment of the invention.
  • Isotopic variants of the compounds of the present invention can be prepared by methods known to those skilled in the art, for example by the methods described below and in the working examples, by using corresponding isotopically modified specific reagents and/or starting compounds .
  • pharmaceutical composition refers to a formulation comprising a compound of the present invention and a vehicle generally accepted in the art for the delivery of a biologically active compound to a mammal (eg, a human).
  • the medium includes a pharmaceutically acceptable carrier.
  • the purpose of the pharmaceutical composition is to promote the administration of the organism, facilitate the absorption of the active ingredient and thus exert its biological activity.
  • pharmaceutically acceptable refers to substances (such as pharmaceutical excipients) that do not affect the biological activity or properties of the compounds of the present invention, and are relatively non-toxic, that is, the substances can be administered to individuals without causing adverse effects Biologically react or interact in an undesirable manner with any component contained in the composition.
  • pharmaceutical excipient or “pharmaceutically acceptable carrier” refers to the excipients and additives used in the production of drugs and formulation of prescriptions, and refers to all substances contained in pharmaceutical preparations except active ingredients.
  • the pharmaceutical excipients can be inert fillers, or provide certain functions, such as stabilizing the overall pH value of the composition or preventing the degradation of the active ingredients of the composition.
  • Described pharmaceutical adjuvant can comprise one or more in the following adjuvant: binding agent, suspending agent, emulsifying agent, diluent, filler, granulating agent, adhesive, disintegrating agent, lubricant, antiadhesive Glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, coloring agents, flavoring agents, and sweeteners.
  • compositions of the present invention may be prepared according to the disclosure using any method known to those skilled in the art. For example, conventional mixing, dissolving, granulating, emulsifying, milling, encapsulating, entrapping or freeze-drying processes.
  • the compound shown in formula I, its pharmaceutically acceptable salt, stereoisomer, racemate, prodrug, co-crystal complex, hydrate or solvate can be Administration in any form of pharmaceutical composition.
  • These compositions may be prepared according to methods well known in the art of pharmacy and may be administered by various routes depending upon the need for local or systemic treatment and the area to be treated. Administration can be topical (including epidermal and transdermal, ocular and mucosal, including intranasal, vaginal, and rectal delivery), pulmonary (eg, by powder or aerosol inhalation or insufflation, including by nebulizer; intratracheal or intranasal) , oral (solid and liquid preparations) or parenteral administration forms.
  • topical including epidermal and transdermal, ocular and mucosal, including intranasal, vaginal, and rectal delivery
  • pulmonary eg, by powder or aerosol inhalation or insufflation, including by nebulizer; intrat
  • Examples of solid oral formulations include, but are not limited to, powders, capsules, caplets, gelcaps, and tablets.
  • Examples of liquid formulations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions.
  • Examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum formulations.
  • Examples of formulations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in pharmaceutically acceptable carriers, suspensions for injection, and emulsions for injection.
  • compositions and formulations for topical administration may include transdermal patches, salves, emulsions, ointments, gels, drops, suppositories, sprays, liquids and powders.
  • suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic formulations; aerosols: such as nasal sprays or inhalants.
  • Oral administration may include dosage forms formulated for once-daily or twice-daily (BID) administration.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, eg, intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or it can be by a continuous infusion pump.
  • Conventional pharmaceutical carriers, water, powder or oil bases, thickeners and the like may be necessary or desirable.
  • Pharmaceutical compositions comprising the present invention may also be in controlled or delayed release dosage forms (eg liposomes or microspheres).
  • treatment refers to therapeutic therapy or palliative measures.
  • treatment means: (1) amelioration of one or more biological manifestations of the disease or condition, (2) interference with (a) one or more points in the biological cascade leading to or causing the condition or (b ) one or more biological manifestations of the disorder, (3) amelioration of one or more symptoms, effects or side effects associated with the disorder, or one or more symptoms, effects or side effects associated with the disorder or its treatment, Or (4) slowing the development of the disorder or one or more biological manifestations of the disorder.
  • Treatment can also refer to prolonging survival as compared to expected survival if not receiving treatment.
  • prevention refers to a reduction in the risk of acquiring or developing a disease or disorder.
  • terapéuticaally effective amount refers to an amount of a compound sufficient to effectively treat a disease or condition described herein when administered to a patient.
  • a “therapeutically effective amount” will vary depending on the compound, the condition and its severity, and the age of the patient to be treated, but can be adjusted as necessary by those skilled in the art.
  • patient refers to any animal that is about to or has received the administration of the compound or composition according to the embodiments of the present invention, preferably a mammal, and most preferably a human.
  • mammal includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being most preferred.
  • groups and substituents thereof can be selected by those skilled in the art to provide stable moieties and compounds.
  • substituents When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the structural formula is written from right to left.
  • C 1 -C 6 alkyl refers to an alkyl group as defined below having a total of 1, 2, 3, 4, 5 or 6 carbon atoms.
  • the total number of carbon atoms in the abbreviated notation does not include carbons that may be present in substituents of the stated group.
  • substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, as long as the valence of the specified atom is normal and the substituted compound is stable.
  • substituted means that one or more hydrogen atoms in a given structure have been replaced by a particular substituent.
  • the substituents are independent of each other, that is, the one or more substituents may be different from each other or the same of.
  • a substituent may substitute at each substitutable position of the substituent. When more than one position in a given formula can be substituted by one or more substituents selected from a particular group, then the substituents can be substituted at each position the same or differently.
  • C x -C y alkyl refers to a straight or branched chain saturated hydrocarbon containing x to y carbon atoms.
  • C 1 -C 6 alkyl or “C 1-6 alkyl” specifically refers to independently disclosed methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl and C 6 alkane
  • C 1-4 alkyl specifically refers to independently disclosed methyl, ethyl, C 3 alkyl (ie propyl, including n-propyl and isopropyl ) , C 4 alkyl (ie butyl, including n-butyl, isobutyl, sec-butyl and tert-butyl).
  • moiety As used herein, the terms “moiety”, “structural moiety”, “chemical moiety”, “group”, “chemical group” refer to a specific segment or functional group in a molecule. Chemical moieties are generally considered to be chemical entities embedded or attached to molecules.
  • variable such as R 1a
  • the definition at each position of the variable has nothing to do with the definitions at other positions, and their meanings are independent of each other and do not affect each other. Therefore, if a group is substituted by 1, 2 or 3 R 1a groups, that is, the group may be substituted by up to 3 R 1a groups , the definition of R 1a in this position is the same as that of the remaining R 1a groups Definitions are independent of each other. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • linking substituents are described.
  • the Markush variables recited for that group are to be understood as linking groups.
  • the Markush group definition for that variable recites “alkyl,” it is understood that “alkyl” represents a linking alkylene group.
  • alkyl group when an alkyl group is clearly indicated as a linking group, then the alkyl group represents a linked alkylene group, for example, the group "halo-C 1 -C 6 alkane C 1 -C 6 alkyl in "group” should be understood as C 1 -C 6 alkylene.
  • halogen means fluorine, chlorine, bromine or iodine, especially F or Cl.
  • hydrocarbyl refers to including branched and straight chains with the specified number of carbon atoms, saturated or not Saturated aliphatic hydrocarbon group consisting only of carbon and hydrogen atoms connected to the rest of the molecule by single bonds.
  • alkyl saturated or not Saturated aliphatic hydrocarbon group consisting only of carbon and hydrogen atoms connected to the rest of the molecule by single bonds.
  • alkyl saturated or not Saturated aliphatic hydrocarbon group consisting only of carbon and hydrogen atoms connected to the rest of the molecule by single bonds.
  • alkyl alkenyl
  • alkynyl alkynyl
  • alkyl as a group or part of another group (for example, in haloalkyl etc.), is meant to include both branched and straight chain saturated aliphatic groups having the indicated number of carbon atoms.
  • a hydrocarbyl group consisting only of carbon and hydrogen atoms, connected to the rest of the molecule by single bonds. For example, it has 1 to 10 (preferably 1 to 6, more preferably 1 to 4) carbon atoms.
  • propyl is C 3 alkyl (including isomers, such as n-propyl or isopropyl); butyl is C 4 alkyl (including isomers, such as n-butyl, sec-butyl , isobutyl or tert-butyl); pentyl is C 5 alkyl (including isomers, such as n-pentyl, 1-methyl-butyl, 1-ethyl-propyl, 2-methyl -1-butyl, 3-methyl-1-butyl, isopentyl, tert-pentyl or neopentyl); hexyl is C 6 alkyl (including isomers, such as n-hexyl, 1-ethyl Base-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl , 1,3-dimethylbutyl, 2-ethylbut
  • Examples include but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2- Dimethylpropyl, n-hexyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, n-octyl, nonyl, decyl and similar alkyl groups.
  • alkylene means a saturated divalent hydrocarbon group obtained by removing two hydrogen atoms from a saturated linear or branched chain hydrocarbon group; i.e. One hydrogen in the alkyl group is substituted, the definition of alkyl group is as above.
  • alkylene groups include methylene (-CH 2 -), ethylene ⁇ including -CH 2 CH 2 - or -CH(CH 3 )- ⁇ , isopropylidene ⁇ including -CH(CH 3 )CH 2 -or -C(CH 3 ) 2 - ⁇ and so on.
  • alkenyl refers to a straight or branched hydrocarbon chain having at least one double bond, consisting only of carbon atoms and hydrogen atoms, having, for example 2 to 12 (preferably 2 to 8, more preferably 2 to 6, most preferably 2 to 4) carbon atoms, and is connected to the rest of the molecule by a single bond, for example including but not limited to vinyl, n-propenyl , isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, n-pentenyl, 2-methylbutenyl, 2,2-dimethylpropenyl, n-hexenyl, Heptenyl, 2-methylhexenyl, 3-methylhexenyl, octenyl, nonenyl, decenyl and the like.
  • alkynyl refers to a straight or branched hydrocarbon chain radical having at least one triple bond, consisting only of carbon and hydrogen atoms, having, for example 2 to 12 (preferably 2 to 8, more preferably 2 to 6, most preferably 2 to 4) carbon atoms and are linked to the rest of the molecule by a single bond, for example including but not limited to ethynyl, n-propyne radical, isopropynyl, n-butynyl, isobutynyl, sec-butynyl, tert-butynyl, n-pentynyl, 2-methylbutynyl, 2,2-dimethylpropynyl , n-hexynyl, heptynyl, 2-methylhexynyl, 3-methylhexynyl, octynyl, nonynyl and decynyl,
  • cycloalkyl as a group or part of another group means a saturated or unsaturated (non-aromatic) monocyclic or polycyclic (e.g. bicyclic, tricyclic or multicyclic bridge ring, fused ring (fused ring) or spiro ring system) and which may be attached to the remainder of the molecule by a single bond via any suitable carbon atom.
  • a 3-12 membered ring hydrocarbon group with 3 to 12 carbon atoms another example is a 3-12 membered cycloalkyl group or a cycloalkenyl group, another example is a C 3-7 monocyclic ring hydrocarbon group, a C 4-12 bridged ring or a combination Cycloalkyl of ring, cycloalkyl of C 7-12 spiro ring.
  • a 3-10 membered cyclohydrocarbyl group with 3 to 10 carbon atoms is preferred, another example is a 3-10 membered cycloalkyl group with 3 to 10 carbon atoms, preferably a 3 to 6 carbon atom - a 6-membered cycloalkyl group; or a 3-10-membered cycloalkenyl group having 3 to 10 carbon atoms, preferably a 3-6-membered cycloalkenyl group having 3 to 6 carbon atoms.
  • a typical monocyclic cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • a "cycloalkenyl” is a monocyclic, unsaturated carbocycloalkenyl group having 5 to 6 ring atoms ("5-6 membered cycloalkenyl").
  • the term includes, but is not limited to, cyclopentenyl (e.g. ), cyclopentadienyl (for example ), cyclohexenyl (for example ) or cyclohexadienyl, and stereoisomers thereof.
  • a 3-10 membered heterocyclic group having 2 to 9 carbon atoms preferably a 3-6 membered heterocyclic group having 3 to 5 carbon atoms
  • a 3-10 membered heterocyclic group having 2 to 9 carbon atoms Alkyl preferably a 3-6 membered heterocycloalkyl group having 3 to 5 carbon atoms
  • a 3-10 membered heterocycloalkenyl group having 2 to 9 carbon atoms preferably a 3-membered heterocycloalkenyl group having 3 to 5 carbon atoms 6-membered heterocycloalkenyl.
  • Heterocyclylbicyclic ring systems may include one or more heteroatoms in one or both rings; and be saturated or unsaturated.
  • a heterocyclyl group can be attached to the rest of the molecule via a carbon atom and by a single bond; in a heterocyclyl group containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom; or, ring-joint to the rest of the molecule; As long as the price permits.
  • heterocycloalkyl is a 5 to 7 membered monocyclic heterocycloalkyl, a 6 to 8 membered ring linked heterocycloalkyl, a 6 to 8 membered bridged ring linked heterocycloalkyl Or a 7- to 10-membered spiro-linked heterocycloalkyl.
  • Exemplary 3-membered heterocycloalkyl groups include, but are not limited to, aziridinyl, oxiranyl, and thiiridine, or stereoisomers thereof;
  • exemplary 4-membered heterocycloalkyl groups Groups include, but are not limited to, azetidinyl, oxirane, thietanyl, or isomers and stereoisomers thereof;
  • exemplary 5-membered heterocycloalkyl groups Including but not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl (For example another example ), thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, imidazolidinyl, pyrazolidinyl, dioxolanyl, oxathiofuranyl, dithiofuranyl, or other Isomers and Stereoisomers.
  • Exemplary 6-membered heterocycloalkyl groups include, but are not limited to, piperidinyl (For example ), tetrahydropyranyl, cyclopentylsulfide, morpholinyl, thiomorpholinyl, dithianyl, dioxanyl, piperazinyl (For example ), triazinyl group, (For example ), or its isomers and stereoisomers.
  • Exemplary 7-membered heterocycloalkyl groups include, but are not limited to, (For example ), (For example ), (For example ), (For example Also for example another example )or (For example Also for example another example ), or its isomers and stereoisomers.
  • Exemplary 8-membered heterocycloalkyl groups include, but are not limited to, (For example ), (For example ), (For example another example ), (For example Also for example another example )or (For example Also for example another example ), or its isomers and stereoisomers.
  • Exemplary 9-membered heterocycloalkyl groups include, but are not limited to, (For example )or (For example ), (For example ) or its isomers and stereoisomers.
  • Exemplary 10-membered heterocycloalkyl groups include, but are not limited to, (For example )or (For example ), or its isomers and stereoisomers.
  • heterocycloalkenyl is 5 to 7 membered monocyclic heterocycloalkenyl, 6 to 8 membered ring-linked heterocycloalkenyl, 6 to 8 membered bridged ring linked heterocycloalkenyl Or a 7- to 10-membered spiro-linked heterocycloalkenyl.
  • heterocyclenyl examples include, but are not limited to, pyranyl, 2,3-dihydropyrrolyl, 2,3-dihydrofuryl, 1,2,3,4-tetrahydropyridyl, 1,2,3 ,6-tetrahydropyridyl, 3,4-dihydro-2H-pyran,
  • pyranyl 2,3-dihydropyrrolyl, 2,3-dihydrofuryl, 1,2,3,4-tetrahydropyridyl, 1,2,3 ,6-tetrahydropyridyl, 3,4-dihydro-2H-pyran
  • “*" indicates that when the carbon atom with "*" is a chiral carbon atom, it is in R configuration, S configuration or a mixture thereof.
  • aryl as a group or part of another group, means a conjugated hydrocarbon ring system group satisfying the 4n+2 rule.
  • conjugated hydrocarbon ring system radicals with 6 to 20 carbon atoms, preferably with 6 to 10 carbon atoms, satisfying the 4n+2 rule.
  • aryl can be a monocyclic, bicyclic, tricyclic or multicyclic ring system, and can also be combined with cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycle as defined above.
  • An alkenyl is fused, provided that the aryl is attached to the rest of the molecule by a single bond via an atom on the aromatic ring.
  • the term "aryl” refers to an aromatic group composed of carbon atoms, each ring having aromaticity. Examples of aryl groups include, but are not limited to, phenyl, naphthyl (e.g. ).
  • heteroaryl means a conjugated ring system group having carbon atoms and at least one heteroatom selected from O, S, and N in the ring.
  • a 5 to 14 membered conjugated ring system group having 1 to 13 carbon atoms (preferably having 2 to 9 carbon atoms) and 1 to 6 heteroatoms selected from O, N and S in the ring.
  • heteroaryl can be a monocyclic, bicyclic, tricyclic or multicyclic ring system, and can also be combined with the above-defined cycloalkyl, cycloalkenyl, heterocycloalkyl or A heterocycloalkenyl is fused, provided that the heteroaryl is attached to the rest of the molecule by a single bond via an atom on the aromatic ring.
  • heteroaryl preferably contains 1 to 5 stable 5 to 14 membered aromatic groups selected from nitrogen, oxygen and sulfur heteroatoms, further preferably contains 1 to 5 heteroatoms selected from nitrogen, A stable 5- to 10-membered aromatic group of oxygen and sulfur heteroatoms.
  • heteroaryl refers to an aromatic group containing heteroatoms, each ring having aromaticity; preferably containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur Atom aromatic 5-6 membered monocyclic ring or 9-10 membered bicyclic ring.
  • heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, diazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, Pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolyl, isoxazolyl, thiadiazolyl, Isoindolyl, indazolyl, isoindazolyl, purinyl, quinolinyl, isoquinolyl, naphthyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carboline Base, phenanthridinyl, phenanthro
  • the present invention adopts traditional methods of mass spectrometry and elemental analysis, and the steps and conditions can refer to the conventional operating steps and conditions in the art.
  • the present invention employs standard nomenclature and standard laboratory procedures and techniques of analytical chemistry, synthetic organic chemistry and optics. In some cases, standard techniques are used for chemical synthesis, chemical analysis, and performance testing of light-emitting devices.
  • the reagents and raw materials used in the present invention are all commercially available.
  • the positive and progressive effect of the present invention is that: as a reversible LSD1 inhibitor with a novel structural skeleton, the compound of the present invention has significant inhibitory activity on LSD1.
  • room temperature refers to ambient temperature, which is 10°C-35°C. Overnight means 8-15 hours. Reflux refers to the solvent reflux temperature at normal pressure.
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF 254 or Qingdao GF 254 silica gel plate.
  • the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm-0.2mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm-0.5mm.
  • Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
  • the known starting materials of the present disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from companies such as Shanghai Haohong Biomedical Technology Co., Ltd. and Bid Pharmaceuticals. Unless otherwise specified in the examples, the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
  • the monitoring of the reaction process in the embodiment adopts thin-layer chromatography (TLC), the developing agent used in reaction, the eluent system of the column chromatography that purification compound adopts and the developing agent system of thin-layer chromatography comprise dichloromethane /methanol system and petroleum ether/ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
  • TLC thin-layer chromatography
  • reaction mixture was stirred at 70 °C for 16 h. After cooling, the reaction solution was concentrated under reduced pressure, 15 mL of water and 15 mL of ethyl acetate were added, mixed evenly, and the layers were separated after standing. The aqueous phase was extracted with ethyl acetate (10 mL ⁇ 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Purification by silica gel column chromatography (EA:PE; 1:8 to 1:4) afforded the title compound 1d (42 mg) as a yellow solid, yield: 77%.
  • EA:PE silica gel column chromatography
  • Example 2 Using the synthetic route of Example 1, the first step raw material (4-cyano-3-fluorophenyl)boronic acid was replaced by (4-cyanophenyl)boronic acid. Substituting tert-butyl piperidin-4-ylcarbamate, the starting material in the second step, with 1-tert-butoxycarbonyl-4-piperidinemethanol, the hydrochloride salt of the title compound 32 (13 mg) was obtained.
  • Example 2 Using the synthetic route of Example 1, replace the second-step raw material piperidin-4-ylcarbamate tert-butyl with tert-butyl N-[(3R,4S)-3-fluoropiperidin-4-yl]aminomethyl Ester, the third step raw material (3-fluoro-4-methoxyphenyl) boronic acid was replaced by 2-fluoro-6-(trifluoromethyl) phenylboronic acid to obtain the hydrochloride (20mg) of the title compound 67 .
  • Example 2 Using the synthetic route of Example 1, replace the second-step raw material piperidin-4-ylcarbamate tert-butyl with tert-butyl N-[(3R,4R)-3-methylpiperidin-4-yl]amino Formate, the third step raw material (3-fluoro-4-methoxyphenyl) boronic acid was replaced by 2-fluoro-6-(trifluoromethyl) phenylboronic acid to obtain the hydrochloride salt of the title compound 68 (16mg ). MS m/z(ESI):524.28[M+l] + .
  • Example 2 Using the synthetic route of Example 1, the second step raw material piperidin-4-ylcarbamate tert-butyl ester is replaced by 3-tert-butoxyacylamino demethyltropane, and the third step raw material (3-fluoro-4 -Methoxyphenyl)boronic acid was replaced by 2-fluoro-6-(trifluoromethyl)phenylboronic acid to give the hydrochloride salt of the title compound 69 (36 mg).
  • Example 2 Using the synthetic route of Example 1, the second step raw material piperidin-4-ylcarbamate tert-butyl ester is replaced by 4-tert-butoxycarbonyl-1H-azepine, and the third step raw material (3-fluoro-4 -Methoxyphenyl)boronic acid was replaced by 2-fluoro-6-(trifluoromethyl)phenylboronic acid to give the hydrochloride salt of title compound 72 (18 mg).
  • reaction mixture was stirred at 70 °C for 16 h. After cooling, the reaction solution was concentrated under reduced pressure, 15 mL of water and 15 mL of ethyl acetate were added, mixed evenly, and the layers were separated after standing. The aqueous phase was extracted with ethyl acetate (10 mL ⁇ 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Purification by silica gel column chromatography (EA:PE; 1:8 to 1:4) gave the title compound 80f (42 mg) (yellow solid), yield: 75%.
  • tert-butyl carbamate 80f (42 mg) was dissolved in 2 mL of dichloromethane, and 2 mL of 4N hydrogen chloride-1,4-dioxane solution was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to obtain hydrochloride (34 mg) of the title compound 80 (yellow solid), yield: 97%.
  • Example 2 Using the synthetic route of Example 1, replace the second-step raw material piperidin-4-ylcarbamate tert-butyl with tert-butyl N-[(3S,4R)-3-fluoropiperidin-4-yl]aminomethyl Ester, the third step raw material (3-fluoro-4-methoxyphenyl)boronic acid was replaced by 2-fluoro-6-(trifluoromethyl)phenylboronic acid to obtain the hydrochloride salt of the title compound 83 (33mg) .
  • Example 2 Using the synthetic route of Example 1, replace the second-step raw material piperidin-4-ylcarbamate tert-butyl with tert-butyl N-[(3R,4R)-3-fluoropiperidin-4-yl]aminomethyl Ester, the third step raw material (3-fluoro-4-methoxyphenyl)boronic acid was replaced by 2-fluoro-6-(trifluoromethyl)phenylboronic acid to obtain the hydrochloride salt of the title compound 84 (36mg) .
  • Example 2 Using the synthetic route of Example 1, replace the second-step raw material piperidin-4-ylcarbamate tert-butyl with tert-butyl N-[(3S,4S)-3-fluoropiperidin-4-yl]aminomethyl Ester, the third step raw material (3-fluoro-4-methoxyphenyl) boronic acid was replaced by 2-fluoro-6-(trifluoromethyl) phenylboronic acid to obtain the hydrochloride salt of the title compound 85 (32mg) .
  • reaction mixture was stirred at 100 °C for 17 h. After cooling, the reaction solution was concentrated under reduced pressure, 15 mL of water and 15 mL of ethyl acetate were added, mixed evenly, and the layers were separated after standing. The aqueous phase was extracted with ethyl acetate (10 mL ⁇ 3). The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Purification by silica gel column chromatography (EA:PE; 1:8 to 1:4) afforded the title compound 92e (21 mg) (yellow solid). Yield: 36.9%.
  • the compound 4,6-dichloro-2-methylthiopyrimidine-5-carbaldehyde 99a (5.00g, 22.41mmol, Shanghai Haohong Biomedical Technology Co., Ltd.) was dissolved in chloroform (40mL), and methylamine (40% aqueous solution) (1.83g, 23.54mmol) and triethylamine (4.67mL, 33.62mmol), stirred at room temperature for 1 hour. After the reaction was monitored by TLC, the reaction solution was concentrated under reduced pressure. Add 60mL of water and 60mL of ethyl acetate, mix evenly, and let stand to separate layers. The aqueous phase was extracted with ethyl acetate (30 mL ⁇ 3).
  • the purpose of this experiment is to detect the inhibitory activity of compounds on LSD1 in vitro.
  • the human recombinant LSD1 protein used in the experiment was purchased from Active Motif, and the enzyme level activity test of LSD1 was carried out using the Lance Ultra LSD1 Histone H3 Lysine 4 Demethylase Assay Kit (PerkinElmer).
  • Tris buffer 50mM Tris-HCl, 50mM NaCl, 0.01% Tween-20, 1mM DTT, 10 ⁇ M FAD, 10% glycerol, pH 9.0
  • the LSD1 group required for the test needs to be prepared In this buffer, and incubated at room temperature for one hour, the components include 4 ⁇ L substrate solution (2.5 ⁇ M Bio-H3K4me2,1-24aa), 4 ⁇ L enzyme solution (4 nM LSD1) and 2 ⁇ L 384-well microplate Inhibitors in. After these operations are completed, another 5 ⁇ L of detection mixture containing Eu-labeled H3K4me0 antibody and ULight-streptavidin needs to be added to the system. After that, Envision (PerkinElmer) is used to detect the components to be tested Fluorescence intensity, the test mode is set in TR-FRET mode (excitation wavelength is 320nm, emission wavelength is 665nm). In order to reduce the error, the test was repeated three times in total. The final IC 50 data was calculated by the software GraphPad Prism 5, and finally the sigmoidal dose-response (variable slope) method was used to obtain the fitting curve.
  • the components include 4 ⁇
  • Table 2 provides the LSD1 inhibitory activity of the representative compounds of the present application and the positive control compound CC90011. All compounds were tested as HCl salts.
  • Test Example 2 Drug efficacy evaluation in mouse xenograft model
  • mice Female NU/NU nude mice, weighing 20 ⁇ 2g, were inoculated with MV4-11 cell line and inoculated subcutaneously in the right axilla of nude mice. The inoculated amount of cells was 5 ⁇ 10 6 per mouse. After tumor formation, measure with a vernier caliper The diameter of the transplanted tumor, the tumor grows to 100-300mm 3 , the animals are divided into the model control group and the treatment group according to the body weight and tumor volume, 6 animals in each group, the treatment group is ground and suspended with 0.5% CMC-Na, and the model control group Give an equal amount of blank solvent. After grouping, the mice were administered orally every day at a dose of 20 mg/kg for 21 days.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种芳杂环类化合物及其应用。本发明提供了一种如式I所示的芳杂环类化合物，其具有较佳的LSD1酶抑制活性，可作为LSD1抑制剂，用于肿瘤等的治疗。

Description

一种芳杂环类化合物及其应用
本申请要求申请日为2021/11/11的中国专利申请2021113320188的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明涉及一种芳杂环类化合物及其应用。
背景技术
组蛋白甲基化是表观遗传调控中一种重要的组蛋白共价修饰类型，以前被认为是一种比较稳定的表观调控修饰，直到2004年施扬等发现第一个特异性赖氨酸去甲基化酶-1(Lysine specific demethylase 1，LSD1，KDM1A)，人们逐渐认识到组蛋白甲基化与去甲基化是一个动态平衡的过程[Cell,2004,119:941-53.]。从结构上来说，LSD1可以被划分为三个部分：Tower结构域、C端氨基氧化酶(AOL)结构域、N端SWIRM结构域。Tower结构域是由一组反向平行的α螺旋所组成，它对于LSD1行使催化功能起着十分重要的作用。N端结构域内包含一个α螺旋，它可以与某些蛋白，如CoREST、NuRD等蛋白形成蛋白-蛋白复合物，这一形态有利于维持蛋白质稳定，从而使得蛋白在行使更高级功能的同时不易解构失活。C端AOL结构域，是整个LSD1行使催化功能的结构中心，它是识别FAD的中枢，同时又是与FAD特异性结合的位点，LSD1酶活性降低，很大程度上，都有可能是这一结构域变构失活所导致的[PLoS Computational Biology,2013,9:e1003158.]。LSD1属于胺氧化酶家族，其依赖FAD催化H3K4和H3K9氧化反应产生一个甲醛和一个去甲基化的赖氨酸残基，以去除甲基基团。
LSD1调控许多细胞信号通路，其功能紊乱与许多疾病的发生发展密切相关，如癌症，神经退行性疾病，心血管疾病，炎症，病毒感染等。异常的LSD1高表达发生在人类血液瘤和实体瘤细胞中，如急性髓系白血病[Cancer Res.2016,76(7),1975-1988.]，小细胞肺癌[Cancer Cell 2015,28(1),57-69.]，乳腺癌，成神经细胞瘤，结直肠癌，前列腺癌[Am.J.Clin.Exp.Urol.2014,2(4),273-285.]，肝癌，胃癌，口腔癌等[Future Med.Chem.,2017,9:1227–1242.]。抑制LSD1的活性，能抑制癌细胞的分化，增殖，迁移，侵袭以及肿瘤生长[Epigenomics 2016,8(8),1103-1116.]。此外，LSD1的抑制能够增强PD-1抗体的肿瘤免疫疗效，这为小分子LSD1抑制剂与肿瘤免疫疗法联合用药提供了理论支持[Cell,2018,174:549-563.e19.]。因此，LSD1是一个非常有潜力的治疗靶标。
目前LSD1抑制剂还没有药物获批上市，有8个化合物处于临床早期阶段，其中6个化合物均具有反式苯基环丙胺骨架。在本领域需要新型结构骨架的LSD1抑制剂分子。
发明内容
本发明要解决的技术问题是现有的LSD1抑制剂结构单一等缺陷，本发明提供了一种芳杂环类化合物及其应用。该类化合物对LSD1具有较好地抑制活性，可作为LSD1抑制剂，用于肿瘤等的治疗。
本发明是通过下述技术方案来解决上述技术问题的。
本发明提供了一种如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物；
Figure PCTCN2022131193-appb-000001
其中，
Figure PCTCN2022131193-appb-000002
表示单键或双键；
A为取代的5-14元杂芳基或取代的6-14元芳基；其中所述取代的5-14元杂芳基和取代的6-14元芳基为独立地被1、2或3个R a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
R a独立地为CN、F、Cl、Br、I或C 1-3烷基，且至少一个为CN；
R 1为氢、卤素、取代或未取代的(氨基)-(C 1-C 4亚烷基)-、取代或未取代的C 3-12环烷基、取代或未取代的3-10元杂环烷基、取代或未取代的C 6-C 14芳基或者取代或未取代的5-14元杂芳基，其中所述取代的(氨基)-(C 1-C 4亚烷基)-、取代的C 3-12环烷基、取代的3-10元杂环烷基、取代的C 6-C 14芳基和取代的5-14元杂芳基为独立地被1、2或3个R 1a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；饱和3-10元杂环基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
R 2为卤素、取代或未取代的C 1-4烷基、取代或未取代的饱和或不饱和的C 3-10环烃基、取代或未取代的C 6-C 14芳基、取代或未取代的3-10元杂环基、取代或未取代的5-14元杂芳基、取代或未取代的3-10元杂环基-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烃基)-；其中所述取代的C 1-4烷基、取代的饱和或不饱和的C 3-10环烃基、取代的C 6-C 14芳基、取代的3-10元杂环基、取代的5-14元杂芳基、取代的3-10元杂环基-N(R 3)-、取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代的3-10元杂环基-O-、取代的3-10元杂环基-(C 1-C 4亚烷基)-O-和取代的N(R 3) 2-(C 1-C 4亚烷基)-O-为独立地被1、2或3个R 1c取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；3-10元杂环基为饱和或不饱和的3-10元杂环基，其中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
每个R 1a和R 1c独立地为F、Cl、Br、I、OH、N(R 3) 2、CN、COOH、CON(R 3) 2、SO 2N(R 3) 2、C 1-3烷基、C 3-12环烷基、C 1-3烷基-O-或C 3-12环烷基-O-，其中所述C 1-3烷基、C 3-12元环烷基、C 1-3烷基-O-和C 3-12元环烷基-O-任选被1、2或3个R 1b取代；
每个R 1b独立地为F、Cl、Br、I、OH或NH 2；
每个R 3独立地为氢、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1- 4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代；
L为-NH-、-N(C 1-C 3烷基)-，-O-或不存在(即连接键，R 1与M直接相连)；
X和Y各自独立地为N或C(R 4)；
M为C、CH或N；
Z 1、Z 2和Z 3各自独立地为连接键、N、N(R 4)、C(H)(R 4)、C(R 4)、-(C＝O)-或-(C＝S)-；且Z 1、Z 2和Z 3中至多一个为连接键；
R 4为氢、卤素、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1-4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代。
在某一方案中，如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物里，
Figure PCTCN2022131193-appb-000003
其中，
Figure PCTCN2022131193-appb-000004
表示单键或双键；
A为取代的5-14元杂芳基或取代的6-14元芳基；其中所述取代的5-14元杂芳基和取代的6-14元芳基为独立地被1、2或3个R a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
R a独立地为CN、F、Cl、Br、I或C 1-3烷基，且至少一个为CN；
R 1为氢、卤素、取代或未取代的(氨基)-(C 1-C 4亚烷基)-、取代或未取代的C 3-12环烷基、取代或未取代的3-10元杂环烷基、取代或未取代的C 6-C 14芳基或者取代或未取代的5-14元杂芳基，其中所述取代的(氨基)-(C 1-C 4亚烷基)-、取代的C 3-12环烷基、取代的3-10元杂环烷基、取代的C 6-C 14芳基和取代的5-14元杂芳基为独立地被1、2或3个R 1a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；饱和3-10元杂环基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
R 2为卤素、取代或未取代的C 1-4烷基、取代或未取代的饱和或不饱和的C 3-10环烃基、取代或未取代的C 6-C 14芳基、取代或未取代的3-10元杂环基、取代或未取代的5-14元杂芳基、取代或未取代的3-10元杂环基-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烃基)-；其中所述取代的C 1-4烷基、取代的饱和或不饱和的C 3-10环烃基、取代的C 6-C 14芳基、取代的3-10元杂环基、取代的5-14元杂芳基、取代的3-10元杂环基-N(R 3)-、取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代的3-10元杂环基-O-、取代的3-10元杂环基-(C 1-C 4亚烷基)-O-和取代的N(R 3) 2-(C 1-C 4亚烷基)-O-为独立地被1、2或3个R 1c取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；3-10元杂环基为饱和或不饱和的3-10元杂环基，其中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
每个R 1a和R 1c独立地为F、Cl、Br、I、OH、N(R 3) 2、CN、COOH、CON(R 3) 2、SO 2N(R 3) 2、C 1-3烷基、C 3-12环烷基、C 1-3烷基-O-或C 3-12环烷基-O-，其中所述C 1-3烷基、C 3-12元环烷基、C 1-3烷基-O-和C 3-12元环烷基-O-任选被1、2或3个R 1b取代；
每个R 1b独立地为F、Cl、Br、I、OH或NH 2；
每个R 3独立地为氢、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1- 4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代；
L为-NH-、-N(C 1-C 3烷基)-，-O-或不存在(即连接键，R 1与M直接相连)；
X和Y各自独立地为N或C(R 4)；
M为C、CH或N；
Z 1、Z 2和Z 3各自独立地为连接键、N、N(R 4)、C(H)(R 4)、C(R 4)或-(C＝O)-；且Z 1、Z 2和Z 3中至多一个为连接键；
R 4为氢、卤素、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1-4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代。
在某一方案中，如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物里，某些基团具有如下定义，未提及的基团的定义如本发明中任一方案所述(本段内容以下简称为“在某一方案中”)，
其中，所述的如式I所示的芳杂环类化合物为如下所示：
Figure PCTCN2022131193-appb-000005
式I-1又例如
Figure PCTCN2022131193-appb-000006
Figure PCTCN2022131193-appb-000007
还例如
Figure PCTCN2022131193-appb-000008
其中，
Figure PCTCN2022131193-appb-000009
R 1、R 2、L、X、Y、Z 1、Z 2和Z 3如本发明中任一方案所述；W 1和W 2各自独立地为N、C(H)或C(R a)；其中，R a可为F、Cl、Br、I或C 1-3烷基。
在某一方案中，A为取代的6-14元芳基、R 1为取代或未取代的C 6-C 14芳基、及R 2为取代或未取代的C 6-C 14芳基中，所述的C 6-C 14芳基独立地为苯基或萘基。
在某一方案中，A为取代的5-14元杂芳基、R 1为取代或未取代的5-14元杂芳基、及R 2为取代或未取代的5-14元杂芳基中，所述的5-14元杂芳基为5-10元杂芳基，杂原子选自N、O和S，杂原子的个数为1或2个；例如
Figure PCTCN2022131193-appb-000010
又例如
Figure PCTCN2022131193-appb-000011
Figure PCTCN2022131193-appb-000012
在某一方案中，R 1、R 2及R 4为卤素中，所述的卤素独立地为F、Cl、Br、I，例如Br。
在某一方案中，R 1为取代或未取代的(氨基)-(C 1-C 4亚烷基)-、及R 2为取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-或取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-O-中，所述的(C 1-C 4亚烷基)为-CH 2-、-CH 2CH 2-、-CH(CH 3)-、-CH(CH 3)CH 2-或-C(CH 3) 2-。
在某一方案中，R 1为取代或未取代的C 3-12环烷基、R 1a和R 1c独立地为C 3-12环烷基或C 3-12环烷基-O-、R 3为取代或未取代的C 3-12环烷基、及R 4为取代或未取代的C 3-12环烷基中，所述的C 3-12环烷基独立地为C 3-7单环的环烷基、C 4-12桥环或并环的环烷基、C 7-12螺环的环烷基；
所述的C 3-7单环的环烷基可为环丙基、环丁基、环戊基或环己基。
在某一方案中，R 1为取代或未取代的3-10元杂环烷基中，所述的3-10元杂环烷基独立地为C 3-7单环的杂环烷基、C 4-12桥环或并环的杂环烷基、C 7-12螺环的杂环烷基，其中的杂原子可选自N、O和S，杂原子的个数可为1或2个；
所述的C 3-7单环的杂环烷基可为吡咯烷基
Figure PCTCN2022131193-appb-000013
(例如
Figure PCTCN2022131193-appb-000014
)，哌啶基
Figure PCTCN2022131193-appb-000015
(例如
Figure PCTCN2022131193-appb-000016
)，哌嗪基
Figure PCTCN2022131193-appb-000017
(例如
Figure PCTCN2022131193-appb-000018
)，
Figure PCTCN2022131193-appb-000019
(例如
Figure PCTCN2022131193-appb-000020
)；
所述的C 4-12桥环或并环的杂环烷基可为
Figure PCTCN2022131193-appb-000021
(例如
Figure PCTCN2022131193-appb-000022
)，
Figure PCTCN2022131193-appb-000023
(例如
Figure PCTCN2022131193-appb-000024
还例如
Figure PCTCN2022131193-appb-000025
Figure PCTCN2022131193-appb-000026
又例如
Figure PCTCN2022131193-appb-000027
)，
Figure PCTCN2022131193-appb-000028
(例如
Figure PCTCN2022131193-appb-000029
)，
所述的C 7-12螺环的杂环烷基可为
Figure PCTCN2022131193-appb-000030
(例如
Figure PCTCN2022131193-appb-000031
)。
在某一方案中，R 2为取代或未取代的C 1-4烷基、R 3为取代或未取代的C 1-4烷基、及R 4为取代或未取代的C 1-4烷基中，所述的C 1-4烷基独立地为甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基或叔丁基。
在某一方案中，R 2为取代或未取代的饱和或不饱和的C 3-12环烃基中，所述的饱和C 3-12环烃基为C 3-12环烷基，例如环丙基、环丁基、环戊基或环己基。
在某一方案中，R 2为取代或未取代的3-10元杂环基、取代或未取代的3-10元杂环基-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-或取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-中，所述的3-10元杂环基独立地为3-10元杂环烷基时，所述的3-10元杂环烷基独立地为C 3-7单环的杂环烷基、C 4-12桥环或并环的杂环烷基、C 7-12螺环的杂环烷基，其中的杂原子可选自N、O和S，杂原子的个数可为1或2个；所述的C 3-7单环的杂环烷基可为吡咯烷基
Figure PCTCN2022131193-appb-000032
(例如
Figure PCTCN2022131193-appb-000033
)，哌啶基
Figure PCTCN2022131193-appb-000034
(例如
Figure PCTCN2022131193-appb-000035
)，哌嗪基
Figure PCTCN2022131193-appb-000036
(例如
Figure PCTCN2022131193-appb-000037
)，
Figure PCTCN2022131193-appb-000038
(例如
Figure PCTCN2022131193-appb-000039
)；
所述的C 4-12桥环或并环的杂环烷基可为
Figure PCTCN2022131193-appb-000040
(例如
Figure PCTCN2022131193-appb-000041
)，
Figure PCTCN2022131193-appb-000042
(例如
Figure PCTCN2022131193-appb-000043
还例如
Figure PCTCN2022131193-appb-000044
Figure PCTCN2022131193-appb-000045
又例如
Figure PCTCN2022131193-appb-000046
)，
Figure PCTCN2022131193-appb-000047
(例如
Figure PCTCN2022131193-appb-000048
)，
所述的C 7-12螺环的杂环烷基可为
Figure PCTCN2022131193-appb-000049
(例如
Figure PCTCN2022131193-appb-000050
)。
在某一方案中，R a独立地为C 1-3烷基、R 1a和R 1c独立地为C 1-3烷基或C 1-3烷基-O-、及L为-N(C 1-C 3烷基)-中，所述的C 1-3烷基独立地为甲基、乙基、正丙基或异丙基。
在某一方案中，A为
Figure PCTCN2022131193-appb-000051
W 1和W 2各自独立地为N、C(H)或C(R a)；
其中，R a可为F、Cl、Br、I或C 1-3烷基；
例如W 1为N、C-H或C-F；W 2为C-H。
在某一方案中，R a独立地为CN或F，且至少一个为CN。
在某一方案中，所述的R a中至少一个为CN，且位于
Figure PCTCN2022131193-appb-000052
的对位。
在某一方案中，R 1为卤素、取代或未取代的C 6-C 14芳基或者取代或未取代的5-14元杂芳基。
在某一方案中，R 2为取代或未取代的3-10元含N杂环基、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-。
在某一方案中，每个R 1a和R 1c独立地为F、Cl、OH、N(R 3) 2、CON(R 3) 2、SO 2N(R 3) 2、C 1-3烷基或C 1-3烷基-O-，其中所述C 1-3烷基和C 1-3烷基-O-任选被1、2或3个R 1b取代，例如被卤素取代。
在某一方案中，每个R 1b独立地为F或NH 2。
在某一方案中，R 3为氢或取代或未取代的C 1-4烷基，例如氢或C 1-4烷基；又例如氢或甲基。
在某一方案中，L为-NH-、-O-或不存在；例如不存在。
在某一方案中，X和Y各自独立地为N；即
Figure PCTCN2022131193-appb-000053
为
Figure PCTCN2022131193-appb-000054
在某一方案中，X和Y各自独立地为N或CH；例如
Figure PCTCN2022131193-appb-000055
为
Figure PCTCN2022131193-appb-000056
在某一方案中，Z 1、Z 2和Z 3各自独立地为N、C(H)(R 4)或C-R 4。
在某一方案中，Z 1、Z 2和Z 3各自独立地为N、N(R 4)、C(H)(R 4)、C-R 4或-(C＝O)-。在某一方案中，R 4为氢或卤素；例如H或F。
在某一方案中，R 4为氢、卤素或C 1-4烷基；例如H、F或甲基。
在某一方案中，R 1a和R 1c独立地为F、Cl、甲基、异丙基、甲基-O-、SO 2NH 2、CF 3-O-、CF 3-、OH-或CONH 2。
在某一方案中，R 1为
Figure PCTCN2022131193-appb-000057
Br、
Figure PCTCN2022131193-appb-000058
Figure PCTCN2022131193-appb-000059
例如，
Figure PCTCN2022131193-appb-000060
为
Figure PCTCN2022131193-appb-000061
Br、
Figure PCTCN2022131193-appb-000062
Figure PCTCN2022131193-appb-000063
Figure PCTCN2022131193-appb-000064
优选
Figure PCTCN2022131193-appb-000065
Figure PCTCN2022131193-appb-000066
更优选
Figure PCTCN2022131193-appb-000067
在某一方案中，R 1为
Figure PCTCN2022131193-appb-000068
Br、
Figure PCTCN2022131193-appb-000069
Figure PCTCN2022131193-appb-000070
Figure PCTCN2022131193-appb-000071
例如，
Figure PCTCN2022131193-appb-000072
为
Figure PCTCN2022131193-appb-000073
Br、
Figure PCTCN2022131193-appb-000074
Figure PCTCN2022131193-appb-000075
Figure PCTCN2022131193-appb-000076
优选
Figure PCTCN2022131193-appb-000077
Figure PCTCN2022131193-appb-000078
Figure PCTCN2022131193-appb-000079
Figure PCTCN2022131193-appb-000080
更优选
Figure PCTCN2022131193-appb-000081
Figure PCTCN2022131193-appb-000082
在某一方案中，A为
Figure PCTCN2022131193-appb-000083
例如
Figure PCTCN2022131193-appb-000084
优选
Figure PCTCN2022131193-appb-000085
在某一方案中，
Figure PCTCN2022131193-appb-000086
为
Figure PCTCN2022131193-appb-000087
例如
Figure PCTCN2022131193-appb-000088
Figure PCTCN2022131193-appb-000089
例如，
Figure PCTCN2022131193-appb-000090
为
Figure PCTCN2022131193-appb-000091
Figure PCTCN2022131193-appb-000092
在某一方案中，
Figure PCTCN2022131193-appb-000093
为
Figure PCTCN2022131193-appb-000094
例如
Figure PCTCN2022131193-appb-000095
Figure PCTCN2022131193-appb-000096
例如，
Figure PCTCN2022131193-appb-000097
为
Figure PCTCN2022131193-appb-000098
Figure PCTCN2022131193-appb-000099
在某一方案中，R 2为
Figure PCTCN2022131193-appb-000100
Figure PCTCN2022131193-appb-000101
Figure PCTCN2022131193-appb-000102
Figure PCTCN2022131193-appb-000103
例如
Figure PCTCN2022131193-appb-000104
Figure PCTCN2022131193-appb-000105
Figure PCTCN2022131193-appb-000106
优选
Figure PCTCN2022131193-appb-000107
在某一方案中，R 2为
Figure PCTCN2022131193-appb-000108
Figure PCTCN2022131193-appb-000109
Figure PCTCN2022131193-appb-000110
Figure PCTCN2022131193-appb-000111
例如
Figure PCTCN2022131193-appb-000112
Figure PCTCN2022131193-appb-000113
Figure PCTCN2022131193-appb-000114
优选
Figure PCTCN2022131193-appb-000115
Figure PCTCN2022131193-appb-000116
Figure PCTCN2022131193-appb-000117
在某一方案中，如式I所示的芳杂环类化合物或其药学上可接受的盐为如下结构化合物或其盐酸盐(表1)：
表1：
Figure PCTCN2022131193-appb-000118
Figure PCTCN2022131193-appb-000119
Figure PCTCN2022131193-appb-000120
Figure PCTCN2022131193-appb-000121
Figure PCTCN2022131193-appb-000122
Figure PCTCN2022131193-appb-000123
Figure PCTCN2022131193-appb-000124
Figure PCTCN2022131193-appb-000125
Figure PCTCN2022131193-appb-000126
本发明提供了一种药物组合物，其包含治疗有效量的物质A以及药学上可接受的载体(药用辅料)；所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
本发明还提供了一种物质A在制备LSD1抑制剂中的应用，所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。在所述的应用中，所述的LSD1抑制剂可用于哺乳动物生物体 内；也可用于生物体外，主要作为实验用途，例如：作为标准样或对照样提供比对，或按照本领域常规方法制成试剂盒，为抑制LSD1的效果提供快速检测。
本发明还提供了一种物质A在制备药物中的应用，所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种；所述的物质A为治疗有效量的；所述的药物用于治疗或预防LSD1介导的疾病。
本发明还提供了一种物质A在制备药物中的应用，所述的药物为用于治疗或预防癌症的药物；所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种；所述的物质A为治疗有效量的。
本发明还提供了一种抑制LSD1的方法，其包括向患者施用治疗有效量的物质A；所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
本发明还提供了一种治疗或预防LSD1介导的疾病的方法，其包括向患者施用治疗有效量的物质A；所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
本发明还提供了一种治疗或预防癌症的方法，其包括向患者施用治疗有效量的物质A；所述的物质A为如上所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
所述的LSD1介导的疾病可为癌症。
如上所述的癌症非限制性的选自膀胱癌、乳腺癌、前列腺癌、胰腺癌、甲状腺癌、肝癌、结肠癌、直肠癌、食道癌、宫颈癌、卵巢癌、急性白血病、急性淋巴细胞白血病、急性髓性白血病(单核细胞的、成髓细胞的、血管肉瘤、星形细胞瘤、髓单核细胞的和早幼粒细胞的)、急性T细胞白血病、软骨肉瘤、慢性淋巴细胞白血病、慢性髓细胞(粒细胞)白血病、大细胞淋巴瘤、纤维肉瘤、睾丸生殖细胞癌、神经胶质瘤、淋巴瘤(霍奇金型或非霍奇金型)、多发性骨髓瘤、淋巴癌、骨髓癌、成神经细胞瘤、神经母细胞瘤、非小细胞肺癌、小细胞肺癌中的一种或多种。
除前述以外，当用于本申请的说明书及权利要求书中时，除非另外特别指明，否则以下术语具有如下所示的含义。
本申请中，当带“*”的碳原子为手性碳原子时，其为R构型、S构型或其混合。
术语“多个”是指2个、3个、4个或5个。
术语“药学上可接受的盐”是指本发明化合物与相对无毒的、药学上可接受的酸或碱制备得到的盐。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括但不限于：锂盐、钠盐、钾盐、钙盐、铝盐、镁盐、锌盐、铋盐、铵盐、二乙醇胺盐。当本发明的化 合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的酸与这类化合物的中性形式接触的方式获得酸加成盐。所述的药学上可接受的酸包括无机酸、有机酸(例如三氟乙酸、盐酸)。具体可参见Berge et al.,"Pharmaceutical Salts",Journal of Pharmaceutical Science 66:1-19(1977)、或、Handbook of Pharmaceutical Salts:Properties,Selection,and Use(P.Heinrich Stahl and Camille G.Wermuth,ed.,Wiley-VCH,2002)。
如本文中所使用的，本发明式I所示的化合物可以含有一个或多个手性中心，并以不同的光学活性形式存在。当化合物含有一个手性中心时，化合物包含对映异构体。本发明包括这两种异构体和异构体的混合物，如外消旋混合物。对映异构体可以通过本专业已知的方法拆分，例如结晶以及手性色谱等方法。当式I化合物含有多于一个手性中心时，可以存在非对映异构体。本发明包括拆分过的光学纯的特定异构体以及非对映异构体的混合物。非对映异构体可由本专业已知方法拆分，比如结晶以及制备色谱。术语“立体异构体”包括构象异构体和构型异构体，其中构型异构体主要包括顺反异构体和旋光异构体。本发明所述化合物可以以立体异构体的形式存在，并因此涵盖所有可能的立体异构体形式，包括但不限于顺反异构体、对映异构体、非对映异构体、阻转异构体等，本发明所述化合物也可以以前述的立体异构体的任何组合或任何混合物，例如内消旋体、外消旋体、阻转异构体的等量混合物等形式存在。例如单一对映异构体，单一非对映异构体或以上的混合物，或单一阻转异构体或其混合物。当本发明所述的化合物含有烯烃双键时，除非特别说明，否则其包括顺式异构体和反式异构体，以及其任何组合。本发明的阻转异构体为基于分子内旋转受限制而产生的轴向或平面手性的立体异构体。有关本发明的阻转异构体，其中化合物具有式I的结构，或式I化合物具有由不对称碳等产生的异构体，它表示每种异构化合物中存在的一对阻转异构体中的任一种。且作为药物，具有优异活性的阻转异构体是优选的。这些立体异构体可以通过不对称合成方法或手性分离法(包括但不限于薄层色谱、旋转色谱、柱色谱、气相色谱、高压液相色谱等)分离、纯化及富集，还可以通过与其它手性化合物成键或成盐等方式进行手性拆分获得。术语“单一的立体异构体”是指本发明化合物的一种立体异构体相对于该化合物的所有立体异构体的质量含量不低于95％。式I化合物具有源于不对称碳、轴向不对称等的光学异构体，必要时单一异构体可通过本领域已知的方法，例如结晶或色谱法(例如手性色谱)等方法进行拆分获得。
如前所述，本发明提供了上述各类结构所示化合物，或其顺反异构体、内消旋体、外消旋体、对映异构体、非对映异构体、阻转异构体或其混合物形式，其中“其混合物形式”包括前述的任一立体异构体(例如顺反异构体、对映异构体、非对映异构体、阻转异构体)和/或混合物(内消旋体、外消旋体)之间的任意形式的混合，例如顺反异构体的混合物，对映异构体和非对映异构体的混合物，非对映异构体的混合物，阻转异构体的混合物，或顺反异构体和外消旋体的混合，对映异构体和非对映异构体混合物的混合，阻转异构体与非对映异构体混合物的混合等。
式I化合物、其立体异构体和其药学上可接受的盐意图涵盖式I化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物的任何同位素标记的(或“放射性标记的”)变体。这种变体是式I化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药 物、共结晶复合物、水合物或溶剂合物中一个或多个原子被原子质量或质量数不同于通常在自然界中所发现的原子质量或质量数的原子置换得到。所使用的放射性核素将取决于该放射性标记的变体的具体应用。举例来说，对于体外受体标记和竞争测定， 3H或 14C常常是有用的。对于放射成像应用， 11C或 18F常常是有用的。
本发明化合物的特定同位素变体，特别是其中已经结合一种或多种放射性同位素的同位素变体，可有益于例如考察作用机制或在体内的活性组分份分布；由于相对容易的可制备性和可检测性，标记有 3H或 14C同位素的化合物特别适用于此目的。另外，纳入同位素如氘，由于该化合物具有更好的代谢稳定性，例如延长体内的半衰期或降低所需的有效剂量，可产生特别的治疗益处；因此本发明化合物的这种修饰还可在一些情况下构成本发明的优选实施方案。本发明化合物的同位素变体可通过本领域技术人员已知的方法，例如通过以下描述的方法及操作实施例中描述的方法，通过使用相应的同位素修饰的特定试剂和/或起始化合物来制备。
在本申请中，“药物组合物”是指包含本发明化合物与本领域通常接受的用于将生物活性化合物输送至哺乳动物(例如人)的介质的制剂。该介质包括药学上可接受的载体。药物组合物的目的是促进生物体的给药，利于活性成分的吸收进而发挥生物活性。
在本申请中，“药学上可接受的”是指不影响本发明化合物的生物活性或性质的物质(如药用辅料)，并且相对无毒，即该物质可施用于个体而不造成不良的生物反应或以不良方式与组合物中包含的任意组分相互作用。
术语“药用辅料”或“药学上可接受的载体”是指生产药品和调配处方时使用的赋形剂和附加剂，是除活性成分以外，包含在药物制剂中的所有物质。可参见中华人民共和国药典(2015年版)四部、或、Handbook of Pharmaceutical Excipients(Raymond C Rowe,2009Sixth Edition)。辅料主要用于提供一个安全、稳定和功能性的药物组合物，还可以提供方法，使受试者接受给药后活性成分以所期望速率溶出，或促进受试者接受组合物给药后活性成分得到有效吸收。所述的药用辅料可以是惰性填充剂，或者提供某种功能，例如稳定该组合物的整体pH值或防止组合物活性成分的降解。所述的药用辅料可以包括下列辅料中的一种或多种：粘合剂、助悬剂、乳化剂、稀释剂、填充剂、成粒剂、胶粘剂、崩解剂、润滑剂、抗粘着剂、助流剂、润湿剂、胶凝剂、吸收延迟剂、溶解抑制剂、增强剂、吸附剂、缓冲剂、螯合剂、防腐剂、着色剂、矫味剂和甜味剂。
本发明的药物组合物可根据公开的内容使用本领域技术人员已知的任何方法来制备。例如，常规混合、溶解、造粒、乳化、磨细、包封、包埋或冻干工艺。
当用作药物时，所述的如式I所示的化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物可以以药物组合物的任何形式给药。这些组合物可根据药学领域熟知的方法制备，可以各种途径施用，视需要局部或系统性治疗和要治疗的区域而定。给予可以是局部(包括表皮和透皮，眼部和粘膜，包括鼻内，阴道和直肠递送)，肺(例如，通过粉末或气溶胶吸入或吹入，包括通过喷雾器；气管内或鼻内)，口服(固体和液体制剂)或胃肠外给予形式。固体口服制剂的实例包括但不限于粉末、胶囊、囊片、软胶囊剂和片剂。口服或粘膜给药的液体制剂实 例包括但不限于悬浮液、乳液、酏剂和溶液。局部用制剂的实例包括但不限于乳剂、凝胶剂、软膏剂、乳膏剂、贴剂、糊剂、泡沫剂、洗剂、滴剂或血清制剂。胃肠外给药的制剂实例包括但不限于注射用溶液、可以溶解或悬浮在药学上可接受载体中的干制剂、注射用悬浮液和注射用乳剂。外用给药的药物组合物和制剂可包括透皮贴片、油膏剂、乳液、软膏剂、凝胶、滴剂、栓剂、喷剂、液体和粉末。所述的药物组合物的其它合适制剂的实例包括但不限于滴眼液和其他眼科制剂；气雾剂：如鼻腔喷雾剂或吸入剂。口服给药可以包括配制为每日一次或每日两次(BID)给药的剂型。胃肠外给药包括静脉内、动脉内、皮下、腹膜内肌肉内或注射或输液；或颅内如鞘内或心室内给药。胃肠外给药可以单次推注剂量形式，或可以是通过连续灌注泵。常规药学载体、水、粉末或油状基底、增稠剂等可能是必须或需要的。包括本发明的药物组合物还可以是控释或延迟释放剂型(例如脂质体或微球)。
术语“治疗”指治疗性疗法或缓解性措施。涉及具体病症时，治疗指：(1)缓解疾病或者病症的一种或多种生物学表现，(2)干扰(a)导致或引起病症的生物级联中的一个或多个点或(b)病症的一种或多种生物学表现，(3)改善与病症相关的一种或多种症状、影响或副作用，或者与病症或其治疗相关的一种或多种症状、影响或副作用，或(4)减缓病症或者病症的一种或多种生物学表现发展。“治疗”也可以指与不接受治疗的期望存活相比延长生存期。
术语“预防”是指获得或发生疾病或障碍的风险降低。
术语“治疗有效量”是指在给予患者时足以有效治疗本文所述的疾病或病症的化合物的量。“治疗有效量”将根据化合物、病症及其严重度、以及欲治疗患者的年龄而变化，但可由本领域技术人员根据需要进行调整。
术语“患者”是指根据本发明的实施例，即将或已经接受了该化合物或组合物给药的任何动物，哺乳动物为优，人类最优。术语“哺乳动物”包括任何哺乳动物。哺乳动物的实例包括但不限于牛、马、羊、猪、猫、狗、小鼠、大鼠、家兔、豚鼠、猴、人等，以人类为最优。
除非另外说明，应当应用本文所使用的下列定义。出于本发明的目的，化学元素与元素周期表CAS版，和《化学和物理手册》，第75版，1994一致。此外，有机化学一般原理可参考"Organic Chemistry",Thomas Sorrell,University Science Books,Sausalito:1999,和"March's Advanced Organic Chemistry”by Michael B.Smith and Jerry March,John Wiley&Sons,New York:2007中的描述，其全部内容通过引用并入本文。
在本说明书中，可由本领域技术人员选择基团及其取代基以提供稳定的结构部分和化合物。当通过从左向右书写的常规化学式描述取代基时，该取代基也同样包括从右向左书写结构式时所得到的在化学上等同的取代基。
在本文中定义的某些化学基团前面通过简化符号来表示该基团中存在的碳原子总数。例如，C 1-C 6烷基是指具有总共1、2、3、4、5或6个碳原子的如下文所定义的烷基。简化符号中的碳原子总数不包括可能存在于所述基团的取代基中的碳。
在本文中，取代基中定义的数值范围如0至4、1-4、1至3等表明该范围内的整数，如1-6为1、2、3、4、5、6。
除前述以外，当用于本申请的说明书及权利要求书中时，除非另外特别指明，否则以下术语具有如下所示的含义。
术语“包括”为开放式表达，即包括本发明所指明的内容，但并不排除其他方面的内容。
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，只要特定原子的价态是正常的并且取代后的化合物是稳定的。
一般而言，术语“取代的”表示所给结构中的一个或多个氢原子被具体取代基所取代。进一步地，当该基团被1个以上所述取代基取代时，所述取代基之间是相互独立，即，所述的1个以上的取代基可以是互不相同的，也可以是相同的。除非其他方面表明，一个取代基团可以在被取代基团的各个可取代的位置进行取代。当所给出的结构式中不只一个位置能被选自具体基团的一个或多个取代基所取代，那么取代基可以相同或不同地在各个位置取代。
在本说明书的各部分，本发明公开化合物的取代基按照基团种类或范围公开。特别指出，本发明包括这些基团种类和范围的各个成员的每一个独立的次级组合。术语“C x-C y烷基"是指含有x至y个碳原子的直链或支链饱和烃。例如，术语“C 1～C 6烷基”或“C 1- 6烷基”特别指独立公开的甲基、乙基、C 3烷基、C 4烷基、C 5烷基和C 6烷基；“C 1- 4烷基”特指独立公开的甲基、乙基、C 3烷基(即丙基，包括正丙基和异丙基)、C 4烷基(即丁基，包括正丁基、异丁基、仲丁基和叔丁基)。
本文所用术语“部分”、“结构部分”、“化学部分”、“基团”、“化学基团”是指分子中的特定片段或官能团。化学部分通常被认为是嵌入或附加到分子上的化学实体。
当所列举的取代基中没有指明其通过哪一个原子连接到化学结构通式(包括但未具体提及的化合物)中时，这种取代基可以通过其任何原子相键合。取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当任意变量(例如R 1a)在化合物的定义中多次出现时，该变量每一位置出现的定义与其余位置出现的定义无关，它们的含义互相独立、互不影响。因此，若某基团被1个、2个或3个R 1a基团取代，也就是说，该基团可能会被最多3个R 1a取代，该位置R 1a的定义与其余位置R 1a的定义是互相独立的。另外，取代基及/或变量的组合只有在该组合产生稳定的化合物时才被允许。
当所列举的基团中没有明确指明其具有取代基时，这种基团仅指未被取代。例如当“C 1-C 4烷基”前没有“取代或未取代的”的限定时，仅指“C 1-C 4烷基”本身或“未取代的C 1-C 4烷基”。
在本发明的各部分，描述了连接取代基。当该结构清楚地需要连接基团时，针对该基团所列举的马库什变量应理解为连接基团。例如，如果该结构需要连接基团并且针对该变量的马库什基团定义列举了“烷基”，则应该理解，该“烷基”代表连接的亚烷基基团。
在一些具体的结构中，当烷基基团清楚地表示为连接基团时，则该烷基基团代表连接的亚烷基基团，例如，基团“卤代-C 1-C 6烷基”中的C 1-C 6烷基应当理解为C 1-C 6亚烷基。
术语“卤素”是指氟、氯、溴或碘，尤其指F或Cl。
在本申请中，作为基团或是其它基团的一部分(例如用在卤代烃基等基团中)，术语“烃基”是指包括具有指定碳原子数目的支链和直链的饱和或不饱和脂族烃基，仅由碳原子和氢原子组成，且通过单 键与分子的其余部分连接。例如“烷基”、“烯基”或“炔基”。
在本申请中，作为基团或是其它基团的一部分(例如用在卤代烷基等基团中)，术语“烷基”是指包括具有指定碳原子数目的支链和直链的饱和脂族烃基，仅由碳原子和氢原子组成，且通过单键与分子的其余部分连接。例如具有1至10个(优选1至6个，更优选1至4个)碳原子。其中，丙基为C 3烷基(包括同分异构体，例如正丙基或异丙基)；丁基为C 4烷基(包括同分异构体，例如正丁基、仲丁基、异丁基或叔丁基)；戊基为C 5烷基(包括同分异构体，例如正戊基、1-甲基-丁基、1-乙基-丙基、2-甲基-1-丁基、3-甲基-1-丁基、异戊基、叔戊基或新戊基)；己基为C 6烷基(包括同分异构体，例如正己基、1-乙基-2-甲基丙基、1，1，2-三甲基丙基、1，1-二甲基丁基、1，2-二甲基丁基、2，2-二甲基丁基、1，3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2，3-二甲基丁基)。例如包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、2-甲基丁基、2,2-二甲基丙基、正己基、正庚基、2-甲基己基、3-甲基己基、正辛基、壬基和癸基等其类似烷基。
在本申请中，作为基团或是其它基团的一部分，术语“亚烷基”表示从饱和的直链或支链烃基中去掉两个氢原子所得到的饱和的二价烃基基团；即烷基中的一个氢被取代，烷基的定义如上所述。亚烷基基团的实例包括亚甲基(-CH 2-)，亚乙基{包括-CH 2CH 2-或-CH(CH 3)-}，亚异丙基{包括-CH(CH 3)CH 2-或-C(CH 3) 2-}等等。
在本申请中，作为基团或是其它基团的一部分，术语“烯基”是指具有至少一个双键的直链或支链的烃链基，仅由碳原子和氢原子组成、具有例如2至12个(优选2至8个，更优选2至6个，最优选2至4个)碳原子，且通过单键与分子的其余部分连接，例如包括但不限于乙烯基、正丙烯基、异丙烯基、正丁烯基、异丁烯基、仲丁烯基、叔丁烯基、正戊烯基、2-甲基丁烯基、2,2-二甲基丙烯基、正己烯基、庚烯基、2-甲基己烯基、3-甲基己烯基、辛烯基、壬烯基和癸烯基等。
在本申请中，作为基团或是其它基团的一部分，术语“炔基”是指具有至少一个三键的直链或支链的烃链基，仅由碳原子和氢原子组成、具有例如2至12个(优选2至8个，更优选2至6个，最优选2至4个)碳原子，且通过单键与分子的其余部分连接，例如包括但不限于乙炔基、正丙炔基、异丙炔基、正丁炔基、异丁炔基、仲丁炔基、叔丁炔基、正戊炔基、2-甲基丁炔基、2,2-二甲基丙炔基、正己炔基、庚炔基、2-甲基己炔基、3-甲基己炔基、辛炔基、壬炔基和癸炔基等。
在本申请中，作为基团或是其它基团的一部分，术语“环烃基”意指饱和或不饱和(非芳香性)的单环或多环(例如双环、三环或更多环的桥环、并环(稠环)或螺环体系)的碳环取代基，且其可经由任何适宜的碳原子通过单键与分子的其余部分连接。例如具有3至12个碳原子的3-12元环烃基，又例如3-12元环烷基或环烯基，还例如C 3-7单环的环烃基、C 4-12桥环或并环的环烃基、C 7-12螺环的环烃基。在一些实施例中，优选具有3至10个碳原子的3-10元环烃基，又例如具有3至10个碳原子的3-10元环烷基，优选具有3至6个碳原子的3-6元环烷基；或具有3至10个碳原子的3-10元环烯基，优选具有3至6个碳原子的3-6元环烯基。在某一方案中，典型的单环环烷基，如环丙基、环丁基、环戊基、环己基或环庚基。在一些实施例中，“环烯基”是具有5至6个环原子的单环的，不饱和的碳环 烯基基团(“5-6元环烯基”)。该术语包括但不限于环戊烯基(例如
Figure PCTCN2022131193-appb-000127
)、环戊二烯基(例如
Figure PCTCN2022131193-appb-000128
)、环己烯基(例如
Figure PCTCN2022131193-appb-000129
)或环己二烯基，以及其立体异构体。
在本申请中，作为基团或是其它基团的一部分，术语“杂环基”意指具有由碳原子以及1个或多个选自O、S、N的杂原子或杂原子团(例如C(＝O)、S(＝O)、S(＝O) 2)组成的稳定的、饱和或不饱和(非芳香性)的单环或多环(例如双环、三环或更多环的桥环、并环(稠环)或螺环体系)的杂环烃基，且其可经由任何适宜的碳原子通过单键与分子的其余部分连接。例如具有2至9个碳原子的3-10元杂环基，优选具有3至5个碳原子的3-6元杂环基，又例如具有2至9个碳原子的3-10元杂环烷基，优选具有3至5个碳原子的3-6元杂环烷基，或具有2至9个碳原子的3-10元杂环烯基，优选具有3至5个碳原子的3-6元杂环烯基。杂环基二环的环系统可以在一个或两个环中包括一个或多个杂原子；并且是饱和或不饱和的。杂环基可以经由碳原子并通过单键与分子其余部分连接；在包含一个或多个氮原子的杂环基中，连接点可以是碳或氮原子；或者，与分子其余部分并环连接；只要化合价许可。在一些实施例中，“杂环烷基”是5至7元单环的杂环烷基、6至8元并环连接的杂环烷基、6至8元桥环连接的杂环烷基或7至10元螺环连接的杂环烷基。示例性3-元杂环烷基基团包括但不限于，氮杂环丙基、环氧乙烷基以及硫杂环丙烷基，或者其立体异构体；示例性4-元杂环烷基基团包括但不限于，氮杂环丁烷基，环氧丙烷基，硫杂环丁烷基，或者其同分异构体和立体异构体；示例性5-元杂环烷基基团包括但不限于，四氢呋喃基，四氢噻吩基，吡咯烷基
Figure PCTCN2022131193-appb-000130
(例如
Figure PCTCN2022131193-appb-000131
又例如
Figure PCTCN2022131193-appb-000132
)，噻唑烷基，异噻唑烷基，噁唑烷基，异噁唑烷基，咪唑烷基，吡唑烷基，二氧戊环基，氧杂硫呋喃基，二硫呋喃基，或者其同分异构体和立体异构体。示例性6-元杂环烷基基团包括但不限于，哌啶基
Figure PCTCN2022131193-appb-000133
(例如
Figure PCTCN2022131193-appb-000134
)，四氢吡喃基，硫化环戊烷基，吗啉基，硫代吗啉基，二噻烷基，二噁烷基，哌嗪基
Figure PCTCN2022131193-appb-000135
(例如
Figure PCTCN2022131193-appb-000136
)，三嗪烷基，
Figure PCTCN2022131193-appb-000137
(例如
Figure PCTCN2022131193-appb-000138
)，或者其同分异构体和立体异构体。示例性7-元杂环烷基基团包括但不限于，
Figure PCTCN2022131193-appb-000139
(例如
Figure PCTCN2022131193-appb-000140
)、
Figure PCTCN2022131193-appb-000141
(例如
Figure PCTCN2022131193-appb-000142
)、
Figure PCTCN2022131193-appb-000143
(例如
Figure PCTCN2022131193-appb-000144
)、
Figure PCTCN2022131193-appb-000145
(例如
Figure PCTCN2022131193-appb-000146
还例如
Figure PCTCN2022131193-appb-000147
又例如
Figure PCTCN2022131193-appb-000148
)或
Figure PCTCN2022131193-appb-000149
(例如
Figure PCTCN2022131193-appb-000150
还例如
Figure PCTCN2022131193-appb-000151
又例如
Figure PCTCN2022131193-appb-000152
)，或者其同分异构体和立体异构体。示例性8-元杂环烷基基团包括但不限于，
Figure PCTCN2022131193-appb-000153
(例如
Figure PCTCN2022131193-appb-000154
)、
Figure PCTCN2022131193-appb-000155
(例如
Figure PCTCN2022131193-appb-000156
)、
Figure PCTCN2022131193-appb-000157
(例如
Figure PCTCN2022131193-appb-000158
又例如
Figure PCTCN2022131193-appb-000159
)、
Figure PCTCN2022131193-appb-000160
(例如
Figure PCTCN2022131193-appb-000161
还例如
Figure PCTCN2022131193-appb-000162
又例如
Figure PCTCN2022131193-appb-000163
)或
Figure PCTCN2022131193-appb-000164
(例如
Figure PCTCN2022131193-appb-000165
还例如
Figure PCTCN2022131193-appb-000166
又例如
Figure PCTCN2022131193-appb-000167
)，或者其同分异构体和立体异构体。示例性9-元杂环烷基基团包括但不限于，
Figure PCTCN2022131193-appb-000168
(例如
Figure PCTCN2022131193-appb-000169
)或
Figure PCTCN2022131193-appb-000170
(例如
Figure PCTCN2022131193-appb-000171
)，
Figure PCTCN2022131193-appb-000172
(例如
Figure PCTCN2022131193-appb-000173
)或者其同分异构体和立体异构体。示例性10-元杂环烷基基团包括但不限于，
Figure PCTCN2022131193-appb-000174
(例如
Figure PCTCN2022131193-appb-000175
)或
Figure PCTCN2022131193-appb-000176
(例如
Figure PCTCN2022131193-appb-000177
)，或者其同分异构体和立体异构体。(“*”表示带“*”的碳原子为手性碳原子时，其为R构型、S构型或其混合)。在一些实施例中，“杂环烯基”是5至7元单环的杂环烯基、6至8元并环连接的杂环烯基、6至8元桥环连接的杂环烯基或7至10元螺环连接的杂环烯基。杂环烯基的实例包括但不限于吡喃基、2,3-二氢吡咯基、2,3-二氢呋喃基、1,2,3,4-四氢吡啶基、1,2,3,6-四氢吡啶基、3,4-二氢-2H-吡喃、
Figure PCTCN2022131193-appb-000178
例如
Figure PCTCN2022131193-appb-000179
还例如
Figure PCTCN2022131193-appb-000180
又例如
Figure PCTCN2022131193-appb-000181
“*”表示带“*”的碳原子为手性碳原子时，其为R构型、S构型或其混合。
在本申请中，作为基团或是其它基团的一部分，术语“芳基”意指满足4n+2规则的共轭烃环体系基团。例如具有6至20个碳原子(优选具有6至10个碳原子)的满足4n+2规则的共轭烃环体系基团。就本发明的目的而言，芳基可以为单环、双环、三环或更多环的环体系，还可以与上文所定义的环烷基、环烯基、杂环烷基或杂环烯基稠合，条件是芳基经由芳香环上的原子通过单键与分子的其余部分连接。在某一方案中，术语“芳基”是指由碳原子组成的芳香基团，每个环均具有芳香性。芳基的实例包括但不限于苯基、萘基(例如
Figure PCTCN2022131193-appb-000182
)。
在本申请中，作为基团或是其它基团的一部分，术语“杂芳基”意指环内具有碳原子和至少一个选自O、S、N的杂原子的共轭环系基团。例如环内具有1至13个碳原子(优选具有2至9个碳原子)和1至6个杂原子选自O、N和S的5至14元共轭环系基团。除非本说明书中另外特别指明，否则杂芳基可为单环、双环、三环或更多环的环体系，还可以与上文所定义的环烷基、环烯基、杂环烷基或杂环烯基稠合，条件是杂芳基经由芳香环上的原子通过单键与分子的其余部分连接。就本发明的目的而言，杂芳基优选包含1至5个选自氮、氧和硫的杂原子的稳定的5至14元芳香性基团，进一步优选包含1至5个选自氮、氧和硫的杂原子的稳定的5至10元芳香性基团。在某一方案中，术语“杂芳基”是指含有杂原子的芳香基团，每个环均具有芳香性；优选含有1个、2个或3个独立选自氮、氧和硫的杂原子的芳族5-6元单环或9-10元双环。杂芳基的实例包括但不限于噻吩基、咪唑基、吡唑基、噻唑基、噁唑基、二唑基、噁二唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、苯并咪唑基、苯并吡唑基、吲哚基、呋喃基、吡咯基、三唑基、四唑基、三嗪基、吲嗪基、异唑基、噻二唑基、异吲哚基、吲唑基、异吲唑基、嘌呤基、喹啉基、异喹啉基、二氮萘基、萘啶基、喹噁啉基、蝶啶基、咔唑基、咔啉基、菲啶基、菲咯啉基、吖啶基、吩嗪基、异噻唑基、苯并噻唑基、苯并异噻唑基、苯并噻吩基、噁三唑基、噌啉基、喹唑啉基、中氮茚基、邻二氮杂菲基、异噁唑基、吩噁嗪基、吩噻嗪基、苯并恶唑基或苯并异唑基。
应该理解，在本发明中使用的单数形式，如“一种”，包括复数指代，除非另有规定。
术语“一种(个)或多种(个)”或“一种(个)或两种(个)以上”是指即1、2、3、4、5、6、7、8、9或更多。
除非另有说明，本发明采用质谱、元素分析的传统方法，各步骤和条件可参照本领域常规的操作步骤和条件。
除非另有指明，本发明采用分析化学、有机合成化学和光学的标准命名及标准实验室步骤和技术。在某些情况下，标准技术被用于化学合成、化学分析、发光器件性能检测。
另外，需要说明的是，除非以其他方式明确指出，在本发明中所采用的描述方式“…独立地为”应做广义理解，是指所描述的各个个体之间是相互独立的，可以独立地为相同或不同的具体基团。更详 细地，描述方式“…独立地为”既可以是指在不同基团中，相同符号之间所表达的具体选项之间互相不影响；也可以表示在相同的基团中，相同符号之间所表达的具体选项之间互相不影响。
本领域技术人员可以理解，根据本领域中使用的惯例，本申请描述基团的结构式中所使用的
Figure PCTCN2022131193-appb-000183
及
Figure PCTCN2022131193-appb-000184
是指，相应的基团R通过该位点与化合物中的其它片段、基团进行连接。
本领域技术人员可以理解，根据本领域中使用的惯例，本申请描述基团的结构式中所使用的
Figure PCTCN2022131193-appb-000185
表示单键或双键。
除非另有规定，本文使用的所有技术术语和科学术语具有要求保护主题所属领域的标准含义。倘若对于某术语存在多个定义，则以本文定义为准。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：作为具有新型结构骨架的可逆LSD1抑制剂，本发明的化合物对LSD1具有显著的抑制活性。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
本发明中，室温指环境温度，为10℃-35℃。过夜是指8-15小时。回流是指常压下溶剂回流温度。
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d 6)、氘代氯仿(CDCl 3)、氘代甲醇(CD 3OD)，内标为四甲基硅烷(TMS)。MS的测定用Finnigan LCQ/Deca(ESI)质谱仪。高效液相色谱法(HPLC)分析使用Gilson-215高压液相色谱仪。
薄层层析硅胶板使用烟台黄海HSGF 254或青岛GF 254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm-0.2mm，薄层层析分离纯化产品采用的规格是0.4mm-0.5mm。硅胶柱色谱法一般使用烟台黄海硅胶200-300目硅胶为载体。
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自上海皓鸿生物医药科技有限公司、毕得医药等公司。实施例中无特殊说明，反应均能够在氩气氛或氮气氛下进行。
实施例中的反应进程的监测采用薄层色谱法(TLC)，反应所使用的展开剂，纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括二氯甲烷/甲醇体系和石油醚/乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
实施例1
4-(2-(4-氨基哌啶-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)-2-氟苯甲腈1的制备
Figure PCTCN2022131193-appb-000186
第一步
4-(6-溴-2-氯喹唑啉-4-基)-2-氟苯甲腈1b
向化合物6-溴-2,4-二氯喹唑啉1a(4.0g，11.03mmol，上海皓鸿生物医药科技有限公司)、双(三苯基膦)氯化钯(Ⅱ)(0.77g，1.10mmol)、碳酸钠水溶液(2.0M，5mL)与乙腈(40mL)的混合物中添加(4-氰基-3-氟苯基)硼酸(1.82g，11.03mmol上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在100℃下加热15分钟。冷却，反应液减压浓缩。乙酸乙酯打浆，过滤，干燥。得到标题化合物1b(3.74g)(白色固体),产率：72％。
1H NMR(400MHz,DMSO-d 6)δ8.28(dd,J＝9.0,2.1Hz,1H),8.23–8.17(m,2H),8.05(d,J＝9.0Hz,1H),7.97(d,J＝9.8Hz,1H),7.80(d,J＝8.0Hz,1H).
第二步
(1-(6-溴-4-(4-氰基-3-氟苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯1c
将化合物4-(6-溴-2-氯喹唑啉-4-基)-2-氟苯甲腈1b(2.0g，5.5mmol)、二异丙基乙胺(1.82mL，11mmol)和哌啶-4-基氨基甲酸叔丁酯(1.65g，8.25mmol毕得医药)溶于N,N-二甲基甲酰胺(20ml)。反应混合物在室温下搅拌过夜。反应液减压浓缩，加入50mL水和50mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(20mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物1c(2.48g)(黄色固体)，产率：85％。 1H NMR(400MHz,Chloroform-d)δ7.81(dd,J＝8.1,6.3Hz,1H),7.75(d,J＝2.2Hz,1H),7.70(dd,J＝9.0,2.2Hz,1H),7.61–7.55(m,2H),7.51(d,J＝9.0Hz,1H),4.84(dt,J＝13.6,3.9Hz,2H),4.52(d,J＝7.9Hz,1H),3.76(s,1H),3.14(t,J＝12.5Hz,2H),2.07(dd,J＝13.1,3.7Hz,2H),1.45(s,9H),1.39(qd,J＝11.8,5.4Hz,2H).
MS m/z(ESI):526.01[M+l] +.
第三步
(1-(4-(4-氰基-3-氟苯基)-6-(3-氟-4-甲氧基苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯1d
向化合物(1-(6-溴-4-(4-氰基-3-氟苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯1c(50mg，0.09mmol)，[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(7.3mg，0.009mol)，碳酸钠(28.6mg，0.27mmol)和四氢呋喃/水(5:1)(2mL)的混合物中加入(3-氟-4-甲氧基苯基)硼酸(30.6mg， 0.18mmol上海皓鸿生物医药科技有限公司)。氮气保护，将反应混合物在70℃下搅拌16h。冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:8至1:4)纯化，得到标题化合物1d(42mg)，黄色固体，产率：77％。 1H NMR(400MHz,Chloroform-d)δ7.87(dd,J＝8.8,2.1Hz,1H),7.82(dd,J＝8.1,6.3Hz,1H),7.74–7.68(m,2H),7.68–7.59(m,2H),7.30–7.22(m,2H),7.02(t,J＝8.8Hz,1H),4.88(d,J＝13.4Hz,2H),4.52(d,J＝7.9Hz,1H),3.92(s,3H),3.77(s,1H),3.16(t,J＝12.4Hz,2H),2.09(dd,J＝12.9,3.8Hz,2H),1.46(s,9H),1.39(qd,J＝11.7,4.0Hz,2H).
MS m/z(ESI):571.15[M+l] +.
第四步
4-(2-(4-氨基哌啶-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)-2-氟苯甲腈1
将化合物(1-(4-(4-氰基-3-氟苯基)-6-(3-氟-4-甲氧基苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯1d(42mg)溶于2mL二氯甲烷中，加入2mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌2小时。反应液减压浓缩，得到标题化合物1的盐酸盐(30mg)，黄色固体，产率：88％。 1H NMR(400MHz,DMSO-d 6)δ8.21–8.13(m,2H),8.00(d,J＝9.7Hz,2H),7.84(dd,J＝10.2,1.9Hz,2H),7.59(dd,J＝12.9,2.2Hz,1H),7.47(dd,J＝8.5,2.2Hz,1H),7.23(t,J＝8.8Hz,1H),4.93(d,J＝13.3Hz,2H),3.46–3.34(m,1H),3.24(t,J＝13.0Hz,2H),2.11(d,J＝12.1Hz,2H),1.64(q,J＝12.2Hz,2H).
实施例2
4-(2-(4-氨基哌啶-1-基)-6-溴-喹唑啉-4-基)-2-氟苯甲腈2
采用实施例1的合成路线中第二步产物1c为原料，方法与实施例中的第四步反应类似，得标题化合物2盐酸盐(20mg)。MS m/z(ESI):426.05[M+l] +.
实施例3
4-(2-(4-氨基哌啶-1-基)-6-(3,5-二甲基异恶唑-4-基)喹唑啉-4-基)-2-氟苯甲腈3
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为((3,5-二甲基异恶唑-4-基)硼酸制得标题化合物3的盐酸盐(29mg)。 1H NMR(400MHz,DMSO-d 6)δ8.16(t,J＝7.3Hz,1H),8.00–7.93(m,1H),7.88(dd,J＝8.7,1.9Hz,1H),7.84–7.78(m,2H),7.65(d,J＝1.8Hz,1H),4.20(d,J＝5.2Hz,4H),3.26–3.18(m,4H),2.40(s,3H),2.21(s,3H).
实施例4
4-(2-(4-氨基哌啶-1-基)-6-(5-甲基-1H-吡唑-4-基)喹唑啉-4-基)-2-氟苯甲腈4
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为(5-甲基-1H-吡唑-4-基)硼酸制得标题化合物4的盐酸盐(31mg)。 1H NMR(400MHz,DMSO-d 6)δ8.17(t,J＝7.3Hz,1H),8.07(s,1H),8.01(t,J＝8.7Hz,2H),7.90(d,J＝8.8Hz,1H),7.84(d,J＝7.9Hz,1H),7.71(s,1H),4.91(d, J＝13.2Hz,2H),3.44–3.32(m,1H),3.19(t,J＝12.6Hz,2H),2.37(s,3H),2.09(d,J＝12.2Hz,2H),1.69–1.55(m,2H).
实施例5
3-(2-(4-氨基哌啶-1-基)-4-(4-氰基-3-氟苯基)喹唑啉-6-基)苯磺酰胺5
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-(氨基磺酰基)苯硼酸制得标题化合物5的盐酸盐(28mg)。MS m/z(ESI):503.16[M+l] +.
实施例6
4-(2-(4-氨基哌啶-1-基)-6-(邻甲苯基)喹唑啉-4-基)-2-氟苯甲腈6
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为邻甲基苯硼酸制得标题化合物4的盐酸盐(26mg)。 1H NMR(400MHz,DMSO-d 6)δ8.14(t,J＝7.2Hz,1H),8.07(d,J＝8.6Hz,1H),7.95(d,J＝9.7Hz,1H),7.92–7.89(m,1H),7.79(d,J＝7.8Hz,1H),7.60(d,J＝1.7Hz,1H),7.32–7.21(m,4H),4.95(d,J＝13.1Hz,2H),3.43–3.39(m,1H),3.28(t,J＝12.8Hz,2H),2.22(s,3H),2.12(d,J＝12.2Hz,2H),1.66(d,J＝11.9Hz,2H).
实施例7
4-(2-(4-氨基哌啶-1-基)-6-(2-异丙基苯基)喹唑啉-4-基)-2-氟苯甲腈7
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-异丙基苯硼酸制得标题化合物7的盐酸盐(26mg)。 1H NMR(400MHz,DMSO-d 6)δ8.12(t,J＝6.9Hz,1H),8.00(d,J＝7.7Hz,1H),7.94(d,J＝9.6Hz,1H),7.79(t,J＝8.2Hz,2H),7.52(s,1H),7.41(d,J＝7.5Hz,1H),7.34(t,J＝7.0Hz,1H),7.19(q,J＝7.9Hz,2H),4.93(d,J＝12.5Hz,2H),3.43–3.34(m,1H),3.22(d,J＝12.5Hz,2H),3.06–2.88(m,1H),2.11(d,J＝11.9Hz,2H),1.64(t,J＝11.8Hz,2H),1.08(d,J＝6.4Hz,6H).
实施例8
4-(2-(4-氨基哌啶-1-基)-6-(间甲苯基)喹唑啉-4-基)-2-氟苯甲腈8
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-甲基苯硼酸制得标题化合物8的盐酸盐(16mg)。 1H NMR(400MHz,DMSO-d 6)δ8.21–8.12(m,2H),8.01(d,J＝9.8Hz,1H),7.93–7.81(m,3H),7.49–7.41(m,2H),7.34(t,J＝7.5Hz,1H),7.18(d,J＝7.3Hz,1H),4.91(d,J＝13.2Hz,2H),3.40–3.36(m,1H),3.19(t,J＝12.6Hz,2H),2.35(s,3H),2.09(d,J＝12.1Hz,2H),1.61(q,J＝12.4,11.2Hz,2H).
实施例9
4-(2-(4-氨基哌啶-1-基)-6-(1-甲基-1H-吲唑-5-基)喹唑啉-4-基)-2-氟苯甲腈9
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为1-甲基引唑-5-硼酸制得标题化合物9的盐酸盐(26mg)。 1H NMR(400MHz,Methanol-d 4)δ8.40(d,J＝8.5Hz,1H),8.15–8.03(m,5H),7.91(d,J＝7.8Hz,1H),7.73(d,J＝8.7Hz,1H),7.66(d,J＝8.7Hz,1H),5.07–5.02(m,2H),4.09(s,3H),3.67–3.59(m,1H),3.52(d,J＝11.5Hz,2H),2.30(d,J＝11.3Hz,2H),1.88(d,J＝12.2Hz,2H).
实施例10
4-(2-(4-氨基哌啶-1-基)-6-(1-甲基-1H-吲唑-4-基)喹唑啉-4-基)-2-氟苯甲腈10
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为1-甲基引唑-4-硼酸制得标题化合物36的盐酸盐(22mg)。 1H NMR(400MHz,Methanol-d 4)δ8.43(dd,J＝8.7,1.8Hz,1H),8.17(d,J＝1.7Hz,1H),8.13(d,J＝8.7Hz,1H),8.07(dd,J＝7.9,6.4Hz,1H),8.03(s,1H),7.98(d,J＝9.5Hz,1H),7.92(d,J＝7.9Hz,1H),7.88–7.81(m,2H),7.44(d,J＝8.4Hz,1H),5.05(d,J＝11.6Hz,2H),4.11(s,3H),3.64(d,J＝12.4Hz,1H),3.50(t,J＝12.9Hz,2H),2.34–2.27(m,2H),1.88(d,J＝12.5Hz,2H).
实施例11
4-(2-(4-氨基哌啶-1-基)-6-(1-甲基-1H-吲唑-7-基)喹唑啉-4-基)-2-氟苯甲腈11
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为1-甲基引唑-7-硼酸制得标题化合物11的盐酸盐(23mg)。 1H NMR(400MHz,Methanol-d 4)δ8.25–8.17(m,2H),8.09(d,J＝1.5Hz,1H),8.06–7.92(m,3H),7.88(d,J＝7.9Hz,1H),7.83(dd,J＝7.9,1.5Hz,1H),7.31(d,J＝6.9Hz,1H),7.23(t,J＝7.5Hz,1H),5.10–5.02(m,2H),3.70–3.55(m,6H),2.33(d,J＝11.2Hz,2H),2.01–1.83(m,2H).
实施例12
4-(2-(4-氨基哌啶-1-基)-6-(2,6-二甲基苯基)喹唑啉-4-基)-2-氟苯甲腈12
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-二甲基苯硼酸制得标题化合物12的盐酸盐(18mg)。 1H NMR(400MHz,Methanol-d 4)δ8.18(d,J＝8.2Hz,1H),7.98(d,J＝6.3Hz,1H),7.89–7.76(m,3H),7.65(s,1H),7.19–7.05(m,3H),5.10–5.03(m,2H),3.70–3.64(m,1H),3.56–3.50(m,2H),2.33(d,J＝11.3Hz,2H),2.01(s,6H),1.96–1.86(m,2H).
实施例13
4-(2-(4-氨基哌啶-1-基)-6-(2-(三氟甲氧基)苯基)喹唑啉-4-基)-2-氟苯甲腈13
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-(三氟甲氧基)苯硼酸制得标题化合物13的盐酸盐(16mg)。 1H NMR(400MHz,Methanol-d 4)δ8.20(s,2H),8.07(t,J＝7.1Hz,1H),8.03(s,1H),7.93(d,J＝9.4Hz,1H),7.88(d,J＝8.1Hz,1H),7.62(d,J＝7.2Hz,1H),7.59–7.44(m,3H),5.10–5.03(m,2H),3.68(s,1H),3.57(t,J＝10.7Hz,2H),2.34(d,J＝12.0Hz,2H),2.01–1.83(m,2H).
实施例14
4-(2-(4-氨基哌啶-1-基)-6-(2-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈14
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-(三氟甲基)苯硼酸制得标题化合物14的盐酸盐(20mg)。 1H NMR(400MHz,Methanol-d 4)δ8.13(d,J＝8.5Hz,1H),8.03(t,J＝6.9Hz,2H),7.88(dd,J＝16.5,8.4Hz,4H),7.73(t,J＝7.4Hz,1H),7.65(t,J＝7.7Hz,1H),7.48(d,J＝7.4Hz,1H),5.10–5.03(m,2H),3.71–3.64(m,1H),3.53(d,J＝13.3Hz,2H),2.39–2.27(m,2H),1.92(d,J＝12.7Hz,2H).
实施例15
4-(2-(4-氨基哌啶-1-基)-6-(2-氟苯基)喹唑啉-4-基)-2-氟苯甲腈15
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟苯硼酸制得标题化合物15的盐酸盐(30mg)。 1H NMR(400MHz,Methanol-d 4)δ8.24(d,J＝9.2Hz,1H),8.13–8.01(m,3H),7.93(d,J＝9.5Hz,1H),7.87(d,J＝7.9Hz,1H),7.57(td,J＝7.9,1.7Hz,1H),7.45(tdd,J＝7.2,5.0,1.7Hz,1H),7.35–7.20(m,2H),5.05(d,J＝12.5Hz,2H),3.66–3.60(m,1H),3.55–3.39(m,2H),2.29(d,J＝12.0Hz,2H),1.95–1.77(m,2H).
实施例16
4-(2-(4-氨基哌啶-1-基)-6-(2-氯苯基)喹唑啉-4-基)-2-氟苯甲腈16
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯苯硼酸制得标题化合物16的盐酸盐(32mg)。 1H NMR(400MHz,Methanol-d 4)δ8.13(q,J＝8.7Hz,2H),8.04(t,J＝7.0Hz,1H),7.98(s,1H),7.93(d,J＝9.5Hz,1H),7.87(d,J＝7.8Hz,1H),7.58–7.52(m,1H),7.50–7.37(m,3H),5.08–5.02(m,2H),3.72–3.60(m,1H),3.58–3.41(m,2H),2.31(d,J＝11.0Hz,2H),1.93–1.86(m,2H).
实施例17
4-(2-(4-氨基哌啶-1-基)-6-(2,3-二氟苯基)喹唑啉-4-基)-2-氟苯甲腈17
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,3-二氟苯硼酸制得标题化合物17的盐酸盐(19mg)。 1H NMR(400MHz,Methanol-d 4)δ8.26(d,J＝8.8Hz,1H),8.17–8.02(m,3H),7.96(d,J＝9.5Hz,1H),7.90(d,J＝8.2Hz,1H),7.43–7.25(m,3H),5.12–5.03(m,2H),3.71–3.58(m,1H),3.57–3.40(m,2H),2.32(d,J＝12.3Hz,2H),1.97–1.78(m,2H).
实施例18
4-(2-(4-氨基哌啶-1-基)-6-(2,6-双(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈18
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-双(三氟甲基)苯硼酸制得标题化合物18的盐酸盐(14mg)。MS m/z(ESI):560.23[M+l] +.
实施例19
4-(2-(4-氨基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈19
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物19的盐酸盐(23mg)。 1H NMR(400MHz,DMSO-d 6)δ8.13(t,J＝7.3Hz,1H),7.95(d,J＝8.7Hz,1H),7.84–7.76(m,2H),7.73–7.61(m,5H),4.93(d,J＝13.5Hz,2H),3.46–3.37(m,1H),3.24(t,J＝12.7Hz,2H),2.11(dd,J＝13.0,3.9Hz,2H),1.63(d,J＝12.5Hz,2H).
实施例20
4-(2-(4-氨基哌啶-1-基)-6-(2,6-二氯苯基)喹唑啉-4-基)-2-氟苯甲腈20
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-二氯苯硼酸制得标题化合物20的盐酸盐(32mg)。 1H NMR(400MHz,DMSO-d 6)δ8.15(dd,J＝8.0,6.6Hz,1H),7.99 (d,J＝8.7Hz,1H),7.86(dd,J＝9.8,1.5Hz,1H),7.77(dd,J＝8.7,1.9Hz,1H),7.73(dd,J＝8.0,1.5Hz,1H),7.67(d,J＝1.9Hz,1H),7.59(d,J＝8.0Hz,2H),7.44(dd,J＝8.7,7.5Hz,1H),4.94(d,J＝13.4Hz,2H),3.43–3.34(m,1H),3.25(t,J＝12.7Hz,2H),2.14–2.09(m,2H),1.64(qd,J＝12.5,4.1Hz,2H).
实施例21
4-(2-(4-氨基哌啶-1-基)-6-(2-氯-6-甲基苯基)喹唑啉-4-基)-2-氟苯甲腈21
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯-6-甲基苯硼酸制得标题化合物21的盐酸盐(22mg)。 1H NMR(400MHz,DMSO-d 6)δ8.13(dd,J＝8.0,6.7Hz,1H),7.88(dd,J＝9.8,1.5Hz,1H),7.80(d,J＝8.7Hz,1H),7.72(dd,J＝8.0,1.5Hz,1H),7.66(dd,J＝8.7,1.9Hz,1H),7.50(d,J＝1.9Hz,1H),7.39(dd,J＝5.4,3.9Hz,1H),7.35–7.27(m,2H),4.90(d,J＝13.4Hz,2H),3.44–3.32(m,1H),3.16(t,J＝12.7Hz,2H),2.07–2.05(s,5H),1.64–1.51(m,2H).
实施例22
4-(2-(4-氨基哌啶-1-基)-6-(2-氯-6-氟苯基)喹唑啉-4-基)-2-氟苯甲腈22
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯-6-氟苯硼酸制得标题化合物22的盐酸盐(12mg)。 1H NMR(400MHz,DMSO-d 6)δ8.15(t,J＝7.3Hz,1H),7.97(d,J＝8.7Hz,1H),7.87(dd,J＝15.4,9.3Hz,2H),7.78–7.71(m,2H),7.47(t,J＝5.3Hz,2H),7.39–7.30(m,1H),4.94(d,J＝13.2Hz,2H),3.50–3.33(m,1H),3.24(t,J＝12.6Hz,2H),2.11(dd,J＝13.0,3.9Hz,2H),1.64(qd,J＝12.0,4.0Hz,2H).
实施例23
4-(2-(4-氨基哌啶-1-基)-6-(3-氟-2-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈23
采用实施例1的合成路线，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-氟-2-(三氟甲基)苯硼酸制得标题化合物23的盐酸盐(32mg)。 1H NMR(400MHz,DMSO-d 6)δ8.18–8.10(m,1H),7.96–7.88(m,2H),7.78(ddt,J＝13.5,10.3,5.3Hz,3H),7.66(d,J＝1.9Hz,1H),7.54(dd,J＝11.6,8.5Hz,1H),7.31(d,J＝7.7Hz,1H),4.93(d,J＝13.5Hz,2H),3.40(dt,J＝13.5,4.9Hz,1H),3.23(t,J＝12.7Hz,2H),2.14–2.08(m,2H),1.64(qd,J＝12.2,4.1Hz,2H).
实施例24
5-(2-(4-氨基哌啶-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)吡啶腈24
采用实施例1的合成路线，将第一步原料(4-氰基-3-氟苯基)硼酸替换为(6-氰基吡啶-3-基)硼酸制得标题化合物24的盐酸盐(10mg)。 1H NMR(400MHz,Methanol-d 4)δ9.21(d,J＝2.1Hz,1H),8.55(dd,J＝8.0,2.2Hz,1H),8.31(dd,J＝8.8,2.0Hz,1H),8.17(d,J＝8.0Hz,1H),8.08(dd,J＝8.8,2.2Hz,1H),8.04(d,J＝2.0Hz,1H),7.51–7.42(m,2H),7.20(t,J＝8.9Hz,1H),5.03(d,J＝12.7Hz,2H),3.92(s,3H),3.61(d,J＝11.1Hz,1H),3.49(t,J＝13.0Hz,2H),2.29(d,J＝12.4Hz,2H),1.86(q,J＝12.1Hz,2H).
实施例25
4-(2-(4-氨基哌啶-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)苯腈25
采用实施例1的合成路线，将第一步原料(4-氰基-3-氟苯基)硼酸替换为(4-氰基苯基)硼酸制得标题化合物25的盐酸盐(24mg)。 1H NMR(400MHz,Methanol-d 4)δ8.27(dd,J＝8.8,2.0Hz,1H),8.11–8.00(m,6H),7.48–7.38(m,2H),7.20(t,J＝8.9Hz,1H),5.04(d,J＝14.3Hz,2H),3.92(s,3H),3.64–3.55(m,2H),3.44(t,J＝13.2Hz,2H),2.27(d,J＝12.6Hz,2H),1.82(qd,J＝12.3,10.4,2.2Hz,2H)..
实施例26
2-氟-4-(6-(3-氟-4-甲氧基苯基)-2-(哌嗪-1-基)喹唑啉-4-基)苯腈26
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为哌嗪-1-羧酸叔丁酯制得标题化合物24的盐酸盐(29mg)。 1H NMR(400MHz,DMSO-d 6)δ8.21–8.12(m,2H),8.01(dd,J＝9.9,1.4Hz,1H),7.89(d,J＝2.0Hz,1H),7.85(dd,J＝7.9,1.4Hz,1H),7.80(d,J＝8.8Hz,1H),7.60(dd,J＝12.9,2.2Hz,1H),7.47(dd,J＝8.4,2.2Hz,1H),7.23(t,J＝8.8Hz,1H),4.18(t,J＝5.1Hz,4H),3.26–3.19(m,4H).
实施例27
(S)-4-(2-(3-氨基吡咯烷-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)-2-氟苯甲腈27
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-3-叔丁氧羰基氨基吡咯烷制得标题化合物27的盐酸盐(32mg)。 1H NMR(400MHz,DMSO-d 6)δ8.24–8.15(m,2H),8.01(d,J＝9.7Hz,2H),7.90(s,1H),7.85(d,J＝7.7Hz,1H),7.61(d,J＝12.6Hz,1H),7.48(d,J＝8.2Hz,1H),7.24(t,J＝8.7Hz,1H),4.03–3.85(m,5H),2.43–2.35(m,1H),2.28–2.17(m,1H).
实施例28
(R)-4-(2-(3-氨基吡咯烷-1-基)-6-(3-氟-4-甲氧基苯基)喹唑啉-4-基)-2-氟苯甲腈28
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-3-叔丁氧羰基氨基吡咯烷制得标题化合物28的盐酸盐(20mg)。 1H NMR(400MHz,DMSO-d 6)δ8.20(q,J＝7.5,6.8Hz,2H),8.01(d,J＝9.7Hz,2H),7.94–7.89(m,1H),7.85(d,J＝7.8Hz,1H),7.62(d,J＝12.7Hz,1H),7.49(d,J＝8.4Hz,1H),7.24(t,J＝8.7Hz,1H),3.94–3.79(m,5H),2.42–2.36(m,1H),2.27–2.18(m,1H).
实施例29
2-氟-4-(6-(3-氟-4-甲氧基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈29
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为N-叔丁氧羰基-3-(氨基甲基)吡咯烷制得标题化合物29的盐酸盐(35mg)。 1H NMR(400MHz,Methanol-d 4)δ8.21(s,1H),8.05(t,J＝7.2Hz,1H),7.97–7.83(m,3H),7.46–7.37(m,2H),7.18(t,J＝8.9Hz,1H),3.91(s,3H),3.80–3.76(m,2H),3.59–3.41(m,2H),3.36-3.32(m,1H),3.20–3.12(m,1H),2.92–2.84(m,1H),2.32–2.28(m,1H),1.96–1.87(m,1H).
实施例30
2-氟-4-(6-(3-氟-4-甲氧基苯基)-2-((哌啶-4-基甲基)氨基)喹唑啉-4-基)苯腈30
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为1-叔丁氧羰基-4-氨甲基哌啶制得标题化合物30的盐酸盐(29mg)。 1H NMR(400MHz,DMSO-d 6)δ8.40–8.22(m,2H), 8.21(t,J＝7.2Hz,1H),7.97(d,J＝9.7Hz,1H),7.92–7.79(m,2H),7.63(d,J＝12.7Hz,1H),7.49(d,J＝8.3Hz,1H),7.25(t,J＝8.8Hz,1H),3.87(s,3H),3.63–3.58(m,2H),3.54–3.50(m,1H),3.28(d,J＝12.2Hz,2H),2.83(q,J＝11.7Hz,2H),2.05–1.99(m,2H),1.57–1.41(m,2H).
实施例31
(S)-4-(6-(3-氟-4-甲氧基苯基)-2-(吡咯烷-3-基甲氧基)喹唑啉-4-基)苯腈31
采用实施例1的合成路线，将第一步原料(4-氰基-3-氟苯基)硼酸替换为(4-氰基苯基)硼酸。将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-1-叔丁氧羰基-3-羟甲基吡咯烷制得标题化合物31的盐酸盐(20mg)。 1H NMR(400MHz,Methanol-d 4)δ8.22(dd,J＝8.8,2.0Hz,1H),8.01(s,5H),7.96(d,J＝8.8Hz,1H),7.44–7.40(m,1H),7.39(d,J＝1.7Hz,1H),7.17(t,J＝8.6Hz,1H),4.69(dd,J＝10.9,5.1Hz,1H),4.62(dd,J＝10.9,6.0Hz,1H),3.91(s,3H),3.68–3.44(m,2H),3.42–3.32(m,2H),2.35(ddt,J＝21.6,14.7,7.6Hz,1H),2.18–1.99(m,2H).
实施例32
4-(6-(3-氟-4-甲氧基苯基)-2-(哌啶-4-基甲氧基)喹唑啉-4-基)苯腈32
采用实施例1的合成路线，将第一步原料(4-氰基-3-氟苯基)硼酸替换为(4-氰基苯基)硼酸。将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为1-叔丁氧羰基-4-哌啶甲醇制得标题化合物32的盐酸盐(13mg)。 1H NMR(400MHz,Methanol-d 4)δ8.21(dd,J＝8.8,2.0Hz,1H),8.05–7.96(m,5H),7.96(d,J＝8.9Hz,1H),7.44–7.37(m,2H),7.18(t,J＝8.8Hz,1H),5.34(t,J＝4.8Hz,2H),4.51(d,J＝5.9Hz,2H),3.91(s,3H),3.48(d,J＝12.3Hz,2H),3.13–3.03(m,2H),2.30(q,J＝7.2Hz,1H),1.80–1.65(m,2H).
实施例33
4-(6-(3,5-二甲基异恶唑-4-基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈33
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为1-叔丁氧羰基-3-(氨基甲基)吡咯烷。将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3,5-二甲基异恶唑-4-硼酸制得标题化合物33的盐酸盐(20mg)。MS m/z(ESI):443.31[M+l] +.
实施例34
2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(邻甲苯基)喹唑啉-4-基)苯腈34
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为1-叔丁氧羰基-3-(氨基甲基)吡咯烷。将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为邻甲基苯硼酸制得标题化合物34的盐酸盐(18mg)。 1H NMR(400MHz,Methanol-d4)δ8.26–7.70(m,6H),7.38–7.14(m,4H),3.94–3.82(m,2H),3.66–3.43(m,2H),3.37–3.32(m,1H),3.22–3.15(m,1H),3.01–2.86(m,1H),2.41–2.25(m,1H),2.26(s,3H),1.97–1.87(m,1H).
实施例35
(S)-2-氟-4-(6-(3-氟-4-甲氧基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈35
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷制得标题化合物35的盐酸盐(15mg)。 1H NMR(400MHz,Methanol-d 4)δ8.21(s, 1H),8.05(t,J＝7.2Hz,1H),7.97–7.83(m,3H),7.46–7.37(m,2H),7.18(t,J＝8.9Hz,1H),3.91(s,3H),3.81–3.77(m,2H),3.59–3.41(m,2H),3.36–3.32(m,1H),3.20–3.12(m,1H),2.92–2.84(m,1H),2.32–2.27(m,1H),1.96–1.87(m,1H).
实施例36
(R)-2-氟-4-(6-(3-氟-4-甲氧基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈36
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷制得标题化合物36的盐酸盐(30mg)。 1H NMR(400MHz,Methanol-d 4)δ8.29(s,1H),8.18–7.83(m,5H),7.43(t,J＝9.2Hz,2H),7.19(t,J＝8.6Hz,1H),3.91(s,3H),3.85–3.79(m,2H),3.65–3.41(m,2H),3.38–3.33(m,1H),3.20–3.13(m,1H),2.92–2.84(m,1H),2.35–2.29(m,1H),1.96–1.88(m,1H).
实施例37
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(邻甲苯基)喹唑啉-4-基)苯腈37
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为邻甲基苯硼酸制得标题化合物37的盐酸盐(25mg)。 1H NMR(400MHz,Methanol-d 4)δ8.28–7.63(m,6H),7.39–7.17(m,4H),3.87(t,J＝7.7Hz,2H),3.71–3.32(m,3H),3.26–3.10(m,1H),3.02–2.82(m,1H),2.46–2.30(m,1H),2.27(s,3H),2.01–1.86(m,1H).
实施例38
(R)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(邻甲苯基)喹唑啉-4-基)苯腈38
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为邻甲基苯硼酸制得标题化合物38的盐酸盐(16mg)。MS m/z(ESI):438.45[M+l] +.
实施例39
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(2-(三氟甲氧基)苯基)喹唑啉-4-基)苯腈39
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-(三氟甲氧基)苯硼酸制得标题化合物39的盐酸盐(36mg)。 1H NMR(400MHz,Methanol-d 4)δ8.31–7.78(m,6H),7.67–7.40(m,4H),3.97–3.79(m,2H),3.67–3.40(m,3H),3.25–3.08(m,1H),3.01–2.81(m,1H),2.45–2.24(m,1H),2.00–1.83(m,1H).
实施例40
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(2-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈40
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-(三氟甲基)苯硼酸制得标题化合物40的盐酸盐(16mg)。 1H NMR(400MHz,Methanol-d 4)δ8.20–8.17(m,1H),8.05–8.01(m,2H),7.95–7.77(m,4H),7.71(t,J＝7.3Hz,1H),7.63(t,J＝7.7Hz,1H),7.46(d,J＝7.6Hz,1H),3.98–3.78(m,2H),3.70–3.32(m,3H),3.26–3.08(m,1H),3.02–2.83(m,1H),2.48–2.23(m,1H),2.00–1.84(m,1H).
实施例41
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(2-氟苯基)喹唑啉-4-基)-2-氟苯甲腈41
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟苯硼酸制得标题化合物41的盐酸盐(30mg)。 1H NMR(400MHz,Methanol-d 4)δ8.32–7.84(m,6H),7.57(t,J＝7.7Hz,1H),7.45(q,J＝7.5Hz,1H),7.31(t,J＝7.5Hz,1H),7.24(dd,J＝11.1,8.2Hz,1H),3.94–3.87(m,2H),3.68–3.43(m,2H),3.41–3.33(m,1H),3.27–3.12(m,1H),2.99–2.87(m,1H),2.45–2.25(m,1H),2.06–1.87(m,1H).
实施例42
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(2-氯苯基)喹唑啉-4-基)-2-氟苯甲腈42
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯苯硼酸制得标题化合物42(18mg)的盐酸盐。 1H NMR(400MHz,Methanol-d 4)δ8.29–7.82(m,6H),7.54(dq,J＝6.6,3.9,3.2Hz,1H),7.50–7.40(m,3H),3.93–3.87(m,2H),3.68–3.43(m,2H),3.40–3.32(m,1H),3.26–3.11(m,1H),2.98–2.87(m,1H),2.44–2.24(m,1H),2.05–1.86(m,1H).
实施例43
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(2,3-二氟苯基)喹唑啉-4-基)-2-氟苯甲腈43
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,3-二氟苯硼酸制得标题化合物43的盐酸盐(20mg)。 1H NMR(400MHz,Methanol-d 4)δ8.33–7.86(m,6H),7.41–7.23(m,3H),3.94–3.88(m,2H),3.68–3.43(m,2H),3.40–3.33(m,1H),3.25–3.13(m,1H),2.98–2.88(m,1H),2.43–2.25(m,1H),2.05–1.86(m,1H).
实施例44
(S)-2-氟-4-(6-(4-甲基噻吩-3-基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈44
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为4-甲基-3-噻吩硼酸制得标题化合物44的盐酸盐(24mg)。 1H NMR(400MHz,Methanol-d 4)δ8.29–7.79(m,6H),7.48(s,1H),7.18(s,1H),3.90–3.84(m,2H),3.70–3.41(m,2H),3.36–3.30(m,1H),3.22–3.16(m,1H),2.98–2.89(m,1H),2.48–2.28(m,1H),2.27(s,3H),2.07–1.87(m,1H).
实施例45
(S)-4-(6-(2,6-二甲基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈45
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-二甲基苯硼酸制得标题化合物45的盐酸盐(25mg)。 1H NMR(400MHz,Methanol-d 4)δ8.36–7.57(m,6H),7.20–7.07(m,3H),3.94–3.88(m,2H),3.70–3.44(m,2H),3.39–3.33(m,1H),3.24–3.18(m,1H),3.01–2.90(m,1H),2.48–2.27(m,1H),2.01(s,6H),2.08–1.87(m,1H).
实施例46
(S)-4-(6-(2,4,6-三甲基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈46
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,4,6-三甲基苯硼酸制得标题化合物46的盐酸盐(20mg)。 1H NMR(400MHz,Methanol-d 4)δ8.29–7.56(m,6H),6.96–6.92(m,2H),3.92–3.86(m,2H),3.59–3.42(m,2H),3.39–3.32(m,1H),3.23–3.16(m,1H),3.02–2.90(m,1H),2.48–2.23(m,1H),2.28(s,3H),1.98(s,6H),2.08–1.88(m,1H).
实施例47
(S)-2-氟-4-(6-(3-氟-2-甲基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈47
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-氟-2-甲基苯硼酸制得标题化合物47的盐酸盐(22mg)。 1H NMR(400MHz,Methanol-d 4)δ8.37–7.74(m,6H),7.29(q,J＝7.1Hz,1H),7.12(dt,J＝8.8,5.2Hz,2H),3.94–3.88(m,2H),3.72–3.45(m,2H),3.38–3.33(m,1H),3.25–3.17(m,1H),3.03–2.90(m,1H),2.49–2.24(m,1H),2.19(d,J＝2.4Hz,3H),2.08–1.87(m,1H).
实施例48
(S)-2-氟-4-(6-(2-氟-6-甲基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈48
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-甲基苯硼酸制得标题化合物48的盐酸盐(12mg)。 1H NMR(400MHz,Methanol-d 4)δ8.38–7.68(m,6H),7.37–7.29(m,1H),7.17(d,J＝7.6Hz,1H),7.04(t,J＝9.0Hz,1H),3.95–3.89(m,2H),3.71–3.44(m,2H),3.39–3.34(m,1H),3.24–3.17(m,1H),3.04–2.91(m,1H),2.44–2.28(m,1H),2.21(s,3H),2.08–1.86(m,1H).
实施例49
(S)-2-氟-4-(2-((吡咯烷-3-基甲基)氨基)-6-(1,3,5-三甲基-1H-吡唑-4-基)喹唑啉-4-基)苯腈49
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为(1,3,5-三甲基-1H-吡唑-4-基)硼酸制得标题化合物49的盐酸盐(15mg)。 1H NMR(400MHz,Methanol-d 4)δ8.43–7.72(m,6H),4.00(s, 3H),3.96–3.87(m,2H),3.72–3.41(m,2H),3.41–3.35(m,1H),3.25–3.17(m,1H),3.05–2.91(m,1H),2.50–2.26(m,7H),2.06–1.86(m,1H).
实施例50
(S)-4-(6-(2,6-二氟苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈50
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-二氟苯硼酸制得标题化合物50的盐酸盐(29mg)。 1H NMR(400MHz,Methanol-d 4)δ8.33–7.78(m,6H),7.47(t,J＝7.1Hz,1H),7.13(t,J＝7.9Hz,2H),3.96–3.88(m,2H),3.69–3.44(m,2H),3.38–3.32(m,1H),3.25–3.14(m,1H),3.02–2.88(m,1H),2.45–2.25(m,1H),2.04–1.89(m,1H).
实施例51
(S)-4-(6-(2,6-二氯苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈51
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,6-二氯苯硼酸制得标题化合物51的盐酸盐(35mg)。 1H NMR(400MHz,Methanol-d 4)δ8.10–7.78(m,6H),7.53(d,J＝8.0Hz,2H),7.41(t,J＝8.0Hz,1H),3.97–3.88(m,2H),3.68–3.42(m,2H),3.38–3.32(m,1H),3.26–3.14(m,1H),3.02–2.89(m,1H),2.45–2.25(m,1H),2.03–1.87(m,1H).
实施例52
(S)-4-(6-(2-氯-6-(三氟甲基)苯基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈52
采用实施例40的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯-6-三氟甲基苯硼酸制得标题化合物52的盐酸盐(35mg)。 1H NMR(400MHz,Methanol-d 4)δ8.36–7.85(m,6H),7.74(q,J＝8.2Hz,2H),3.97–3.88(m,2H),3.71–3.44(m,2H),3.39–3.33(m,1H),3.28–3.16(m,1H),3.02–2.89(m,1H),2.47–2.27(m,1H),2.03–1.93(m,1H).
实施例53
(S)-4-(6-(2-氯-6-甲基苯基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈53
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯-6-甲基苯硼酸制得标题化合物53的盐酸盐(35mg)。 1H NMR(400MHz,Methanol-d 4)δ8.34–7.69(m,6H),7.38–7.32(m,1H),7.28(d,J＝4.8Hz,2H),3.95–3.86(m,2H),3.70–3.44(m,2H),3.38–3.32(m,1H),3.27–3.13(m,1H),3.01–2.87(m,1H),2.45–2.25(m,1H),2.11(s,3H),2.03–1.87(m,1H).
实施例54
(S)-4-(6-(2-氟-6-(三氟甲基苯基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈54
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-三氟甲基苯硼酸制得标题化合物54的盐酸盐(36mg)。 1H NMR(400MHz,Methanol-d 4)δ8.32–7.74(m,6H),7.69(d,J＝3.5Hz,2H),7.58–7.49(m,1H),3.95–3.86(m,2H),3.70–3.43(m,2H),3.35(d,J＝8.8Hz,1H),3.25–3.14(m,1H),3.00–2.87(m,1H),2.40–2.28(m,1H),2.05–1.88(m,1H).
实施例55
(S)-4-(6-(2-氯-6-氟苯基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈55
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氯-6-氟苯硼酸制得标题化合物55的盐酸盐(40mg)。MS m/z(ESI):476.48[M+l] +.
实施例56
(S)-4-(6-(5-氟-2-(三氟甲基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈56
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为5-氟-2-三氟甲基苯硼酸制得标题化合物56的盐酸盐(36mg)。 1H NMR(400MHz,Methanol-d 4)δ8.30–7.78(m,7H),7.38(td,J＝8.4,2.4Hz,1H),7.29(dd,J＝9.0,2.6Hz,1H),3.95–3.86(m,2H),3.69–3.42(m,2H),3.37(d,J＝8.6Hz,1H),3.25–3.14(m,1H),2.98–2.85(m,1H),2.40–2.28(m,1H),2.02–1.88(m,1H).
实施例57
(S)-4-(6-(3-氟-2-(三氟甲基苯基)-2-(吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈57
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-氟-2-三氟甲基苯硼酸制得标题化合物57的盐酸盐(26mg)。 1H NMR(400MHz,Methanol-d 4)δ8.29–7.77(m,6H),7.72(d,J＝6.4Hz,1H),7.41(dd,J＝11.3,8.1Hz,1H),7.27(d,J＝7.3Hz,1H),3.96–3.87(m,2H),3.70–3.43(m,2H),3.35(d,J＝7.9Hz,1H),3.25–3.15(m,1H),3.01–2.89(m,1H),2.42–2.30(m,1H),2.04–1.88(m,1H).
实施例58
(S)-4-(6-(2,5-双(三氟甲基)苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯腈58
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2,5-双(三氟甲基)苯硼酸制得标题化合物58的盐酸盐(18mg)。 1H NMR(400MHz,Methanol-d 4)δ8.33–7.72(m,9H),3.97–3.88(m,2H),3.68–3.44(m,2H),3.37–3.31(m,1H),3.24–3.14(m,1H),3.00–2.87(m,1H),2.41–2.30(m,1H),1.98–1.87(m,1H).
实施例59
(S)-2-氟-4-(6-(3-甲基-2-(三氟甲基)苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈59
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-甲基-2-(三氟甲基)苯硼酸制得标题化合物59的盐酸盐(17mg)。 1H NMR(400MHz,Methanol-d 4)δ7.91(d,J＝81.3Hz,6H),7.52(t,J＝6.5Hz,1H),7.45(d,J＝7.2Hz,1H),7.21(s,1H),3.96–3.87(m,2H),3.68–3.41(m,2H),3.38–3.32(m,1H),3.25–3.15(m,1H),3.01–2.88(m,1H),2.56(s,3H),2.41–2.30(m,1H),1.99–1.89(m,1H).
实施例60
((S)-4-(6-(2,6-二氟-3-羟基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)-2-氟苯甲腈60
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为6-(2,6-二氟-3-羟基苯硼酸制得标题化合物60的盐酸盐(30mg)。 1H NMR(400MHz,Methanol-d 4)δ8.23–7.80(m,6H),7.05–6.88(m,2H),3.88(q,J＝6.5,6.1Hz,2H),3.65–3.42(m,2H),3.36–3.31(m,1H),3.26–3.16(m,1H),3.02–2.89(m,1H),2.43–2,29(m,1H),2.00–1.89(m,1H).
实施例61
(S)-2-氟-4-(6-(2-氟-3-羟基苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-4-基)苯腈61
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为6-(2-氟-3-羟基)苯硼酸制得标题化合物61的盐酸盐(13mg)。 1H NMR(400MHz,Methanol-d 4)δ8.34–7.75(m,6H),7.08(t,J＝7.7Hz,1H),7.02–6.93(m,2H),3.95–3.86(m,2H),3.69–3.43(m,2H),3.39–3.33(m,1H),3.24–3.14(m,1H),3.02–2.89(m,1H),2.41–2.29(m,1H),2.01–1.91(m,1H).
实施例62
(S)-3-(4-(4-氰基-3-氟苯基)-2-((吡咯烷-3-基甲基)氨基)喹唑啉-6-基)苯甲酰胺62
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-N-叔丁氧羰基-3-(氨基甲基)吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为3-氨基甲酰基苯硼酸制得标题化合物62的盐酸盐(13mg)。MS m/z(ESI):467.46[M+l] +.
实施例63
4-(2-(4-氨基-4-甲基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈63
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(4-甲基哌啶-4-基)氨基甲酸叔丁酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物63的盐酸盐(20mg)。 1H NMR(400MHz,DMSO-d 6)δ8.13(t,J＝7.3Hz,1H),7.89(d,J＝8.7Hz,1H),7.84–7.74(m,2H),7.68(dt,J＝11.3,3.0Hz,5H),4.43(dt,J＝14.6,5.1Hz,2H),3.81–3.76(m,2H),1.91–1.81(m,4H),1.42(s,3H).
实施例64
4-(2-(4-氨基-3,3-二氟哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈64
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(3,3-二氟哌啶-4-基)氨基甲酸叔丁酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物64的盐酸盐(26mg)。 1H NMR(400MHz,DMSO-d 6)δ8.15(dd,J＝8.0,6.7Hz,1H),7.84(dd,J＝9.8,1.5Hz,1H),7.78(s,2H),7.74–7.62(m,5H),5.32–5.21(m,1H),4.93(d,J＝13.6Hz,1H),4.13–4.00(m,1H),3.71(dd,J＝31.2,14.1Hz,1H),3.38–3.29(m,1H),2.30(d,J＝12.9Hz,1H),1.88–1.71(m,1H).
实施例65
4-(2-(6-氨基-3-氮杂双环[3.1.0]己烷-3-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈65
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(3-氮杂双环[3.1.0]-6-己基)-氨基甲酸叔丁酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物65的盐酸盐(13mg)。 1H NMR(400MHz,DMSO-d 6)δ8.17–8.12(m,1H),8.06(d,J＝8.7Hz,1H),7.84(dd,J＝8.8,1.8Hz,1H),7.79(d,J＝9.8Hz,1H),7.74–7.62(m,5H),4.13(d,J＝11.9Hz,2H),3.80(dd,J＝11.9,4.0Hz,2H),2.51–2.44(m,1H),2.33–2.19(m,2H).
实施例66
2-氟-4-(6-(2-氟-6-(三氟甲基)苯基)-2-(4-(甲氨基)哌啶-1-基)喹唑啉-4-基)苯腈66
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为4-N-叔丁氧羰基-4-N-甲基氨基哌啶，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物66的盐酸盐(16mg)。 1H NMR(400MHz,DMSO-d 6)δ8.14(dd,J＝8.0,6.7Hz,1H),7.85–7.80(m,2H),7.76(dd,J＝8.8,1.8Hz,1H),7.74–7.64(m,5H),4.97(d,J＝13.4Hz,2H),3.38–3.27(m,1H),3.13(t,J＝12.2Hz,2H),2.56(t,J＝5.3Hz,3H),2.18(d,J＝12.2Hz,2H),1.69–1.55(m,2H).
实施例67
4-(2-((3R，4S)-4-氨基-3-氟哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈67
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为叔丁基N-[(3R，4S)-3-氟哌啶-4-基]氨基甲酸酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物67的盐酸盐(20mg)。 1H NMR(400MHz,Methanol-d 4)δ8.18(d,J＝8.6Hz,1H),8.05–7.97(m,2H),7.91(d,J＝1.8Hz,1H),7.80(dd,J＝15.6,8.6Hz,2H),7.68(dd,J＝6.8,3.8Hz,2H),7.58–7.49(m,1H),5.51–5.49(m,1H),5.27(d,J＝48.6Hz,1H),5.17–5.14(m,1H),4.00–3.68(m,2H),3.65–3.52(m,1H),2.30–2.12(m,2H).
实施例68
4-(2-((3R，4R)-4-氨基-3-甲基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟 苯甲腈68
Figure PCTCN2022131193-appb-000187
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为叔丁基N-[(3R，4R)-3-甲基哌啶-4-基]氨基甲酸酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物68的盐酸盐(16mg)。MS m/z(ESI):524.28[M+l] +.
实施例69
4-(2-(3-氨基-8-氮杂双环[3.2.1]辛烷-8-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈69
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为3-叔丁氧酰基氨基脱甲托品烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物69的盐酸盐(36mg)。 1H NMR(400MHz,DMSO-d 6)δ8.21–8.13(m,1H),8.05(d,J＝8.7Hz,2H),7.85(dd,J＝8.8,1.8Hz,1H),7.81(d,J＝9.7Hz,1H),7.76–7.63(m,4H),5.17–5.07(m,1H),5.06–4.90(m,1H),3.69(dq,J＝12.0,6.7Hz,1H),2.22–1.75(m,8H).
实施例70
4-(2-(3-氨基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈70
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为3-叔丁氧羰基氨基哌啶，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物70的盐酸盐(16mg)。 1H NMR(400MHz,DMSO-d 6)δ8.18–8.10(m,1H),7.86(t,J＝9.9Hz,2H),7.78(dd,J＝8.8,1.8Hz,1H),7.69(tdd,J＝11.0,7.2,2.3Hz,5H),4.76–4.60(m,1H),4.40(d,J＝10.8Hz,1H),3.75–3.41(m,3H),3.29(dd,J＝9.4,4.9Hz,1H),2.11–2.07(m,1H),1.93–1.70(m,2H),1.64–1.54(m,1H).
实施例71
4-(2-(4-氨基-3,3-二甲基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈71
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(3,3-二甲基哌啶-4-基)氨基甲酸叔丁酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物71的盐酸盐(18mg)。 1H NMR(400MHz,DMSO-d 6)δ8.13(t,J＝7.3Hz,1H),7.91(d,J＝8.7Hz,1H),7.77(t,J＝8.4Hz,2H),7.73–7.62(m,5H),4.87(d,J＝13.3Hz,1H),4.64–4.61(m,1H),3.27(t,J＝13.0Hz,1H),3.20(p,J＝5.2Hz,1H),3.11(d,J＝13.5Hz,1H),2.03–1.97(m,1H),1.80(tt,J＝12.1,6.3Hz,1H),1.13(s,3H),0.93(s,3H).
实施例72
4-(2-(4-氨基氮杂环庚烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈72
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为4-叔丁氧羰-1H-氮杂卓，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物72的盐酸盐(18mg)。 1H NMR(400MHz,Methanol-d 4)δ8.23(d,J＝9.5Hz,1H),8.02(t,J＝7.2Hz,2H),7.91(s,1H),7.83(dd,J＝17.1,8.5Hz,2H),7.73–7.63(m,2H),7.54(td,J＝8.8,3.3Hz,1H),4.60(d,J＝14.5Hz,1H),4.39–4.22(m,1H),4.15–3.90(m,2H),3.50(d,J＝12.0Hz,1H),2.58–1.77(m,6H).
实施例73
4-(2-(4-(二甲氨基)哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈73
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为4-二甲氨基哌啶，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物73的盐酸盐(16mg)。 1H NMR(400MHz,DMSO-d 6)δ8.14(dd,J＝8.0,6.7Hz,1H),7.89–7.74(m,3H),7.73–7.63(m,5H),5.06(d,J＝13.3Hz,2H),3.58–3.48(m,1H),3.12–3.03(m,2H),2.70(d,J＝4.9Hz,6H),2.18(d,J＝11.8Hz,2H),1.75–1.61(m,2H).
实施例74
(R)-4-(2-(3-氨基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈74
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-3-叔丁氧羰基氨基哌啶，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物74的盐酸盐(26mg)。 1H NMR(400MHz,Methanol-d 4)δ8.14(t,J＝8.2Hz,1H),8.00(q,J＝8.9,8.0Hz,2H),7.92–7.84(m,2H),7.81(d,J＝7.6Hz,1H),7.68(dd,J＝7.3,3.8Hz,2H),7.61–7.46(m,1H),4.87–4.76(m,1H),4.45–4.27(m,1H),4.10–3.98(m,1H),3.94–3.84(m,1H),3.67–3.58(m,1H),2.31–2.25(m,1H),2.17–2.06(m,1H),1.97–1.88(m,2H).
实施例75
(S)-4-(2-(3-氨基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈75
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-3-叔丁氧羰基氨基哌啶，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物74的盐酸盐(15mg)。 1H NMR(400MHz,Methanol-d 4)δ8.14(d,J＝8.2Hz,1H),7.99(t,J＝8.0Hz,2H),7.93–7.85(m,2H),7.81(d,J＝6.7Hz,1H),7.72–7.63(m,2H),7.54(d,J＝8.0Hz,1H),5.08–5.02(m,1H),4.43–4.35(m,1H),4.07–3.98(m,1H),3.93–3.84(m,1H),3.69–3.55(m,1H),2.37–2.19(m,1H),2.14–2.06(m,1H),2.00–1.85(m,2H).
实施例76
2-氟-4-(6-(2-氟-6-(三氟甲基)苯基)-2-(八氢-5H-吡咯[3,2-c]吡啶-5-基)喹唑啉-4-基)苯腈76
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为八氢-1H-吡咯并[3,2-C]吡啶-1-羧酸叔丁酯,将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物76的盐酸盐(28mg)。 1H NMR(400MHz,Methanol-d 4)δ8.15(t,J＝7.9Hz,1H),8.04– 7.94(m,2H),7.89(d,J＝5.3Hz,1H),7.85–7.76(m,2H),7.68(t,J＝4.1Hz,2H),7.54(dt,J＝12.3,5.2Hz,1H),4.53–4.42(m,1H),4.36–4.21(m,2H),4.13–4.04(m,1H),3.95–3.80(m,1H),3.58–3.49(m,1H),3.40(d,J＝16.4Hz,1H),2.95–2.84(m,1H),2.45–2.17(m,3H),2.07–1.94(m,1H).
实施例77
2-氟-4-(6-(2-氟-6-(三氟甲基)苯基)-2-(1,8-二氮螺环[4.5]癸-8-基)喹唑啉-4-基)苯腈77
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为1,8-二氮杂螺[4.5]癸烷-1-羧酸叔丁酯,将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物77的盐酸盐(18mg)。 1H NMR(400MHz,Methanol-d 4)δ8.04(d,J＝8.0Hz,1H),7.97(s,1H),7.91–7.71(m,3H),7.67–7.64(m,1H),7.51(d,J＝7.4Hz,1H),4.68–4.63(m,2H),3.92–3.87(m,2H),3.49–3.45(m,2H),2.15–2.14(m,8H).
实施例78
4-(2-(4-氨基哌啶-1-基)-7-氟-6-(2-氟苯基)喹唑啉-4-基)-2-氟苯甲腈78
Figure PCTCN2022131193-appb-000188
第一步
6-溴-7-氟喹唑啉-2,4(1H，3H)-二酮78b
将化合物2-氨基-5-溴-4-氟苯甲酸78a(1g，4.27mmol，毕得医药)与脲(2.56g，42.73mmol)研磨得均匀混合物，氮气保护下，加热到180℃反应3小时。冷却，所得固体混合物加水研磨，过滤，水洗涤，干燥后得粗产物78b(1.1g)(淡黄色固体)。无需纯化，直接下一步。
第二步
6-溴-2,4-二氯-7-氟喹唑啉78c
将粗产物78b(1.1g，4.25mmol)溶于三氯氧磷(2.38mL，25.5mmol)中，加入N,N-二乙基苯胺(2.03mL，12.75mmol)。将反应混合物在110℃下回流3小时。冷却，反应液减压浓缩。倾入冷水中，加二氯甲烷萃取3次，合并有机层，饱和氯化钠溶液洗涤，干燥，浓缩。用硅胶柱色谱法(EA:PE；1:100至1:60)纯化，得到标题化合物78c(0.56g)(淡黄色固体)，产率：45％。 1H NMR(400MHz,Chloroform-d)δ8.54(d,J＝7.0Hz,1H),7.70(d,J＝8.4Hz,1H).
第三步
4-(6-溴-2-氯-7-氟喹唑啉-4-基)-2-氟苯甲腈78d
向化合物6-溴-2,4-二氯-7-氟喹唑啉78c(300mg，1.01mmol，)、双(三苯基膦)氯化钯(Ⅱ)(42.5mg，0.06mmol)、磷酸钾(430mg，2.02mmol)与MeCN/H 2O(8:1)(40mL)的混合物中添加(4-氰基-3-氟苯基)硼酸(167.2mg，1.01mmol上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在100℃下加热15分钟。冷却，反应液减压浓缩。乙酸乙酯打浆，过滤，干燥。得到标题化合物78d(235mg)(白色固体)，产率：61％。 1H NMR(400MHz,Chloroform-d)δ8.24(d,J＝7.0Hz,1H),7.90(dd,J＝8.2,6.3Hz,1H),7.79(d,J＝8.5Hz,1H),7.69–7.67(m,1H),7.66(q,J＝1.6Hz,1H).
第四步
(1-(6-溴-4-(4-氰基-3-氟苯基)-7-氟喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯78e
将化合物78d(235mg，0.62mmol)、二异丙基乙胺(0.216mL，1.24mmol)和哌啶-4-基氨基甲酸叔丁酯(186mg，0.93mmol毕得医药)溶于N,N-二甲基甲酰胺(6ml)。反应混合物在室温下搅拌过夜。反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物78e(214mg)(黄色固体)，产率：64％。 1H NMR(400MHz,Chloroform-d)δ7.83(t,J＝3.3Hz,1H),7.82–7.80(m,1H),7.57(dd,J＝4.4,1.6Hz,1H),7.55(dd,J＝5.7,1.3Hz,1H),7.30(d,J＝9.9Hz,1H),4.83(dd,J＝13.6,3.9Hz,2H),4.52(d,J＝7.9Hz,1H),3.76(s,1H),3.14(ddd,J＝14.0,11.6,2.7Hz,2H),2.10–2.03(m,2H),1.45(s,9H),1.42–1.34(m,2H).
第五步
(1-(4-(4-氰基-3-氟苯基)-7-氟-6-(2-氟苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯78f
向化合物78e(50mg，0.09mmol)，[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(7.3mg，0.009mol)，碳酸钠(28.6mg，0.27mmol)和四氢呋喃/水(5:1)(2mL)的混合物中加入(2-氟苯基)硼酸(25.7mg，0.18mmol上海皓鸿生物医药科技有限公司)。氮气保护，将反应混合物在70℃下搅拌16h。冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:8至1:4)纯化，得到标题化合物78f(34mg)(黄色固体)，产率：66％。 1H NMR(400MHz,Chloroform-d)δ7.78(dd,J＝8.1,6.3Hz,1H),7.68(d,J＝7.9Hz,1H),7.62(dd,J＝4.9,1.6Hz,1H),7.60(dd,J＝6.3,1.4Hz,1H),7.42–7.31(m,3H),7.25–7.12(m,2H),4.89(d,J＝13.4Hz,2H),4.49(s,1H),3.78(s,1H),3.18(td,J＝12.5,11.3,2.7Hz,2H),2.12–2.05(m,2H),1.46(s,9H),1.44–1.36(m,2H).
第六步
4-(2-(4-氨基哌啶-1-基)-7-氟-6-(2-氟苯基)喹唑啉-4-基)-2-氟苯甲腈78
将化合物78f(34mg)溶于2mL二氯甲烷中，加入2mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌2小时。反应液减压浓缩,得到标题化合物78的盐酸盐(26mg)(黄色固体)，产率：88％。 1H NMR(400MHz,Methanol-d 4)δ8.02(t,J＝6.6Hz,1H),7.96(d,J＝7.1Hz,1H),7.91(d,J＝9.2Hz,1H),7.85(d,J＝7.0Hz,1H),7.80(d,J＝10.4Hz,1H),7.50(p,J＝6.6,6.0Hz,2H),7.31(t,J＝ 7.2Hz,1H),7.25(dd,J＝10.3,8.2Hz,1H),5.09(s,2H),3.71–3.59(m,1H),3.46(t,J＝12.4Hz,2H),2.30(d,J＝10.8Hz,2H),1.88(s,2H).
实施例79
4-(2-(4-氨基哌啶-1-基)-7-氟-6-(2-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈79
采用实施例78的合成路线，将第五步原料2-氟苯硼酸替换为2-三氟甲基苯硼酸制得标题化合物79的盐酸盐(30mg)。 1H NMR(400MHz,Methanol-d 4)δ7.96(t,J＝6.9Hz,1H),7.86–7.60(m,7H),7.46(d,J＝7.2Hz,1H),5.08(d,J＝12.8Hz,2H),3.59(t,J＝4.6Hz,1H),3.35(d,J＝12.6Hz,2H),2.29–2.16(m,2H),1.80(d,J＝11.9Hz,2H).
实施例80
4-(2-(4-氨基哌啶-1-基)-7-氟-6-(2-氟苯基)喹唑啉-4-基)-2-氟苯甲腈80
Figure PCTCN2022131193-appb-000189
第一步
6-溴-8-氟喹唑啉-2,4(1H，3H)-二酮80b
将化合物2-氨基-5-溴-3-氟苯甲酸80a(1g，4.27mmol，毕得医药)与脲(2.56g，42.73mmol)研磨得均匀混合物，氮气保护下，加热到180℃反应3小时。冷却，所得固体混合物加水研磨，过滤，水洗涤，干燥后得粗产物80b(1.05g)(淡黄色固体)。无需纯化，直接下一步。
第二步
6-溴-2,4-二氯-8-氟喹唑啉80c
将粗产物80b(1.05g，4.05mmol)溶于三氯氧磷(2.27mL，24.32mmol)中，加入N,N-二乙基苯胺(1.93mL，12.16mmol)。将反应混合物在110℃下回流3小时。冷却，反应液减压浓缩。倾入冷水中，加二氯甲烷萃取3次，合并有机层，饱和氯化钠溶液洗涤，干燥，浓缩。用硅胶柱色谱法(EA:PE；1:100至1:60)纯化，得到标题化合物80c(0.81g)(淡黄色固体)，产率：68％。 1H NMR(400MHz,Chloroform-d)δ8.18(d,J＝2.0Hz,1H),7.78(dd,J＝8.8,2.9Hz,1H).
第三步
4-(6-溴-2-氯-8-氟喹唑啉-4-基)-2-氟苯甲腈80d
向化合物6-溴-2,4-二氯-8-氟喹唑啉80c(600mg，2.02mmol，)、双(三苯基膦)氯化钯(Ⅱ)(85mg，0.12mmol)、磷酸钾(860mg，4.04mmol)与MeCN/H 2O(8:1)(18mL)的混合物中添加(4-氰基-3- 氟苯基)硼酸(334.4mg，2.02mmol上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在100℃下加热15分钟。冷却，反应液减压浓缩。乙酸乙酯打浆，过滤，干燥。得到标题化合物80d(490mg)(白色固体)，产率：64％。 1H NMR(400MHz,Chloroform-d)δ7.95(t,J＝1.6Hz,1H),7.90(dd,J＝8.1,6.3Hz,1H),7.82(dd,J＝8.7,1.9Hz,1H),7.69(s,1H),7.67(s,1H).
第四步
(1-(6-溴-4-(4-氰基-3-氟苯基)-8-氟喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯80e
将化合物4-(6-溴-2-氯-8-氟喹唑啉-4-基)-2-氟苯甲腈80d(300mg，0.79mmol)、二异丙基乙胺(0.274mL，1.58mmol)和哌啶-4-基氨基甲酸叔丁酯(237mg，1.18mmol毕得医药)溶于N,N-二甲基甲酰胺(8ml)。反应混合物在室温下搅拌过夜。反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物80e(210mg)(黄色固体)，产率：49％。 1H NMR(400MHz,Chloroform-d)δ7.82(dd,J＝8.2,6.3Hz,1H),7.61–7.53(m,3H),7.48(dd,J＝9.6,2.0Hz,1H),4.86(d,J＝13.5Hz,2H),4.51(s,1H),3.76(s,1H),3.22–3.11(m,2H),2.08(dd,J＝13.0,3.7Hz,2H),1.45(s,9H),1.43–1.34(m,2H).
第五步
(1-(4-(4-氰基-3-氟苯基)-8-氟-6-(2-三氟甲基苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯80f
向化合物(1-(6-溴-4-(4-氰基-3-氟苯基)-8-氟喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯80e(50mg，0.09mmol)，[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(7.3mg，0.009mol)，碳酸钠(28.6mg，0.27mmol)和四氢呋喃/水(5:1)(2mL)的混合物中加入(2-三氟甲基氟苯基)硼酸(34.9mg，0.18mmol上海皓鸿生物医药科技有限公司)。氮气保护，将反应混合物在70℃下搅拌16h。冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:8至1:4)纯化，得到标题化合物80f(42mg)(黄色固体)，产率：75％。 1H NMR(400MHz,Chloroform-d)δ7.80–7.71(m,2H),7.70–7.47(m,3H),7.43–7.36(m,2H),7.31(d,J＝7.6Hz,1H),4.92(d,J＝13.6Hz,2H),4.52(s,1H),3.77(s,1H),3.25–3.15(m,2H),2.09(dd,J＝13.2,3.8Hz,2H),1.46(s,9H),1.43–1.36(m,2H).
第六步
4-(2-(4-氨基哌啶-1-基)-8-氟-6-(2-三氟甲基苯基)喹唑啉-4-基)-2-氟苯甲腈80
将化合物(1-(4-(4-氰基-3-氟苯基)-8-氟-6-(2-三氟甲基苯基)喹唑啉-2-基)哌啶-4-基)氨基甲酸叔丁酯80f(42mg)溶于2mL二氯甲烷中，加入2mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌2小时。反应液减压浓缩，得到标题化合物80的盐酸盐(34mg)(黄色固体)，产率：97％。 1H NMR(400MHz,Methanol-d 4)δ7.93(dd,J＝8.0,6.5Hz,1H),7.80(dd,J＝7.9,1.3Hz,1H),7.74(dd,J＝9.7,1.4Hz,1H),7.71(dd,J＝8.0,1.5Hz,1H),7.67(td,J＝7.7,1.3Hz,1H),7.58(t,J＝ 7.7Hz,1H),7.50(dd,J＝11.0,1.8Hz,1H),7.47–7.42(m,2H),5.15(dt,J＝13.6,2.7Hz,2H),3.50(tt,J＝11.6,4.2Hz,1H),3.17(ddd,J＝14.2,12.3,2.6Hz,2H),2.19–2.12(m,2H),1.65(qd,J＝12.3,4.3Hz,2H).
实施例81
4-(2-(4-氨基哌啶-1-基)-8-氟-6-(2-氟)苯基)喹唑啉-4-基)-2-氟苯甲腈81
采用实施例80的合成路线，将第五步原料2-三氟甲基苯硼酸替换为2-氟苯硼酸制得标题化合物81的盐酸盐(40mg)。 1H NMR(400MHz,Methanol-d 4)δ7.98(t,J＝7.1Hz,1H),7.84–7.74(m,3H),7.73(s,1H),7.51(t,J＝7.8Hz,1H),7.39(t,J＝6.8Hz,1H),7.26(t,J＝7.6Hz,1H),7.20(dd,J＝11.3,8.2Hz,1H),5.12(d,J＝13.4Hz,2H),3.57–3.44(m,1H),3.21(t,J＝12.8Hz,2H),2.18(d,J＝12.3Hz,2H),1.77–1.60(m,2H).
实施例82
4-(2-(4-氨基哌啶-1-基)-8-氟-6-(2-氟-6-三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈82
采用实施例80的合成路线，将第五步原料2-三氟甲基苯硼酸替换为2-氟-6-三氟甲基苯硼酸制得标题化合物82的盐酸盐(24mg)。 1H NMR(400MHz,Methanol-d 4)δ7.93(ddd,J＝8.3,6.5,1.9Hz,1H),7.74–7.58(m,4H),7.53–7.44(m,3H),5.15(d,J＝13.7Hz,2H),3.50(dq,J＝11.7,5.9,4.3Hz,1H),3.22–3.11(m,2H),2.20–2.13(m,2H),1.72–1.60(m,2H).
实施例83
4-(2-((3S，4R)-4-氨基-3-氟哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈83
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为叔丁基N-[(3S，4R)-3-氟哌啶-4-基]氨基甲酸酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物83的盐酸盐(33mg)。
1H NMR(400MHz,DMSO-d 6)δ8.13(t,J＝7.3Hz,1H),7.80(d,J＝9.8Hz,1H),7.74(s,2H),7.72–7.61(m,5H),5.37–5.25(m,1H),5.16(d,J＝49.1Hz,1H),5.00(d,J＝13.5Hz,1H),3.40(dd,J＝40.2,14.9Hz,1H),3.16(t,J＝12.8Hz,1H),1.99(dq,J＝9.5,6.1Hz,2H),1.89–1.73(m,1H).
实施例84
4-(2-((3R，4R)-4-氨基-3-氟哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈84
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为叔丁基N-[(3R，4R)-3-氟哌啶-4-基]氨基甲酸酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物84的盐酸盐(36mg)。 1H NMR(400MHz,Methanol-d 4)δ8.08(d,J＝8.5Hz,1H),7.99(t,J＝7.0Hz,1H),7.94(d,J＝8.6Hz,1H),7.87(s,1H),7.82(d,J＝9.5Hz,1H),7.77(d,J＝7.7Hz,1H),7.67(qd,J＝7.7,3.3Hz,2H),7.56–7.48(m,1H),5.36(d,J＝12.0Hz,1H),5.05(d,J＝12.8Hz,1H),4.82(s,1H),3.77(d,J＝12.0Hz,1H),3.55–3.38(m,2H),2.38(d,J＝12.4Hz,1H),1.99(d,J＝14.1Hz,1H).
实施例85
4-(2-((3S，4S)-4-氨基-3-氟哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈85
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为叔丁基N-[(3S，4S)-3-氟哌啶-4-基]氨基甲酸酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物85的盐酸盐(32mg)。
1H NMR(400MHz,Methanol-d 4)δ8.09(d,J＝8.7Hz,1H),7.99(t,J＝7.0Hz,1H),7.94(d,J＝8.4Hz,1H),7.87(s,1H),7.82(d,J＝9.5Hz,1H),7.77(d,J＝7.7Hz,1H),7.67(dd,J＝7.3,3.7Hz,2H),7.56–7.48(m,1H),5.42–5.30(m,1H),5.05(d,J＝13.0Hz,1H),4.83(s,1H),3.83–3.72(m,1H),3.48(d,J＝12.7Hz,2H),2.38(s,1H),2.09–1.92(m,1H).
实施例86
(S)-4-(2-(3-氨基氮杂环庚烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈86
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-氮杂环庚烷-3-基氨基甲酸叔丁酯，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物86的盐酸盐(18mg)。
1H NMR(400MHz,Methanol-d 4)δ8.31(d,J＝8.4Hz,1H),8.10–8.00(m,2H),7.91(d,J＝11.5Hz,2H),7.84(d,J＝7.7Hz,1H),7.72–7.63(m,2H),7.54(t,J＝7.2Hz,1H),4.60(d,J＝14.3Hz,1H),4.32(d,J＝14.0Hz,1H),4.15–4.03(m,2H),3.79–3.71(m,1H),2.32–1.98(m,4H),1.93–1.66(m,2H).
实施例87
(R)-4-(2-(3-氨基氮杂环庚烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈87
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-氮杂环庚烷-3-基氨基甲酸叔丁酯,将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物87的盐酸盐(25mg)。 1H NMR(400MHz,DMSO-d 6)δ8.37(s,1H),8.13(t,J＝7.3Hz,1H),8.00(t,J＝10.8Hz,1H),7.91–7.57(m,6H),4.41–4.31(m,1H),4.18–3.75(m,3H),3.57(d,J＝46.6Hz,1H),1.96(d,J＝8.1Hz,2H),1.92–1.61(m,3H),1.48–1.43(m,1H).
实施例88
(S)-4-(2-(4-氨基氮杂环庚烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈88
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-4-叔丁氧羰-1H-氮杂卓，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物88的盐酸盐(22mg)。 1H NMR(400MHz,Methanol-d 4)δ8.19(d,J＝8.4Hz,1H),8.06–7.98(m,2H),7.92 –7.89(m,1H),7.81(dd,J＝16.7,8.6Hz,2H),7.68(dd,J＝6.9,3.7Hz,2H),7.58–7.49(m,1H),4.65–3.89(m,3H),3.52–3.44(m,1H),2.56–1.79(m,3H).
实施例89
4-(2-(4-氨基氮杂环庚烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈89
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-4-叔丁氧羰-1H-氮杂卓,将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物89的盐酸盐(59mg)。 1H NMR(400MHz,Methanol-d 4)δ8.30–8.16(m,1H),8.06–7.98(m,2H),7.93–7.90(m,1H),7.83(dd,J＝17.1,8.5Hz,2H),7.68(dd,J＝6.2,3.8Hz,2H),7.54(td,J＝9.0,3.3Hz,1H),4.69–3.89(m,4H),2.56–1.78(m,2H).
实施例90
(S)-4-(2-(3-氨基吡咯烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈90
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(S)-3-叔丁氧羰基氨基吡咯烷，将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物90(30mg)。 1H NMR(400MHz,Chloroform-d)δ7.74(dd,J＝8.7,6.0Hz,2H),7.63–7.55(m,5H),7.47(td,J＝8.0,5.1Hz,1H),7.33(t,J＝8.4Hz,1H),3.94(ddd,J＝19.1,15.3,6.5Hz,2H),3.79(q,J＝11.2,9.0Hz,2H),3.62–3.43(m,1H),2.23(dt,J＝19.8,7.0Hz,2H).
实施例91
(R)-4-(2-(3-氨基吡咯烷-1-基)-6-(2-氟-6-(三氟甲基)苯基)喹唑啉-4-基)-2-氟苯甲腈91
采用实施例1的合成路线，将第二步原料哌啶-4-基氨基甲酸叔丁酯替换为(R)-3-叔丁氧羰基氨基吡咯烷,将第三步原料(3-氟-4-甲氧基苯基)硼酸替换为2-氟-6-(三氟甲基)苯硼酸制得标题化合物91(38mg)。 1H NMR(400MHz,Chloroform-d)δ7.77–7.72(m,2H),7.62(q,J＝1.5Hz,1H),7.60(dd,J＝4.3,1.4Hz,2H),7.58–7.56(m,2H),7.47(td,J＝8.1,5.2Hz,1H),7.33(t,J＝8.5Hz,1H),3.94(ddd,J＝18.9,12.6,6.4Hz,2H),3.79(td,J＝11.9,9.9,6.5Hz,2H),3.50(dd,J＝11.4,4.6Hz,1H),2.24(dq,J＝15.0,7.8,7.1Hz,1H),1.86(dq,J＝12.7,6.1Hz,1H).
实施例92
4-(2-(4-氨基哌啶-1-基)-6-(2-(三氟甲基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈92
Figure PCTCN2022131193-appb-000190
第一步
4-(6-苄基-2-氯-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈92b
向化合物6-苄基-2,4-二氯-5,6,7,8-四氢吡啶[4,3-d]嘧啶92a(1g，3.38mmol)、双(三苯基膦)氯化钯(Ⅱ)(237mg，0.34mmol)、磷酸钾(1.43g，6.75mmol)与MeCN/H 2O(8:1)(18mL)的混合物中添加(4-氰基-3-氟苯基)硼酸(612mg，3.71mmol上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在100℃下加热15分钟。冷却，反应液减压浓缩。乙酸乙酯打浆，过滤，干燥。得到标题化合物92b(908mg)(白色固体)，产率：70.6％。
第二步
(1-(6-苄基-4-(4-氰基-3-氟苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-基)哌啶-4-基氨基甲酸叔丁酯92c
将化合物4-(6-苄基-2-氯-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈92b(600mg，1.58mmol)、二异丙基乙胺(0.55mL，3.15mmol)和哌啶-4-基氨基甲酸叔丁酯(473mg，2.36mmol毕得医药)溶于N,N-二甲基甲酰胺(8ml)。反应混合物在室温下搅拌过夜。反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物92c(760mg)(白色固体)，产率：88.9％。 1H NMR(400MHz,Chloroform-d)δ7.66(t,J＝7.1Hz,1H),7.39(d,J＝8.8Hz,2H),7.35–7.25(m,5H),4.66(d,J＝13.3Hz,2H),4.46(s,1H),3.74–3.66(m,1H),3.64(s,2H),3.49(s,2H),3.01(t,J＝11.9Hz,2H),2.85(d,J＝5.9Hz,2H),2.78(d,J＝6.1Hz,2H),2.00(d,J＝12.4Hz,2H),1.45(s,9H),1.32(dtt,J＝12.1,8.7,4.5Hz,2H).
第三步
(1-(4-(4-氰基-3-氟苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-基)哌啶-4-基)氨基甲酸叔丁酯92d
将化合物(1-(6-苄基-4-(4-氰基-3-氟苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-基)哌啶-4-基氨基甲酸叔丁酯92c(600mg，1.11mmol)、10％Pd-C催化剂(60mg)和甲醇(10mL)的混合物在氢气下室温搅拌，直到氢气的吸收停止。过滤出催化剂后，蒸发滤液。用硅胶柱色谱法(DCM:MeOH；1:20至1:15)纯化，得到标题化合物92d(210mg)(白色固体)，产率：42.0％。 1H NMR(400MHz,Chloroform-d)δ7.68(t,J＝7.1Hz,1H),7.39(d,J＝8.7Hz,2H),4.65(d,J＝13.6Hz,1H),4.51(d,J＝7.7Hz,2H),3.83 (s,2H),3.69(s,1H),3.19(t,J＝6.2Hz,2H),3.05–2.96(m,2H),2.80(t,J＝6.1Hz,2H),2.03–1.96(m,2H),1.44(s,9H),1.33(qd,J＝11.8,4.3Hz,2H).
第四步
叔丁基(1-(4-(4-氰基-3-氟苯基)-6-(2-(三氟甲基)苯基)-4a，5,6,7,8,8a-六氢喹唑啉-2-基)哌啶-4-基)氨基甲酸酯92e
向化合物(1-(4-(4-氰基-3-氟苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-2-基)哌啶-4-基)氨基甲酸叔丁酯92d(41mg，0.09mmol)，双二亚苄基丙酮钯(2.73mg，4.75μmol)，4,5-双(二苯基膦)-9,9-二甲基氧杂蒽(5.5mg，9.50μmol)，碳酸铯(61.89mg，0.27mmol)和干燥的二氧六环(2mL)的混合物中加入邻溴三氟甲苯(30.6mg，0.18mmol)。氮气保护，将反应混合物在100℃下搅拌17h。冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mLX 3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:8至1:4)纯化，得到标题化合物92e(21mg)(黄色固体)产率：36.9％。 1H NMR(400MHz,Chloroform-d)δ7.67–7.60(m,2H),7.54(t,J＝8.1Hz,1H),7.43–7.34(m,3H),7.31–7.21(m,1H),4.70(d,J＝13.3Hz,2H),4.51–4.48(m,1H),3.90–3.87(m,2H),3.74–3.69(m,1H),3.28(t,J＝5.9Hz,2H),3.09–2.97(m,4H),2.03(d,J＝11.3Hz,2H),1.46(s,9H),1.43–1.30(m,2H).
第五步
4-(2-(4-氨基哌啶-1-基)-6-(2-(三氟甲基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈92
将化合物叔丁基(1-(4-(4-氰基-3-氟苯基)-6-(2-(三氟甲基)苯基)-4a，5,6,7,8,8a-六氢喹唑啉-2-基)哌啶-4-基)氨基甲酸酯92e(21mg)溶于2mL二氯甲烷中，加入2mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌2小时。反应液减压浓缩，得到标题化合物92的盐酸盐(15mg)(黄色固体)，产率：85.8％。 1H NMR(600MHz,Methanol-d 4)δ7.99–7.92(m,1H),7.87(t,J＝6.9Hz,1H),7.63(p,J＝9.7,8.2Hz,4H),7.34(t,J＝7.3Hz,1H),4.01–3.97(m,2H),3.52–3.48(m,1H),3.34(d,J＝6.4Hz,2H),3.19(t,J＝12.7Hz,2H),3.15–3.11(m,2H),2.30–2.19(m,1H),2.14(d,J＝12.0Hz,2H),2.05–1.99(m,1H),1.72–1.67(m,2H).
实施例93
4-(2-(4-氨基哌啶-1-基)-6-(2-氟-6-(三氟甲基)苯基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈93
采用实施例92的合成路线，将第四步原料邻溴三氟甲苯替换为2-溴-3-氟-三氟甲苯制得标题化合物93的盐酸盐(8mg)。MS m/z(ESI):515.20[M+l] +.
实施例94
4-(2-(4-氨基哌啶-1-基)-6-(1-甲基-1H-吲唑-7-基)-5,6,7,8-四氢吡啶[4,3-d]嘧啶-4-基)-2-氟苯甲腈94
采用实施例92的合成路线，将第四步原料邻溴三氟甲苯替换为7-溴-1-甲基吲唑制得标题化合物94的盐酸盐(10mg)。MS m/z(ESI):482.52[M+l] +.
实施例95
4-(3-(4-氨基哌啶-1-基)-7-(2-氟-6-(三氟甲基)苯基)异喹啉-1-基)-2-氟苯腈98
Figure PCTCN2022131193-appb-000191
第一步
4-(7-溴-3-氯异喹啉-1-基)-2-氟苯腈98b
向化合物7-溴-1，3-二氯异喹啉98a(1.00g，3.61mmol)、双(三苯基膦)氯化钯(Ⅱ)(127mg，180.54μmol)、磷酸钾(1.53g，7.22mmol)与乙腈/水(8:1)(18mL)的混合物中加入(4-氰基-3-氟苯基)硼酸(596mg，3.61mmol，上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在100℃下加热15分钟。TLC监测反应完毕后，冷却，反应液减压浓缩。乙酸乙酯打浆，过滤，干燥。得到标题化合物98b(1.10g)(白色固体)，产率：84.3％。 1H NMR(400MHz,Chloroform-d)δ8.11(s,1H),7.84(td,J＝5.9,5.3,2.6Hz,2H),7.80–7.74(m,2H),7.61(s,1H),7.59(s,1H).
第二步
4-(3-氯-7-(2-氟-6-(三氟甲基)苯基)异喹啉-1-基)-2-氟苯腈98c
向化合物4-(7-溴-3-氯异喹啉-1-基)-2-氟苯腈98b(500mg，1.38mmol)，[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(56mg，0.069mol)，碳酸钠(293mg，2.77mmol)和四氢呋喃/水(5:1)(35mL)的混合物中加入2-氟-6-三氟甲基苯硼酸(288mg，1.38mmol，上海皓鸿生物医药科技有限公司)。氮气保护，将反应混合物在70℃下搅拌16小时。TLC监测反应完毕后，冷却，反应液减压浓缩，加入35mL水和35mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(20mL×3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:20至1:15)纯化，得到标题化合物98c(420mg)，淡黄色固体，产率：68.3％。MS m/z(ESI):445.35[M+l] +.
第三步
(1-(1-(4-氰基-3-氟苯基)-7-(2-氟-6-(三氟甲基)苯基)异喹啉-3-基)哌啶-4-基)氨基甲酸叔丁酯98d
向化合物4-(3-氯-7-(2-氟-6-(三氟甲基)苯基)异喹啉-1-基)-2-氟苯腈98c(100mg，224.83μmol)，4-叔丁氧羰基氨基哌啶(90mg，449.65μmol)，碳酸铯(147mg，449.65μmol)和干燥的1，4-二氧六环(4mL)的混合物中加入醋酸钯(5mg，22.48μmol)和BINAP(28mg，44.97μmol)。氮气保护，将反应混合物在110℃下搅拌12小时。TLC监测反应完毕后，冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10Ml×3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物98d(57mg)，黄色固体，产率：41.7％。MS m/z(ESI):609.13[M+l] +.
第四步
4-(3-(4-氨基哌啶-1-基)-7-(2-氟-6-(三氟甲基)苯基)异喹啉-1-基)-2-氟苯腈98
将化合物(1-(1-(4-氰基-3-氟苯基)-7-(2-氟-6-(三氟甲基)苯基)异喹啉-3-基)哌啶-4-基)氨基甲酸叔丁酯98d(57mg)溶于2mL二氯甲烷中，加入2mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌3小时。反应液减压浓缩，用乙酸乙酯溶液洗涤，得到标题化合物98的盐酸盐(41mg)(黄色固体)，产率：80.6％。MS m/z(ESI):509.21[M+l] +.
实施例96
4-(2-(4-氨基哌啶-1-基)-8-甲基-7-氧代-6-(2-三氟甲基苯基)-7，8-二氢吡啶[2，3-d]嘧啶-4-基)-2-氟苯腈99
Figure PCTCN2022131193-appb-000192
第一步
4-氯-6-甲氨基-2-甲硫基嘧啶-5-甲醛99b
将化合物4，6-二氯-2-甲硫基嘧啶-5-甲醛99a(5.00g，22.41mmol，上海皓鸿生物医药科技有限公司)溶于氯仿(40mL)，滴加甲胺(40％水溶液)(1.83g，23.54mmol)和三乙胺(4.67mL，33.62mmol)，室温条件下搅拌1小时。TLC监测反应完毕后，反应液减压浓缩。加入60mL水和60mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(30mL×3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物96b(4.50g)(白色固体)，产率：90.2％。 1H NMR(400MHz,DMSO-d 6)δ9.81(s,1H),3.04(d,J＝4.9Hz,3H),2.53(s,3H).
第二步
2-氟-4-(5-甲酰基-6-(甲氨基)-2-(甲硫基)嘧啶-4-基)苄腈99c
向化合物4-氯-6-甲氨基-2-甲硫基嘧啶-5-甲醛99b(4.50g，20.67mmol)、四(三苯基膦)钯(477mg，413.47μmol)、碳酸钾(5.71g，41.35mmol)与1，4-二氧六环/水(4:1)(40mL)的混合物中添加(4-氰基-3-氟苯基)硼酸(4.43g，26.88mmol上海皓鸿生物医药科技有限公司)。氮气保护，搅拌反应混合物在110℃下加热16小时。TLC监测反应完毕后，冷却，反应液减压浓缩。乙酸乙酯打 浆，过滤，干燥。得到标题化合物99c(4.20g)(白色固体)，产率：67.2％。 1H NMR(400MHz,Chloroform-d)δ9.73(d,J＝0.6Hz,1H),9.16(s,1H),7.73(dd,J＝7.9,6.3Hz,1H),7.44(ddd,J＝16.7,8.4,1.5Hz,2H),3.17(d,J＝4.9Hz,3H),2.59(s,3H).
第三步
(E)-3-(4-(4-氰基-3-氟苯基)-6-(甲氨基)-2-(甲硫基)嘧啶-5-基)丙烯酸乙酯99d
将化合物2-氟-4-(5-甲酰基-6-(甲氨基)-2-(甲硫基)嘧啶-4-基)苄腈99c(4.00g，13.23mmol)溶解于四氢呋喃(50mL)中，加入乙氧甲酰基亚甲基三苯基膦(5.99g，17.20mmol)。将反应混合物加热至回流1.5小时。TLC监测反应完毕，反应液冷却到室温，减压浓缩，直接进行柱层析(EA:PE；1:10至1:5)纯化，得到标题化合物99d(4.10g)(白色固体)，产率：83.2％。 1H NMR(400MHz,DMSO-d 6)δ8.05–7.96(m,1H),7.64(dd,J＝10.3,1.5Hz,1H),7.51–7.44(m,2H),7.36(d,J＝16.3Hz,1H),5.99(d,J＝16.3Hz,1H),4.11(q,J＝7.1Hz,2H),2.91(d,J＝4.4Hz,3H),2.48(s,3H),1.20(t,J＝7.1Hz,3H).
第四步
2-氟-4-(8-甲基-2-(甲硫基)-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-4-基)苄腈99e
向化合物(E)-3-(4-(4-氰基-3-氟苯基)-6-(甲氨基)-2-(甲硫基)嘧啶-5-基)丙烯酸乙酯99d(4.00g，10.74mmol)悬浮于甲醇中，加入甲醇钠(29mg，537.03μmol)，搅拌反应混合物在70℃下加热6小时。TLC监测反应完毕，反应液冷却到室温，有固体析出，过滤，干燥，得到标题化合物99e的粗产物，不经纯化直接进行下一步。MS m/z(ESI):327.31[M+l] +.
第五步
6-溴-8-甲基-2-甲硫基-7-氧代-7，8-二氢吡啶-2，3-二羟基嘧啶-4-基-2-氟苯腈99f
将化合物2-氟-4-(8-甲基-2-(甲硫基)-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-4-基)苄腈99e(2.00g，6.13mmol)溶解于二氯甲烷(30mL)中，然后缓慢滴加液溴(1.96g，12.26mmol)。该反应混合物在室温下搅拌12小时，TLC监测反应完毕后，将反应液中倾入饱和硫代硫酸钠溶液中，用乙酸乙酯萃取。有机相用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:10至1:5)纯化，得到标题化合物99f(1.90g)(白色固体)，产率：76.5％。 1H NMR(400MHz,Chloroform-d)δ8.06(s,1H),7.84(dd,J＝7.8,6.3Hz,1H),7.58–7.49(m,2H),3.88(s,3H),2.66(s,3H).
第六步
4-溴-8-甲基-2-甲磺酰基-7-氧代-7，8-二氢吡啶[2，3-d]嘧啶-4-基)-2-氟苯腈99g
将化合物6-溴-8-甲基-2-甲硫基-7-氧代-7，8-二氢吡啶-2，3-二羟基嘧啶-4-基-2-氟苯腈99f(1.90g，4.96mmol)溶解于二氯甲烷(30mL)中，0℃下分批次加入间氯过氧苯甲酸(2.43g，14.07mmol)，反应混合物在室温下搅拌1小时，TLC监测反应完毕后，将反应液倾入饱和碳酸氢钠溶液中，用乙酸乙酯萃取。有机相用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。得到标题化合物99g的粗产物，不经纯化直接进行下一步。
第七步
1-(6-溴-4-(4-氰基-3-氟苯基)-8-甲基-7-氧代-7，8-二氢吡啶[2，3-d]嘧啶-2-基哌啶-4-氨基甲酸叔丁酯99h
将化合物4-溴-8-甲基-2-甲磺酰基-7-氧代-7，8-二氢吡啶[2，3-d]嘧啶-4-基)-2-氟苯腈99g(2.05g，4.96mmol)和4-叔丁氧羰基氨基哌啶(1.13g，5.63mmol)溶解于乙腈(20mL)中，加入碳酸钾(1.30g，9.38mmol)，反应混合物在室温下搅拌12小时，TLC监测反应完毕后，反应液减压浓缩。加入30mL水和30mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(30mL×3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(MeOH:DCM；1:100至1:50)纯化，得到标题化合物99h(2.40g)(黄色固体)，产率：91.8％。 1H NMR(400MHz,Chloroform-d)δ7.89(s,1H),7.81(dd,J＝8.1,6.3Hz,1H),7.48(ddd,J＝8.2,4.8,1.4Hz,2H),4.84–4.76(m,2H),4.51–4.43(m,1H),3.76(s,3H),3.22–3.11(m,2H),2.14–2.05(m,2H),1.46(s,9H),1.44–1.36(m,2H).
第八步
1-(4-(4-氰基-3-氟苯基)-8-甲基-7-氧代-6-(2-三氟甲基苯基)-7，8-二氢吡啶[2，3-d]嘧啶-2-基)氨基甲酸叔丁酯99i
向化合物1-(6-溴-4-(4-氰基-3-氟苯基)-8-甲基-7-氧代-7，8-二氢吡啶[2，3-d]嘧啶-2-基哌啶-4-氨基甲酸叔丁酯99h(200mg，358.79μmol)，四三苯基膦钯(20.73mg，17.94μmol)，碳酸钾(149mg，1.08mmol)与1，4-二氧六环/水(4：1)(5mL)的混合物中加入2-三氟甲基苯硼酸(102mg，538.19μmol)。氮气保护，将反应混合物在110℃下搅拌2小时。TLC监测反应完毕后，冷却，反应液减压浓缩，加入15mL水和15mL乙酸乙酯，均匀混合，静置分层。水相用乙酸乙酯萃取(10mL×3)。合并有机相，饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液浓缩。用硅胶柱色谱法(EA:PE；1:4至1:2)纯化，得到标题化合物99i(181mg)(黄色固体)产率：81.0％。 1H NMR(400MHz,Chloroform-d)δ7.72(dd,J＝8.1,6.3Hz,2H),7.58–7.52(m,1H),7.51–7.43(m,4H),7.32(d,J＝7.6Hz,1H),4.88–4.80(m,2H),4.55–4.48(m,1H),3.75(s,3H),3.24–3.13(m,2H),2.14–2.06(m,2H),1.46(s,9H),1.44–1.35(m,2H).
第九步
4-(2-(4-氨基哌啶-1-基)-8-甲基-7-氧代-6-(2-三氟甲基苯基)-7，8-二氢吡啶[2，3-d]嘧啶-4-基)-2-氟苯腈99
将化合物1-(4-(4-氰基-3-氟苯基)-8-甲基-7-氧代-6-(2-三氟甲基苯基)-7，8-二氢吡啶[2，3-d]嘧啶-2-基)氨基甲酸叔丁酯99i(181mg)溶于4mL二氯甲烷中，加入4mL的4N氯化氢-1,4-二氧六环溶液。反应混合物在室温下搅拌3小时。反应液减压浓缩，用乙酸乙酯溶液洗涤，得到标题化合物99的盐酸盐(152mg)(黄色固体)，产率：93.8％。 1H NMR(400MHz,Methanol-d 4)δ7.90(dd,J＝8.0,6.5Hz,1H),7.77(d,J＝7.8Hz,1H),7.67–7.62(m,2H),7.61–7.53(m,3H),7.39(d,J＝7.6Hz,1H),5.13–5.06(m,2H),3.77(s,3H),3.54–3.43(m,1H),3.23–3.12(m,2H),2.21–2.11(m,2H),1.70–1.57(m,2H).
生物学评价
测试例1：体外酶抑制活性测定-LSD1
本实验目的是检测化合物对LSD1体外抑制活性。实验所用的人源重组LSD1蛋白购自Active Motif公司，LSD1的酶水平活性测试实验采用Lance Ultra LSD1组蛋白H3赖氨酸4脱甲基酶测定试剂盒(PerkinElmer)进行。首先需配制Tris缓冲液(50mM Tris-HCl,50mM NaCl,0.01％Tween-20,1mM DTT,10μM FAD,10％glycerol,pH 9.0)，待配制完成后，需将测试所需的LSD1组分置于该缓冲液中，并于室温下培养一小时，该组分中包括4μL底物溶液(2.5μM Bio-H3K4me2,1-24aa)、4μL酶溶液(4nM LSD1)和2μL的384孔微量培养板中的抑制剂。在这些操作完成之后，另需向体系中加入5μL的检测混合物，其内含有Eu标记的H3K4me0抗体和ULight-链霉抗生物素蛋白，在这之后，采用Envision(PerkinElmer)来检测待测组分的荧光强度，测试模式设置在TR-FRET模式(激发波长为320nm，发射波长为665nm)。为降低误差，测试总共重复三次。最终IC 50数据由软件GraphPad Prism 5计算得出，最后采用sigmoidal dose-response(variable slope)的方法来得到拟合曲线。
在表2中提供了本申请代表性化合物以及阳性对照化合物CC90011的LSD1抑制活性。所有化合物均以HCl盐形式测试。
表2
化合物编号 LSD1 IC 50
CC90011 A
3 B
6 B
8 B
9 B
10 B
11 A
12 A
13 B
14 A
15 B
16 A
17 B
19 A
20 A
21 A
22 A
23 A
24 B
25 B
29 B
34 A
35 B
36 B
37 B
38 B
39 B
40 A
41 B
42 A
43 B
44 B
45 A
46 A
47 B
48 A
49 B
50 B
51 A
52 B
53 A
54 A
55 A
56 B
57 A
59 B
60 B
61 B
63 A
65 B
66 A
67 A
68 A
69 A
70 A
71 A
72 A
73 A
74 A
75 B
76 A
77 A
78 A
79 B
80 A
81 B
82 A
83 B
84 B
85 B
86 A
87 A
88 A
89 A
90 A
91 A
92 B
93 B
94 B
98 A
99 A
注：1.生物化学测定IC 50数据被指定在以下范围内：
A：≤30nM
B：>30nM至≤300nM
C：>300nM至≤10000nM
D：>10000nM。
2.CC90011化学结构式：
Figure PCTCN2022131193-appb-000193
测试例2：小鼠移植瘤模型体内药效评价
实验目的：测试化合物在小鼠移植瘤模型的体内药效
实验材料：雌性NU/NU裸小鼠，MV4-11细胞株
实验方法：雌性NU/NU裸小鼠，体重20±2g，接种MV4-11细胞株接种裸小鼠右侧腋窝皮下，细胞接种量为5×10 6/只，待成瘤后，用游标卡尺测量移植瘤直径，肿瘤长至100-300mm 3，将动物按体重和肿瘤体积分为模型对照组和给药组，每组6只，给药组用0.5％CMC-Na研磨混悬，模型对照组则给等量空白溶剂。分组后每天口服给药，给药剂量为20mg/kg，持续21天，实验过程中，每周2次测量移植瘤直径及称量小鼠体重,并于第21天安乐死动物后取肿瘤组织。观察指标：肿瘤体积TV＝1/2×a×b 2(注：其中a、b分别表示长、宽。)，相对肿瘤体积RTV＝TV t/TV 0(注：其中TV 0为分笼给药时(即d 0)测量所得肿瘤体积，TV t为每一次测量时的肿瘤体积。)，相对肿瘤增殖率T/C(％)＝(T RTV/C RTV)×100％(注：T RTV：治疗组RTV；C RTV：阴性对照组RTV)，瘤重抑制率％＝(Wc-W T)/Wc×100％(注：Wc：对照组瘤重，W T：治疗组瘤重)。
实验结论：代表性测试化合物19和化合物89表现出显著的体内抗肿瘤活性(灌胃给药20mg/kg剂量下T/C小于50％)。

Claims (12)

  1. 一种如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物；
    Figure PCTCN2022131193-appb-100001
    其中，
    Figure PCTCN2022131193-appb-100002
    表示单键或双键；
    A为取代的5-14元杂芳基或取代的6-14元芳基；其中所述取代的5-14元杂芳基和取代的6-14元芳基为独立地被1、2或3个R a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
    R a独立地为CN、F、Cl、Br、I或C 1-3烷基，且至少一个为CN；
    R 1为氢、卤素、取代或未取代的(氨基)-(C 1-C 4亚烷基)-、取代或未取代的C 3-12环烷基、取代或未取代的3-10元杂环烷基、取代或未取代的C 6-C 14芳基或者取代或未取代的5-14元杂芳基，其中所述取代的(氨基)-(C 1-C 4亚烷基)-、取代的C 3-12环烷基、取代的3-10元杂环烷基、取代的C 6-C 14芳基和取代的5-14元杂芳基独立地为被1、2或3个R 1a取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；3-10元杂环基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
    R 2为卤素、取代或未取代的C 1-4烷基、取代或未取代的饱和或不饱和的C 3-10环烃基、取代或未取代的C 6-C 14芳基、取代或未取代的3-10元杂环基、取代或未取代的5-14元杂芳基、取代或未取代的3-10元杂环基-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烃基)-；其中所述取代的C 1-4烷基、取代的饱和或不饱和的C 3-10环烃基、取代的C 6-C 14芳基、取代的3-10元杂环基、取代的5-14元杂芳基、取代的3-10元杂环基-N(R 3)-、取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代的3-10元杂环基-O-、取代的3-10元杂环基-(C 1-C 4亚烷基)-O-和取代的N(R 3) 2-(C 1-C 4亚烷基)-O-为独立地被1、2或3个R 1c取代；5-14元杂芳基中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；3-10元杂环基为饱和或不饱和的3-10元杂环基，其中的杂原子选自N、O和S，杂原子的个数为1、2、3或4个；
    每个R 1a和R 1c独立地为F、Cl、Br、I、OH、N(R 3) 2、CN、COOH、CON(R 3) 2、SO 2N(R 3) 2、C 1-3烷基、C 3-12环烷基、C 1-3烷基-O-或C 3-12环烷基-O-，其中所述C 1-3烷基、C 3-12元环烷基、C 1-3烷基-O-和C 3-12元环烷基-O-任选被1、2或3个R 1b取代；
    每个R 1b独立地为F、Cl、Br、I、OH或NH 2；
    每个R 3独立地为氢、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1- 4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代；
    L为-NH-、-N(C 1-C 3烷基)-，-O-或不存在；
    X和Y各自独立地为N或C(R 4)；
    M为C、CH或N；
    Z 1、Z 2和Z 3各自独立地为连接键、N、N(R 4)、C(H)(R 4)、C(R 4)、-(C＝O)-或-(C＝S)-；且Z 1、Z 2和Z 3中至多一个为连接键；
    R 4为氢、卤素、取代或未取代的C 1-4烷基、取代或未取代的C 3-12环烷基；所述的取代的C 1-4烷基和取代的C 3-12环烷基为独立地被1、2或3个R 1b取代。
  2. 如权利要求1所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物满足下述条件中的一个或多个：
    (1)Z 1、Z 2和Z 3各自独立地为连接键、N、N(R 4)、C(H)(R 4)、C(R 4)或-(C＝O)-；且Z 1、Z 2和Z 3中至多一个为连接键；
    (2)R 4为氢、卤素或C 1-4烷基。
  3. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，
    所述的如式I所示的芳杂环类化合物为如下所示：
    Figure PCTCN2022131193-appb-100003
    其中，W 1和W 2各自独立地为N、C(H)或C(R a)；
    Figure PCTCN2022131193-appb-100004
    R 1、R 2、L、X、Y、Z 1、Z 2、Z 3和R a如权利要求1所述。
  4. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物满足下述条件中的一个或多个：
    (1)A为取代的6-14元芳基、R 1为取代或未取代的C 6-C 14芳基、及R 2为取代或未取代的C 6-C 14芳基中，所述的C 6-C 14芳基独立地为苯基或萘基；
    (2)A为取代的5-14元杂芳基、R 1为取代或未取代的5-14元杂芳基、及R 2为取代或未取代的 5-14元杂芳基中，所述的5-14元杂芳基为5-10元杂芳基，杂原子选自N、O和S，杂原子的个数为1或2个；例如
    Figure PCTCN2022131193-appb-100005
    又例如
    Figure PCTCN2022131193-appb-100006
    Figure PCTCN2022131193-appb-100007
    (3)R 1、R 2及R 4为卤素中，所述的卤素独立地为F、Cl、Br、I，例如Br；
    (4)R 1为取代或未取代的(氨基)-(C 1-C 4亚烷基)-、及R 2为取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-或取代或未取代的N(R 3) 2-(C 1-C 4亚烷基)-O-中，所述的(C 1-C 4亚烷基)为-CH 2-、-CH 2CH 2-、-CH(CH 3)-、-CH(CH 3)CH 2-或-C(CH 3) 2-；
    (5)R 1为取代或未取代的C 3-12环烷基、R 1a和R 1c独立地为C 3-12环烷基或C 3-12环烷基-O-、R 3为取代或未取代的C 3-12环烷基、及R 4为取代或未取代的C 3-12环烷基中，所述的C 3-12环烷基独立地为C 3-7单环的环烷基、C 4-12桥环或并环的环烷基、C 7-12螺环的环烷基；所述的C 3-7单环的环烷基可为环丙基、环丁基、环戊基或环己基；
    (6)R 1为取代或未取代的3-10元杂环烷基中，所述的3-10元杂环烷基独立地为C 3-7单环的杂环烷基、C 4-12桥环或并环的杂环烷基、C 7-12螺环的杂环烷基；所述的C 3-7单环的杂环烷基可为
    Figure PCTCN2022131193-appb-100008
    Figure PCTCN2022131193-appb-100009
    例如
    Figure PCTCN2022131193-appb-100010
    所述的C 4-12桥环或并环的杂环烷基可为
    Figure PCTCN2022131193-appb-100011
    例如
    Figure PCTCN2022131193-appb-100012
    Figure PCTCN2022131193-appb-100013
    所述的C 7-12螺环的杂环烷基可为
    Figure PCTCN2022131193-appb-100014
    例如
    Figure PCTCN2022131193-appb-100015
    (7)R 2为取代或未取代的C 1-4烷基、R 3为取代或未取代的C 1-4烷基、及R 4为取代或未取代的C 1-4烷基中，所述的C 1-4烷基独立地为甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基或叔丁基；
    (8)R 2为取代或未取代的饱和或不饱和的C 3-12环烃基中，所述的饱和C 3-12环烃基为C 3-12环烷 基，例如环丙基、环丁基、环戊基或环己基；
    (9)R 2为取代或未取代的3-10元杂环基、取代或未取代的3-10元杂环基-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-O-或取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-中，所述的3-10元杂环基独立地为3-10元杂环烷基时，所述的3-10元杂环烷基独立地为C 3-7单环的杂环烷基、C 4-12桥环或并环的杂环烷基、C 7-12螺环的杂环烷基；所述的C 3- 7单环的杂环烷基可为
    Figure PCTCN2022131193-appb-100016
    例如
    Figure PCTCN2022131193-appb-100017
    Figure PCTCN2022131193-appb-100018
    所述的C 4-12桥环或并环的杂环烷基可为
    Figure PCTCN2022131193-appb-100019
    例如
    Figure PCTCN2022131193-appb-100020
    所述的C 7-12螺环的杂环烷基可为
    Figure PCTCN2022131193-appb-100021
    例如
    Figure PCTCN2022131193-appb-100022
    (10)R a独立地为C 1-3烷基、R 1a和R 1c独立地为C 1-3烷基或C 1-3烷基-O-、及L为-N(C 1-C 3烷基)-中，所述的C 1-3烷基独立地为甲基、乙基、正丙基或异丙基。
  5. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物满足下述条件中的一个或多个：
    (1)A为
    Figure PCTCN2022131193-appb-100023
    W 1和W 2各自独立地为N、C(H)或C(R a)；其中，R a为F、Cl、Br、I或C 1- 3烷基；
    (2)R 1为卤素、取代或未取代的C 6-C 14芳基或者取代或未取代的5-14元杂芳基；
    (3)R 2为取代或未取代的3-10元含N杂环基、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-N(R 3)-、取代或未取代的3-10元杂环基-(C 1-C 4亚烷基)-O-；
    (4)每个R 1a和R 1c独立地为F、Cl、OH、N(R 3) 2、CON(R 3) 2、SO 2N(R 3) 2、C 1-3烷基或C 1-3烷基 -O-，其中所述C 1-3烷基和C 1-3烷基-O-任选被1、2或3个R 1b取代；
    (5)每个R 1b独立地为F或NH 2；
    (6)R 3为氢或取代或未取代的C 1-4烷基；
    (7)L为-NH-、-O-或不存在；
    (8)X和Y各自独立地为N；
    (9)Z 1、Z 2和Z 3各自独立地为N、C(H)(R 4)或C(R 4)；
    (10)R 4为氢或卤素。
  6. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物满足下述条件中的一个或多个：
    (1)R 1为
    Figure PCTCN2022131193-appb-100024
    Br、
    Figure PCTCN2022131193-appb-100025
    Figure PCTCN2022131193-appb-100026
    (2)A为
    Figure PCTCN2022131193-appb-100027
    (3)
    Figure PCTCN2022131193-appb-100028
    为
    Figure PCTCN2022131193-appb-100029
    Figure PCTCN2022131193-appb-100030
    (4)R 2为
    Figure PCTCN2022131193-appb-100031
    Figure PCTCN2022131193-appb-100032
  7. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物满足下述条件中的一个或多个：
    (1)R 1为
    Figure PCTCN2022131193-appb-100033
    (2)
    Figure PCTCN2022131193-appb-100034
    为
    Figure PCTCN2022131193-appb-100035
    (3)R 2为
    Figure PCTCN2022131193-appb-100036
    (4)R 4为H、F或甲基。
  8. 如权利要求1或2所述的如式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂合物，其特征在于，所述的如式I所示的芳杂环类化合物或其药学上可接受的盐为如下结构化合物或其盐酸盐：
    Figure PCTCN2022131193-appb-100037
    Figure PCTCN2022131193-appb-100038
    Figure PCTCN2022131193-appb-100039
    Figure PCTCN2022131193-appb-100040
    Figure PCTCN2022131193-appb-100041
    Figure PCTCN2022131193-appb-100042
    Figure PCTCN2022131193-appb-100043
    Figure PCTCN2022131193-appb-100044
    Figure PCTCN2022131193-appb-100045
    Figure PCTCN2022131193-appb-100046
  9. 一种药物组合物，其包含治疗有效量的物质A以及药学上可接受的载体，其特征在于，所述的物质A为如权利要求1-8中任一项所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
  10. 一种物质A在制备LSD1抑制剂中的应用，其特征在于，所述的物质A为如如权利要求1-8中任一项所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种。
  11. 一种物质A在制备药物中的应用，其特征在于，所述的物质A为如如权利要求1-8中任一项所述的式I所示的芳杂环类化合物、其药学上可以接受的盐、立体异构体、外消旋体、前体药物、共结晶复合物、水合物或溶剂化合物中的一种或多种；
    所述的药物可为用于治疗或预防LSD1介导的疾病或癌症的药物。
  12. 如权利要求11所述的应用，其特征在于，所述的LSD1介导的疾病为癌症；
    所述的癌症选自膀胱癌、乳腺癌、前列腺癌、胰腺癌、甲状腺癌、肝癌、结肠癌、直肠癌、食道癌、宫颈癌、卵巢癌、急性白血病、急性淋巴细胞白血病、急性髓性白血病、急性T细胞白血病、软骨肉瘤、慢性淋巴细胞白血病、慢性髓细胞白血病、大细胞淋巴瘤、纤维肉瘤、睾丸生殖细胞癌、神经胶质瘤、淋巴瘤、多发性骨髓瘤、淋巴癌、骨髓癌、成神经细胞瘤、神经母细胞瘤、非小细胞肺癌、小细胞肺癌中的一种或多种。
PCT/CN2022/131193 2021-11-11 2022-11-10 一种芳杂环类化合物及其应用 WO2023083269A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202280075128.7A CN118302418A (zh) 2021-11-11 2022-11-10 一种芳杂环类化合物及其应用
EP22892062.5A EP4431504A1 (en) 2021-11-11 2022-11-10 Aromatic heterocyclic compound and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111332018.8 2021-11-11
CN202111332018.8A CN116102533A (zh) 2021-11-11 2021-11-11 一种芳杂环类化合物及其应用

Publications (1)

Publication Number Publication Date
WO2023083269A1 true WO2023083269A1 (zh) 2023-05-19

Family

ID=86264358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/131193 WO2023083269A1 (zh) 2021-11-11 2022-11-10 一种芳杂环类化合物及其应用

Country Status (3)

Country Link
EP (1) EP4431504A1 (zh)
CN (2) CN116102533A (zh)
WO (1) WO2023083269A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066122A1 (en) * 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
CN106795103A (zh) * 2014-07-03 2017-05-31 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶‑1的抑制剂
CN107660205A (zh) * 2015-04-03 2018-02-02 因赛特公司 作为lsd1抑制剂的杂环化合物
KR20190073009A (ko) * 2017-12-18 2019-06-26 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
CN111032641A (zh) * 2017-06-19 2020-04-17 诺华股份有限公司 经取代的5-氰基吲哚化合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066122A1 (en) * 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
CN106795103A (zh) * 2014-07-03 2017-05-31 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶‑1的抑制剂
CN107660205A (zh) * 2015-04-03 2018-02-02 因赛特公司 作为lsd1抑制剂的杂环化合物
CN111032641A (zh) * 2017-06-19 2020-04-17 诺华股份有限公司 经取代的5-氰基吲哚化合物及其用途
KR20190073009A (ko) * 2017-12-18 2019-06-26 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
"March's Advanced Organic Chemistry", 2007, JOHN WILEY & SONS
AM. J. CLIN. EXP. UROL., vol. 2, no. 4, 2014, pages 273 - 285
BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
CANCER CELL, vol. 28, no. 1, 2015, pages 57 - 69
CANCER RES., vol. 76, no. 7, 2016, pages 1975 - 1988
CELL, vol. 174, 2018, pages 549 - 563
EPIGENOMICS, vol. 8, no. 8, 2016, pages 1103 - 1116
FUTURE MED. CHEM., vol. 9, 2017, pages 1227 - 1242
SHI YANG ET AL., CELL, vol. 119, 2004, pages 941 - 53

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Also Published As

Publication number Publication date
EP4431504A1 (en) 2024-09-18
CN118302418A (zh) 2024-07-05
CN116102533A (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
CN113651814B (zh) Kras突变蛋白抑制剂
CN113286794B (zh) Kras突变蛋白抑制剂
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
WO2020064002A1 (zh) 异吲哚啉类化合物、其制备方法、药物组合物及用途
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
TW201702226A (zh) 尿素衍生物或其醫藥上可接受鹽
CN112300196A (zh) 一类哌啶稠环类化合物、制备方法和用途
EP3705480A1 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
JP2015533778A (ja) がんの治療のための新規フェニル−ピリジン／ピラジンアミド
WO2022063297A1 (zh) 喹唑啉衍生物及其制备方法和用途
CN102066322A (zh) 具有npy y5受体拮抗作用的化合物
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
JP2008513428A (ja) Ｄｎａ−ｐｋ阻害剤
WO2023083269A1 (zh) 一种芳杂环类化合物及其应用
WO2018036470A1 (zh) 作为pde4抑制剂的并环类化合物
CN108341819B (zh) 磷酸二酯酶抑制剂及其用途
WO2022006433A1 (en) Compounds, compositions and methods
CN115340555A (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
WO2010004198A2 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
JP7358372B2 (ja) イミダゾピロロン化合物及びその使用
WO2022148439A1 (zh) 作为bcl-2抑制剂的杂环化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22892062

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 18709473

Country of ref document: US

Ref document number: 202280075128.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2022892062

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022892062

Country of ref document: EP

Effective date: 20240611